WO2009023253A2 - IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Google Patents
IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Download PDFInfo
- Publication number
- WO2009023253A2 WO2009023253A2 PCT/US2008/009740 US2008009740W WO2009023253A2 WO 2009023253 A2 WO2009023253 A2 WO 2009023253A2 US 2008009740 W US2008009740 W US 2008009740W WO 2009023253 A2 WO2009023253 A2 WO 2009023253A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imidazo
- piperazin
- compound according
- group
- sleep
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 81
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 title abstract 3
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 title abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 361
- 238000000034 method Methods 0.000 claims abstract description 133
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 51
- 208000035475 disorder Diseases 0.000 claims abstract description 43
- 208000019116 sleep disease Diseases 0.000 claims abstract description 40
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 18
- 206010022437 insomnia Diseases 0.000 claims abstract description 16
- 206010013980 Dyssomnias Diseases 0.000 claims abstract description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 12
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 208000006199 Parasomnias Diseases 0.000 claims abstract description 8
- -1 Ci-C6 alkylureyl Chemical group 0.000 claims description 165
- 230000007958 sleep Effects 0.000 claims description 132
- 229910052739 hydrogen Inorganic materials 0.000 claims description 81
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 74
- 239000000203 mixture Substances 0.000 claims description 72
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 150000002367 halogens Chemical class 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 41
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 125000001188 haloalkyl group Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 23
- 150000003857 carboxamides Chemical class 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 17
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 17
- 208000020685 sleep-wake disease Diseases 0.000 claims description 17
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 15
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 15
- 125000004423 acyloxy group Chemical group 0.000 claims description 14
- 150000004677 hydrates Chemical class 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- 238000007596 consolidation process Methods 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 230000037322 slow-wave sleep Effects 0.000 claims description 12
- 125000001246 bromo group Chemical group Br* 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 10
- 238000012423 maintenance Methods 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 9
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims description 8
- 229940124530 sulfonamide Drugs 0.000 claims description 8
- 150000003456 sulfonamides Chemical class 0.000 claims description 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004440 haloalkylsulfinyl group Chemical group 0.000 claims description 5
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- BBFQNJGJAFYLPB-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 BBFQNJGJAFYLPB-UHFFFAOYSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- WIRTYVGMQVIVDM-UHFFFAOYSA-N pyridine-3-carbonitrile Chemical compound N#CC1=C=NC=C[CH]1 WIRTYVGMQVIVDM-UHFFFAOYSA-N 0.000 claims description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- LVMDLJZSGYPANL-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-(4-thiophen-2-ylphenyl)ethanone Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(=O)C(C=C1)=CC=C1C1=CC=CS1 LVMDLJZSGYPANL-UHFFFAOYSA-N 0.000 claims 1
- YEAMDHONLJCKAM-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-[2-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 YEAMDHONLJCKAM-UHFFFAOYSA-N 0.000 claims 1
- USTBGZUJKCBYAR-UHFFFAOYSA-N [4-[2-(2,4-difluorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 USTBGZUJKCBYAR-UHFFFAOYSA-N 0.000 claims 1
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 54
- 208000024891 symptom Diseases 0.000 abstract description 25
- 208000028017 Psychotic disease Diseases 0.000 abstract description 23
- 201000000980 schizophrenia Diseases 0.000 abstract description 17
- 238000013019 agitation Methods 0.000 abstract description 16
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract description 14
- 208000006011 Stroke Diseases 0.000 abstract description 13
- 208000007536 Thrombosis Diseases 0.000 abstract description 12
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 abstract description 12
- 208000010125 myocardial infarction Diseases 0.000 abstract description 11
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract description 8
- 208000006673 asthma Diseases 0.000 abstract description 7
- 230000003542 behavioural effect Effects 0.000 abstract description 7
- 208000029078 coronary artery disease Diseases 0.000 abstract description 7
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract description 7
- 208000020925 Bipolar disease Diseases 0.000 abstract description 5
- 208000011963 Substance-induced psychotic disease Diseases 0.000 abstract description 5
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 abstract description 5
- 208000000323 Tourette Syndrome Diseases 0.000 abstract description 5
- 208000016620 Tourette disease Diseases 0.000 abstract description 5
- 201000002545 drug psychosis Diseases 0.000 abstract description 5
- 230000002964 excitative effect Effects 0.000 abstract description 5
- 210000002816 gill Anatomy 0.000 abstract description 5
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 5
- 150000003222 pyridines Chemical class 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 description 112
- 239000007787 solid Substances 0.000 description 89
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 65
- 238000005160 1H NMR spectroscopy Methods 0.000 description 57
- 239000000243 solution Substances 0.000 description 44
- 239000007858 starting material Substances 0.000 description 43
- 102000005962 receptors Human genes 0.000 description 42
- 108020003175 receptors Proteins 0.000 description 42
- 229910001868 water Inorganic materials 0.000 description 36
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 28
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 229940125425 inverse agonist Drugs 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- 230000037053 non-rapid eye movement Effects 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 20
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 239000000556 agonist Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 206010001497 Agitation Diseases 0.000 description 15
- 238000007792 addition Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- WTDFFADXONGQOM-UHFFFAOYSA-N formaldehyde;hydrochloride Chemical class Cl.O=C WTDFFADXONGQOM-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000035602 clotting Effects 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 229960003878 haloperidol Drugs 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 11
- 229940076279 serotonin Drugs 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
- 206010012289 Dementia Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- COSPVUFTLGQDQL-UHFFFAOYSA-N Nelotanserin Chemical compound C1=C(C=2N(N=CC=2Br)C)C(OC)=CC=C1NC(=O)NC1=CC=C(F)C=C1F COSPVUFTLGQDQL-UHFFFAOYSA-N 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000002287 radioligand Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical class NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 241000701460 JC polyomavirus Species 0.000 description 6
- 206010062519 Poor quality sleep Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000002399 angioplasty Methods 0.000 description 6
- 230000000702 anti-platelet effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 125000003636 chemical group Chemical group 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 230000004622 sleep time Effects 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 229910052722 tritium Inorganic materials 0.000 description 6
- 230000002618 waking effect Effects 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 208000010340 Sleep Deprivation Diseases 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 5
- 229940011051 isopropyl acetate Drugs 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- NZZDEODTCXHCRS-UHFFFAOYSA-N methyl 2-aminopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1N NZZDEODTCXHCRS-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 238000003653 radioligand binding assay Methods 0.000 description 5
- 230000004461 rapid eye movement Effects 0.000 description 5
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 5
- 229950005789 sarpogrelate Drugs 0.000 description 5
- 230000008667 sleep stage Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 5
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 5
- 229960001475 zolpidem Drugs 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 4
- 208000020706 Autistic disease Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 208000022249 Sleep-Wake Transition disease Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 229950009005 altanserin Drugs 0.000 description 4
- 238000013176 antiplatelet therapy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 238000002650 immunosuppressive therapy Methods 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 4
- 229960005417 ketanserin Drugs 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QPKZIGHNRLZBCL-UHFFFAOYSA-N 2-(2,4-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1F QPKZIGHNRLZBCL-UHFFFAOYSA-N 0.000 description 3
- BGMZUEKZENQUJY-UHFFFAOYSA-N 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine Chemical compound COC1=CC(CC(C)N)=C(OC)C=C1I BGMZUEKZENQUJY-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000015814 Intrinsic Sleep disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229940095895 haldol Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000002469 receptor inverse agonist Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 3
- 229950009626 ritanserin Drugs 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- DYNFFOWHSAVRSO-UHFFFAOYSA-N tert-butyl 4-[2-(2,4-difluorophenyl)acetyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)CC1=CC=C(F)C=C1F DYNFFOWHSAVRSO-UHFFFAOYSA-N 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- FIKUTJXXUOHGLW-UHFFFAOYSA-N 1-[2-(2,4-difluorophenyl)ethyl]piperazine;dihydrochloride Chemical compound Cl.Cl.FC1=CC(F)=CC=C1CCN1CCNCC1 FIKUTJXXUOHGLW-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- BIQRPLMAKJWHIH-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyridine-2-carboxylic acid Chemical class C1=CN=C2NC(C(=O)O)=NC2=C1 BIQRPLMAKJWHIH-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 206010023163 JC virus infection Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 125000005596 alkyl carboxamido group Chemical group 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- STNNHWPJRRODGI-UHFFFAOYSA-N carbonic acid;n,n-diethylethanamine Chemical compound [O-]C([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC STNNHWPJRRODGI-UHFFFAOYSA-N 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical class Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 150000002576 ketones Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 229960001779 pargyline Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- BGMZUEKZENQUJY-SSDOTTSWSA-N (2r)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC(C[C@@H](C)N)=C(OC)C=C1I BGMZUEKZENQUJY-SSDOTTSWSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- IOQORVDNYPOZPL-VQTJNVASSA-N (5S,6R)-5-(4-chlorophenyl)-6-cyclopropyl-3-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-2H-1,2,4-oxadiazine Chemical compound ClC1=CC=C(C=C1)[C@@H]1NC(=NO[C@@H]1C1CC1)C1=NC(=C(C=C1)N1C=NC(=C1)C)OC IOQORVDNYPOZPL-VQTJNVASSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000004749 (C1-C6) haloalkylsulfinyl group Chemical group 0.000 description 1
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 1
- 0 *C1(*)c2c(*)c(*)c(*)c(*)c2*C1(*)N(CC1)CCN1C(c1ccc[n]2c1ncc2)=O Chemical compound *C1(*)c2c(*)c(*)c(*)c(*)c2*C1(*)N(CC1)CCN1C(c1ccc[n]2c1ncc2)=O 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- VZCHCIWHJLPPNF-UHFFFAOYSA-N 1-(4-thiophen-2-ylphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=CS1 VZCHCIWHJLPPNF-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ALKPXBLADACOTC-UHFFFAOYSA-N 1-[2-(2,4-difluorophenyl)ethyl]piperazine Chemical compound FC1=CC(F)=CC=C1CCN1CCNCC1 ALKPXBLADACOTC-UHFFFAOYSA-N 0.000 description 1
- XCJQNAMEFYFVQC-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)ethyl]piperazine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CCN1CCNCC1 XCJQNAMEFYFVQC-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- BHEFURJIYSUKTG-UHFFFAOYSA-N 1-[2-fluoro-2-(4-fluorophenyl)ethyl]piperazine;hydrochloride Chemical compound Cl.C=1C=C(F)C=CC=1C(F)CN1CCNCC1 BHEFURJIYSUKTG-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- ZYTAWRJYVOUJBP-UHFFFAOYSA-N 2-amino-4,6-dimethylpyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.CC1=CC(C)=C(C(O)=O)C(N)=N1 ZYTAWRJYVOUJBP-UHFFFAOYSA-N 0.000 description 1
- ULYBLKYAFIOZRK-UHFFFAOYSA-N 2-amino-4-methoxypyridine-3-carbonitrile Chemical compound COC1=CC=NC(N)=C1C#N ULYBLKYAFIOZRK-UHFFFAOYSA-N 0.000 description 1
- IEPDTLRHISNBLB-UHFFFAOYSA-N 2-amino-5-bromopyridine-3-carboxylic acid Chemical compound NC1=NC=C(Br)C=C1C(O)=O IEPDTLRHISNBLB-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- CSGDTHXBRAAOHV-UHFFFAOYSA-N 2-bromo-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CBr)C(F)=C1 CSGDTHXBRAAOHV-UHFFFAOYSA-N 0.000 description 1
- UJBGPTKBKJYQQH-UHFFFAOYSA-N 2-bromo-1-(4-chloro-2-fluoro-5-methylphenyl)ethanone Chemical compound CC1=CC(C(=O)CBr)=C(F)C=C1Cl UJBGPTKBKJYQQH-UHFFFAOYSA-N 0.000 description 1
- JMCBGXFQNHCVBY-UHFFFAOYSA-N 2-bromo-1-(4-cyclohexylphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1C1CCCCC1 JMCBGXFQNHCVBY-UHFFFAOYSA-N 0.000 description 1
- ZJFWCELATJMDNO-UHFFFAOYSA-N 2-bromo-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CBr)C=C1 ZJFWCELATJMDNO-UHFFFAOYSA-N 0.000 description 1
- LJYOFQHKEWTQRH-UHFFFAOYSA-N 2-bromo-1-(4-hydroxyphenyl)ethanone Chemical compound OC1=CC=C(C(=O)CBr)C=C1 LJYOFQHKEWTQRH-UHFFFAOYSA-N 0.000 description 1
- JOCMYOUZIDSYFO-UHFFFAOYSA-N 2-bromo-1-(4-methylsulfonylphenyl)ethanone Chemical compound CS(=O)(=O)C1=CC=C(C(=O)CBr)C=C1 JOCMYOUZIDSYFO-UHFFFAOYSA-N 0.000 description 1
- OUGMZFJPRSTGMJ-UHFFFAOYSA-N 2-bromo-1-(4-morpholin-4-ylphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1N1CCOCC1 OUGMZFJPRSTGMJ-UHFFFAOYSA-N 0.000 description 1
- WLRIUCQUMKJOGT-UHFFFAOYSA-N 2-bromo-1-(4-pyrrolidin-1-ylphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1N1CCCC1 WLRIUCQUMKJOGT-UHFFFAOYSA-N 0.000 description 1
- QFHKNYPNLSJEQI-UHFFFAOYSA-N 2-bromo-1-(4-thiophen-2-ylphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1C1=CC=CS1 QFHKNYPNLSJEQI-UHFFFAOYSA-N 0.000 description 1
- MRJQMHKVHNQGJR-UHFFFAOYSA-N 2-bromo-1-(5-chloro-2-methoxy-4-methyl-3-nitrophenyl)ethanone Chemical compound COC1=C(C(=O)CBr)C=C(Cl)C(C)=C1[N+]([O-])=O MRJQMHKVHNQGJR-UHFFFAOYSA-N 0.000 description 1
- BYBYETVLFBNBBH-UHFFFAOYSA-N 2-bromo-1-(5-chloro-2-methoxy-4-methylphenyl)ethanone Chemical compound COC1=CC(C)=C(Cl)C=C1C(=O)CBr BYBYETVLFBNBBH-UHFFFAOYSA-N 0.000 description 1
- KWZCBMKXNYOQAK-UHFFFAOYSA-N 2-bromo-1-[2-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)CBr KWZCBMKXNYOQAK-UHFFFAOYSA-N 0.000 description 1
- YVTHTWZIUKRHCF-UHFFFAOYSA-N 2-bromo-1-[2-chloro-5-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)CBr)=C1 YVTHTWZIUKRHCF-UHFFFAOYSA-N 0.000 description 1
- JMUKUVDYZQDUSP-UHFFFAOYSA-N 2-bromo-1-[4-(difluoromethoxy)phenyl]ethanone Chemical compound FC(F)OC1=CC=C(C(=O)CBr)C=C1 JMUKUVDYZQDUSP-UHFFFAOYSA-N 0.000 description 1
- YWNKTZFJKMGVRP-UHFFFAOYSA-N 2-bromo-1-[4-(dimethylamino)phenyl]ethanone Chemical compound CN(C)C1=CC=C(C(=O)CBr)C=C1 YWNKTZFJKMGVRP-UHFFFAOYSA-N 0.000 description 1
- AOAGGWLQIILIIV-UHFFFAOYSA-N 2-bromo-1-[4-(trifluoromethoxy)phenyl]ethanone Chemical compound FC(F)(F)OC1=CC=C(C(=O)CBr)C=C1 AOAGGWLQIILIIV-UHFFFAOYSA-N 0.000 description 1
- HEMROKPXTCOASZ-UHFFFAOYSA-N 2-bromo-1-[4-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=C(C(=O)CBr)C=C1 HEMROKPXTCOASZ-UHFFFAOYSA-N 0.000 description 1
- WPDWOCRJBPXJFM-UHFFFAOYSA-N 2-bromo-1-phenylpropan-1-one Chemical compound CC(Br)C(=O)C1=CC=CC=C1 WPDWOCRJBPXJFM-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-MICDWDOJSA-N 2-deuterioacetonitrile Chemical compound [2H]CC#N WEVYAHXRMPXWCK-MICDWDOJSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WBKCKEHGXNWYMO-UHFFFAOYSA-N 3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid ethyl ester Chemical compound N=1C(NCCC(=O)OCC)=CC(N2CCC3=CC=CC=C3CC2)=NC=1C1=CC=CC=N1 WBKCKEHGXNWYMO-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LJANCPRIUMHGJE-UHFFFAOYSA-N 4-(2-bromoacetyl)benzonitrile Chemical compound BrCC(=O)C1=CC=C(C#N)C=C1 LJANCPRIUMHGJE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHJZEBARCMOKNX-UHFFFAOYSA-N 4-[2-fluoro-2-(4-fluorophenyl)ethyl]piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1CC(F)C1=CC=C(F)C=C1 FHJZEBARCMOKNX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VXWSXLSUWGZOHD-UHFFFAOYSA-N 5-(2-bromoacetyl)-2-hydroxybenzamide Chemical compound NC(=O)C1=CC(C(=O)CBr)=CC=C1O VXWSXLSUWGZOHD-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- OXYLMGLKAKEZBC-UHFFFAOYSA-N Cc1c[n](cccc2C(N3CCN(CCc(cc4)ccc4F)CC3)=O)c2n1 Chemical compound Cc1c[n](cccc2C(N3CCN(CCc(cc4)ccc4F)CC3)=O)c2n1 OXYLMGLKAKEZBC-UHFFFAOYSA-N 0.000 description 1
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229910020323 ClF3 Inorganic materials 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005794 Hairy Leukoplakia Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 description 1
- RFQBISKRBWMSHN-UHFFFAOYSA-N O=C(c1ccc[n]2c1ncc2)N1CCN(CC(c(cc2)ccc2F)F)CC1 Chemical compound O=C(c1ccc[n]2c1ncc2)N1CCN(CC(c(cc2)ccc2F)F)CC1 RFQBISKRBWMSHN-UHFFFAOYSA-N 0.000 description 1
- DPMWZOFTOGCSCJ-UHFFFAOYSA-N O=C(c1ccc[n]2c1ncc2)N1CCN(CCc(cccc2)c2Cl)CC1 Chemical compound O=C(c1ccc[n]2c1ncc2)N1CCN(CCc(cccc2)c2Cl)CC1 DPMWZOFTOGCSCJ-UHFFFAOYSA-N 0.000 description 1
- FHHNEEMCBOUXDT-UHFFFAOYSA-N O=C(c1ccc[n]2c1ncc2)N1CCN(CCc(cccc2)c2F)CC1 Chemical compound O=C(c1ccc[n]2c1ncc2)N1CCN(CCc(cccc2)c2F)CC1 FHHNEEMCBOUXDT-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- YOLJECWHMSPAJR-UHFFFAOYSA-N Oc(cc1)ccc1C(CN(CC1)CCN1C(c1ccc[n]2c1ncc2)=O)=O Chemical compound Oc(cc1)ccc1C(CN(CC1)CCN1C(c1ccc[n]2c1ncc2)=O)=O YOLJECWHMSPAJR-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150071725 SMDT1 gene Proteins 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- XTZNCVSCVHTPAI-UHFFFAOYSA-N Salmeterol xinafoate Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 XTZNCVSCVHTPAI-UHFFFAOYSA-N 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000022841 Sleep Arousal disease Diseases 0.000 description 1
- 206010041009 Sleep talking Diseases 0.000 description 1
- 208000022890 Sleep-related eating disease Diseases 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LVBMFPUTQOHXQE-UHFFFAOYSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-(3-aminopropylamino)butyl]carbamate Chemical compound NCCCNCCCCNC(=O)OCC(=O)NCCCCCCN=C(N)N LVBMFPUTQOHXQE-UHFFFAOYSA-N 0.000 description 1
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007034 advanced sleep phase syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 125000004320 azepan-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 1
- 125000004267 aziridin-2-yl group Chemical group [H]N1C([H])([H])C1([H])* 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000014486 central sleep apnea syndrome Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006640 cycloheptyl carbonyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 1
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- VIPHVHVAGBKHGR-UHFFFAOYSA-N hydron;pyridine-2-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CC=N1 VIPHVHVAGBKHGR-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000033923 irregular sleep wake type circadian rhythm sleep disease Diseases 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YBHKBMJREUZHOV-QGZVFWFLSA-N n-(2-hydroxyethyl)-n,2-dimethyl-8-[[(4r)-5-methyl-3,4-dihydro-2h-chromen-4-yl]amino]imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1COC2=CC=CC(C)=C2[C@@H]1NC1=CC(C(=O)N(CCO)C)=CN2C=C(C)N=C21 YBHKBMJREUZHOV-QGZVFWFLSA-N 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- GYEQBFBEBZJFLU-UHFFFAOYSA-N n-[5-(2-bromoacetyl)-2-hydroxyphenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC(C(=O)CBr)=CC=C1O GYEQBFBEBZJFLU-UHFFFAOYSA-N 0.000 description 1
- NRMJMIGWXUCEEW-UHFFFAOYSA-N n-butan-2-ylformamide Chemical compound CCC(C)NC=O NRMJMIGWXUCEEW-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FJLHLDBEZKTSOK-UHFFFAOYSA-N n-ethyl-n-methylformamide Chemical compound CCN(C)C=O FJLHLDBEZKTSOK-UHFFFAOYSA-N 0.000 description 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
- ZKTLKYRAZWGBDB-UHFFFAOYSA-N n-methyl-n-propan-2-ylformamide Chemical compound CC(C)N(C)C=O ZKTLKYRAZWGBDB-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SUUDTPGCUKBECW-UHFFFAOYSA-N n-propylformamide Chemical compound CCCNC=O SUUDTPGCUKBECW-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 206010030979 oral hairy leukoplakia Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 208000023515 periodic limb movement disease Diseases 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009288 screen filtration Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002400 serotonin 2A antagonist Substances 0.000 description 1
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- YFXPXHLZCVOHNM-UHFFFAOYSA-N tert-butyl 4-[1-fluoro-2-(4-fluorophenyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(F)CC1=CC=C(F)C=C1 YFXPXHLZCVOHNM-UHFFFAOYSA-N 0.000 description 1
- DLYLITULTOMNQT-UHFFFAOYSA-N tert-butyl 4-[2-(2,4-difluorophenyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCC1=CC=C(F)C=C1F DLYLITULTOMNQT-UHFFFAOYSA-N 0.000 description 1
- XBZVOOTUCLBUEY-UHFFFAOYSA-N tert-butyl 4-[2-(4-fluorophenyl)-2-oxoethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC(=O)C1=CC=C(F)C=C1 XBZVOOTUCLBUEY-UHFFFAOYSA-N 0.000 description 1
- JRLBGINRRYSZMY-UHFFFAOYSA-N tert-butyl 4-[2-(4-fluorophenyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCC1=CC=C(F)C=C1 JRLBGINRRYSZMY-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000005243 upper chamber Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to certain imidazo[l,2- ⁇ ]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor.
- Compounds of Formula (Ia) and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.
- the present invention also relates to methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
- Serotonin (5-hydroxytryptamine, 5-HT) are an important class of G protein coupled receptors. Serotonin is thought to play a role in processes related to learning and memory, sleep, thermoregulation, mood, motor activity, pain, sexual and aggressive behaviors, appetite, neurodegenerative regulation and biological rhythms. Not surprisingly, serotonin is linked to pathophysiological conditions such as anxiety, depression, obsessive compulsive disorders, schizophrenia, suicide, autism, migraine, emesis, alcoholism and neurodegenerative disorders.
- Serotonin receptors are divided into seven subfamilies, referred to as 5-HT 1 through 5- HT 7 , inclusive. These subfamilies are further divided into subtypes.
- the 5-HT 2 subfamily is divided into three receptor subtypes: 5-HT 2A , 5-HT 2B and 5-HT 2C -
- the human 5- HT 2C receptor was first isolated and cloned in 1987 and the human 5-HT 2A receptor was first isolated and cloned in 1990.
- One aspect of the present invention encompasses certain imidazo[l,2- ⁇ ]pyridine derivatives selected from compounds as shown in Formula (Ia):
- R 1 and R 2 are each independently selected from the group consisting of H, Ci-C 6 acyl, Ci-C 6 acyloxy, C]-C 6 alkoxy, Ci-C 6 alkoxycarbonylamino, Cj-C 6 alkyl, C 1 -C 6 alkylamino, C 2 -C 8 dialkylamino, Ci-C 6 alkylcarboxamide, Ci-C 6 alkylsulfonamide, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 alkylureyl, amino, aryl, aryl-Ci-C 4 -alkylenyl, carbo-Q-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 6 dialkylcarboxamide, Ci-C 6 haloalkoxy, Cj-C 6 haloalkyl, C]-C 6
- R 3 , R 4 and R 5 re each independently selected from the group consisting of H, Ci -C 6 acyl, Ci-C 6 acyloxy, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonylamino, Q-C 6 alkyl, C]-C 6 alkylamino, C 2 -C 8 dialkylamino, Ci-C 6 alkylcarboxamide, Q-C 6 alkylsulfonamide, C]-C 6 alkylsulfinyl, Q-C 6 alkylsulfonyl, C]-C 6 alkylureyl, amino, aryl, aryl-Q-C 4 -alkylenyl, carbo-Q-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 6 dialkylcarboxamide, C]-C 6 haloalkoxy, Ci-C 6 haloalkyl, C
- R 6 and R 7 are each independently selected from the group consisting of H, Cj-C 6 acyl, Cj-C 3 alkyl, aryl, carboxamide, carboxy, C 3 -C 7 cycloalkyl, Cj-C 6 haloalkyl, heteroaryl and heterocyclyl;
- R 8 and R 9 are each independently selected from the group consisting of H, Cj-C 6 acyl, Cj-C 3 alkyl, aryl, carboxamide, Cj-C 3 alkoxy, carboxy, cyano, C 3 -C 7 cycloalkyl, Cj-C 3 haloalkyl, halogen and hydroxyl; or
- R 8 and R 9 together with the atom to which they are both bonded form a C 3 -C 7 cycloalkyl ring; and R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, Ci-C 6 acyl, Ci-C 6 acyloxy, Q-C 6 alkoxy, Ci-C 6 alkoxycarbonylamino, Q-C 6 alkyl, Ci-C 6 alkylamino, Ci-C 6 alkylcarboxamide, Q-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonamide, Ci-C 6 alkylsulfonyl, Ci-C 6 alkylureyl, amino, carbo-Ci-C 6 alkoxy, carboxamide, carboxy, cyano, C 3 - C 6 cycloalkyl, C 3 -C 7 cycloalkylcarbonyl, C 2 -C 8 dialkylamino, C 2 -
- One aspect of the present invention pertains to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to methods for treating 5-HT 2A mediated disorders in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating 5-HT 2A mediated disorders selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke and atrial fibrillation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating sleep disorders in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating dyssomnias.
- One aspect of the present invention pertains to methods for treating insomnia.
- One aspect of the present invention pertains to methods for treating parasomnias.
- One aspect of the present invention pertains to methods for increasing slow wave sleep in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for improving sleep consolidation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for improving sleep maintenance in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating conditions associated with platelet aggregation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for reducing the risk of blood clot formation in an angioplasty or coronary bypass surgery individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for reducing the risk of blood clot formation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for reducing the risk of blood clot formation in an individual suffering from atrial fibrillation, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating diabetic-related disorders in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating progressive multifocal leukoencephalopathy in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating hypertension in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to methods for treating pain in an individual, comprising administering to said individual in need thereof a therapeutically x effective amount of a compound of the present invention or a pharmaceutical composition thereof.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a sleep disorder.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a dyssomnia.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of insomnia.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a parasomnia.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for increasing slow wave sleep.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for improving sleep consolidation.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for improving sleep maintenance.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a 5-HT 2A mediated disorder.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke or atrial fibrillation.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a condition associated with platelet aggregation.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the reduction of the risk of blood clot formation in an angioplasty or coronary bypass surgery individual.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the reduction of the risk of blood clot formation in an individual.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the reduction of the risk of blood clot formation in an individual suffering from atrial fibrillation.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a diabetic-related disorder.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of progressive multifocal leukoencephalopathy.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of hypertension.
- One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of pain.
- One aspect of the present invention pertains to compounds of the present invention for use in a method of treatment of the human or animal body by therapy.
- One aspect of the present invention pertains to compounds of the present invention for use in a method of treatment of the human or animal body by surgery.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a 5-HT 2A mediated disorder.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke or atrial fibrillation.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a sleep disorder.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a dyssomnia.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of insomnia.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a parasomnia.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for increasing slow wave sleep.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for improving sleep consolidation.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for improving sleep maintenance.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a condition associated with platelet aggregation.
- One aspect of the present invention pertains to compounds of the present invention for use in a method of reducing the risk of blood clot formation in an angioplasty or coronary bypass surgery individual.
- One aspect of the present invention pertains to compounds of the present invention for use in a method of reducing the risk of blood clot formation in an individual.
- One aspect of the present invention pertains to compounds of the present invention for use in a method of reducing the risk of blood clot formation in an individual suffering from atrial fibrillation.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a diabetic-related disorder.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of progressive multifocal leukoencephalopathy.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of hypertension.
- One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of pain.
- One aspect of the present invention pertains to processes for preparing a composition comprising admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- Figure 1 shows a general synthetic scheme for preparation of compounds of Formula (Ia). Boc-piperazine is coupled with a phenylacetic acid derivative in the presence of a coupling agent. The resulting amide is reduced and the Boc protecting group is removed. The final step, is coupling with an imidazopyridine carboxylic acid derivative.
- Figure 2 shows a second general synthetic scheme for preparation of compounds of Formula (Ia).
- Boc-piperazine is coupled with a phenethyl halide derivative, followed by deprotection and finally coupling with an imidazopyridine carboxylic acid derivative.
- Figure 3 shows synthetic schemes for preparation of certain imidazo[l,2- ⁇ ]pyridines.
- the first synthesis involves the reaction between an acetaldehyde derivative and a 2- aminonicotinic acid derivative to produce an imidazo[l,2- ⁇ ]pyridine-8 -carboxylic acid, which can then be chlorinated to form the acid chloride.
- 2-aminonicotinic acids are methylated with TMS-diazomethane and reacted with disubstituted carbonyl compounds to produce certain imidazo[l,2- ⁇ ]pyridine-8-carboxylic acid methyl esters, which can be subsequently demethylated.
- Halogenation at the 3-position of an imidazo[l,2- ⁇ ]pyridine-8-carboxylic acid derivative, by treatment with a halogenating agent, is also shown.
- Figure 4 shows halogenation of a compound of Formula (Ia) with a halogenating agent and cyanation of a compound of Formula (Ia) with dicyanozinc.
- Figure 5 shows a third route for preparing compounds of Formula (Ia) wherein the imidazo[l,2- ⁇ ]pyridine derivative is coupled first to the Boc-piperidine. After deprotection the final step is coupling with a phenethyl halide derivative.
- Figure 6 shows the efficacy of compound 18 in the attenuation of DOI-induced hypolocomotion in rats.
- Figure 7 shows the efficacy of compound in 19 the attenuation of DOI-induced hypolocomotion in rats.
- agonists is intended to mean moieties that interact and activate the receptor, such as the 5-HT 2A serotonin receptor and initiate a physiological or pharmacological response characteristic of that receptor. For example, when moieties activate the intracellular response upon binding to the receptor, or enhance GTP binding to membranes.
- antagonists is intended to mean moieties that competitively bind to the receptor at the same site as agonists (for example, the endogenous ligand), but which do not activate the intracellular response initiated by the active form of the receptor and can thereby inhibit the intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
- contacting is intended to mean bringing the indicated moieties together, whether in an in vitro system or an in vivo system.
- "contacting" a 5-HT 2A serotonin receptor with a compound of the invention includes the administration of a compound of the present invention to an individual, preferably a human, having a 5-HT 2A serotonin receptor, as well as, for example, introducing a compound of the invention into a sample containing a cellular or more purified preparation containing a 5-HT 2A serotonin receptor.
- in need of treatment and the term “in need thereof when referring to treatment are used interchangeably to mean a judgment made by a caregiver (e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of a caregiver's expertise, but that includes the knowledge that the individual or animal is ill, or will become ill, as the result of a disease, condition or disorder that is treatable by the compounds of the invention. Accordingly, the compounds of the invention can be used in a protective or preventive manner; or compounds of the invention can be used to alleviate, inhibit or ameliorate the disease, condition or disorder.
- a caregiver e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals
- mice rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates and most preferably humans.
- inverse agonists is intended to mean moieties that bind to the endogenous form of the receptor or to the constitutively activated form of the receptor and which inhibit the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of agonists or partial agonists, or decrease GTP binding to membranes.
- the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50% and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist.
- modulate or modulating is intended to mean an increase or decrease in the amount, quality, response or effect of a particular activity, function or molecule.
- composition is intended to mean a composition comprising at least one active ingredient; including but not limited to, salts, solvates and hydrates of compounds of the present invention; whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
- a mammal for example, without limitation, a human.
- terapéuticaally effective amount is intended to mean the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician or caregiver; or by an individual, which includes one or more of the following:
- Preventing the disease for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease,
- Inhibiting the disease for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology) and
- Ameliorating the disease for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
- Ci-C 6 acyl is intended to mean a Q-C 6 alkyl radical attached to the carbon of a carbonyl group wherein the definition of alkyl has the same definition as described herein; some examples include, but are not limited to, acetyl, propionyl, n-butanoyl, sec-butanoyl, pivaloyl, pentanoyl and the like.
- the term "Ci-C 6 acyloxy” is intended to mean an acyl radical attached to an oxygen atom wherein acyl has the same definition has described herein; some embodiments are when acyloxy is Ci-C 5 acyloxy, some embodiments are when acyloxy is Ci-C 6 acyloxy. Some examples include, but are not limited to, acetyloxy, propionyloxy, butanoyloxy, iso- butanoyloxy, pentanoyloxy, hexanoyloxy and the like.
- C 1 -C 6 alkoxy is intended to mean a Ci-C 6 alkyl radical, as defined herein, attached directly to an oxygen atom, some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons. Examples include methoxy, ethoxy, rc-propoxy, /s ⁇ -propoxy, n-butoxy, /-butoxy, iso- butoxy, sec-butoxy and the like.
- Ci-C 6 alkoxycarbonylamino is intended to mean a single Ci-C 6 alkoxy group attached to the carbon of an amide group wherein alkoxy has the same definition as found herein.
- the alkoxycarbonylamino group may be represented by the following:
- Ci-C 6 alkyl is intended to mean a straight or branched carbon radical containing 1 to 6 carbons, some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons.
- alkyl examples include, but not limited to, methyl, ethyl, w-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, f-butyl, pentyl, iso-pentyl, ⁇ -pentyl, neo-pentyl, 1-methylbutyl [i.e., -CH(CH 3 )CH 2 CH 2 CH 3 ], 2-methylbutyl [i.e., -CH 2 CH(CH 3 )CH 2 CH 3 ], rc-hexyl and the like.
- Ci-C 6 alkylcarboxamido or "Ci-C 6 alkylcarboxamide” is intended to mean a single Ci-C 6 alkyl group attached to either the carbon or the nitrogen of an amide group, wherein alkyl has the same definition as found herein.
- the Ci-C 6 alkylcarboxamido group may be represented by the following:
- Examples include, but are not limited to, N-methylcarboxamide, N-ethylcarboxamide, N-n-propylcarboxamide, N- /so-propylcarboxamide, N-H-butylcarboxamide, N-sec- butylcarboxamide, N- /s ⁇ -butylcarboxamide, N-7-butylcarboxamide and the like.
- Ci-C 6 alkylsulfinyl is intended to mean a Ci-C 6 alkyl radical attached to the sulfur of a sulfoxide radical having the formula: -S(O)- wherein the alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfinyl, ethylsulfinyl, «-propylsulfmyl, wo-propylsulfinyl, rc-butylsulfinyl, sec-butylsulfinyl, iso- butylsulfmyl, f-butylsulfinyl and the like.
- Ci-C 6 alkylsulfonamide is intended to mean the groups shown below: wherein Ci-Ce alkyl has the same definition as described herein.
- Ci-C 6 alkylsulfonyl is intended to mean a Cj-C 6 alkyl radical attached to the sulfur of a sulfone radical having the formula: -S(O) 2 - wherein the alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, w-propylsulfonyl, /so-propylsulfonyl, /i-butylsulfonyl, sec-butylsulfonyl, iso- butylsulfonyl, /-butylsulfonyl and the like.
- Ci-C 6 alkylureyl is intended to mean the group of the formula: -NC(O)N- wherein one or both of the nitrogens are substituted with the same or different Cj-C 6 alkyl group wherein alkyl has the same definition as described herein.
- alkylureyl include, but are not limited to, CH 3 NHC(O)NH-, NH 2 C(O)NCH 3 -, (CH 3 ) 2 NC(O)NH-, (CH 3 ) 2 NC(O)NCH 3 -, CH 3 CH 2 NHC(O)NH-, CH 3 CH 2 NHC(O)NCH 3 - and the like.
- amino is intended to mean the group -NH 2 .
- Ci-C 6 alkylamino is intended to mean one alkyl radical attached to a -NH- radical wherein the alkyl radical has the same meaning as described herein. Some examples include, but are not limited to, methylamino, ethylamino, «-propylamino, tso-propylamino, n- butylamino, sec-butylamino, zs ⁇ -butylamino, r-butylamino and the like. Some embodiments are "C 1 -C 2 alkylamino.”
- aryl is intended to mean an aromatic ring radical containing 6 to 10 ring carbons. Examples include phenyl and naphthyl.
- aryl-Ci-C 4 -alkylenyl is intended to mean a Ci-C 4 alkylene group bonded to an aryl group, each as defined herein.
- aryl-Ci-C 4 -alkylenyl refers to, for example, benzyl (-CH 2 -phenyl), phenylethyl (-CH 2 CH 2 -phenyl) and the like
- carbo-Ci-C 6 -alkoxy is intended to mean a Q-C 6 alkyl ester of a carboxylic acid, wherein the alkyl group is as defined herein.
- carboxylic acid group is intended to mean the group -CONH 2 .
- carboxy or “carboxyl” is intended to mean the group -CO 2 H; also referred to as a carboxylic acid group.
- cyano is intended to mean the group -CN.
- C 3 -C 7 cycloalkyl is intended to mean a saturated ring radical containing 3 to 7 carbons; some embodiments contain 3 to 6 carbons; some embodiments contain 3 to 5 carbons; some embodiments contain 5 to 7 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- C 3 -C 7 cycloalkylcarbonyl is intended to mean a C 3 -C 7 cycloalkyl attached to the carbon of a carbonyl group wherein C 3 -C 7 cycloalkyl has the same definition as described herein.
- C 2 -C 8 dialkylamino is intended to mean an amino substituted with two of the same or different Ci -C 4 alkyl radicals wherein alkyl radical has the same definition as described herein.
- Some examples include, but are not limited to, dimethylamino, methylethylamino, diethylamino, methylpropylamino, methylisopropylamino, ethylpropylamino, ethylisopropylamino, dipropylamino, propylisopropylamino and the like. Some embodiments are "C 2 -C 4 dialkylamino.”
- C 2 -C 6 dialkylcarboxamido or "C 2 -C 6 dialkylcarboxamide” is intended to mean two alkyl radicals, that are the same or different, attached to an amide group, wherein alkyl has the same definition as described herein.
- a C 2 -C 6 dialkylcarboxamido may be represented by the following groups:
- dialkylcarboxamide examples include, but are not limited to, N,N-dimethylcarboxamide, N-methyl-N-ethylcarboxamide, N,N- diethylcarboxamide, N-methyl-N-isopropylcarboxamide and the like.
- Ci-C 6 haloalkoxy is intended to mean a Ci-C 6 haloalkyl, as defined herein, which is directly attached to an oxygen atom. Examples include, but are not limited to, difluoromethoxy, trifiuoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy and the like.
- C 1 -C 6 haloalkyl is intended to mean an Ci-C 6 alkyl group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted and a fully substituted C r C 6 haloalkyl can be represented by the formula C n L 2n+I wherein L is a halogen and "n" is 1, 2, 3, 4, 5 or 6; when more than one halogen is present then they may be the same or different and selected from the group consisting of F, Cl, Br and I, preferably F, some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons.
- haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2- trifluoroethyl, pentafluoroethyl and the like.
- C 1 -C 6 haloalkylsulfinyl is intended to mean a Ci -C 6 haloalkyl radical attached to the sulfur atom of a sulfoxide group having the formula: -S(O)- wherein the haloalkyl radical has the same definition as described herein. Examples include, but are not limited to, trifluoromethylsulf ⁇ nyl, 2,2,2-trifluoroethylsulfmyl, 2,2-difluoroethylsulfinyl and the like.
- C 1 -C 6 haloalkylsulfonyl is intended to mean a C]-C 6 haloalkyl radical attached to the sulfur atom of a sulfone group having the formula: -S(O) 2 - wherein haloalkyl has the same definition as described herein. Examples include, but are not limited to, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2,2-difluoroethylsulfonyl and the like.
- halogen or "halo” is intended to mean to a fluoro, chloro, bromo or iodo group.
- heteroaryl is intended to mean an aromatic ring system containing 5 to 14 aromatic ring atoms that may be a single ring, two fused rings or three fused rings wherein at least one aromatic ring atom is a heteroatom selected from, for example, but not limited to, the group consisting of O, S and N wherein the N can be optionally substituted with H, Ci-C 4 acyl or C 1 -C 4 alkyl.
- Some embodiments contain 5 to 6 ring atoms for example furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl and the like.
- Some embodiments contain 8 to 14 ring atoms for example quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, triazinyl, indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl.
- the nitrogen is optionally substituted with Ci-C 4 acyl or Ci-C 4 alkyl and ring carbon atoms are optionally substituted with oxo or a thiooxo thus forming a carbonyl or thiocarbonyl group.
- the heterocyclic group can be attached/bonded to any available ring atom, for example, ring carbon, ring nitrogen and the like.
- the heterocyclic group is a 3-, A-, 5-, 6- or 7- membered ring.
- Examples of a heterocyclic group include, but are not limited to, aziridin-1-yl, aziridin-2-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin- 3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, piperzin-1-yl, piperzin-2- yl, piperzin-3-yl, piperzin-4-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, [l,3]-dio
- hydroxyl is intended to mean the group -OH.
- nitro is intended to mean the group -NO 2 .
- sulfonamide is intended to mean the group -SO 2 NH 2 .
- sulfonic acid is intended to mean the group -SO 3 H.
- One aspect of the present invention pertains to certain compounds as shown in Formula (Ia):
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and R 14 have the same definitions as described herein , supra and infra.
- substituted indicates that at least one hydrogen atom of the chemical group is replaced by a non-hydrogen substituent or group, the non-hydrogen substituent or group can be monovalent or divalent. When the substituent or group is divalent, then it is understood that this group is further substituted with another substituent or group.
- a chemical group herein when a chemical group herein is "substituted" it may have up to the full valance of substitution; for example, a methyl group can be substituted by 1, 2, or 3 substituents, a methylene group can be substituted by 1 or 2 substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5 substituents, a naphthyl group can be substituted by 1, 2, 3, 4, 5, 6, or 7 substituents and the like.
- substituted with one or more substituents refers to the substitution of a group with one substituent up to the total number of substituents physically allowed by the group. Further, when a group is substituted with more than one group they can be identical or they can be different.
- Compounds of the invention can also include tautomeric forms, such as keto-enol tautomers and the like. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is understood that the various tautomeric forms are within the scope of the compounds of the present invention.
- Compounds of the invention can also include all isotopes of atoms occurring in the intermediates and/or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include deuterium and tritium.
- R 1 and R 2 are each independently selected from the group consisting of H, Ci-C 6 acyloxy, C 1 -C 6 alkoxy, C]-C 6 alkyl, C r C 6 alkylsulfonyl, aryl, aryl-Ci-C 4 - alkylenyl, carbo-C r C 6 alkoxy, carboxy, cyano, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkoxy, C]-C 6 haloalkyl, halogen, heteroaryl, heterocyclyl and hydroxyl.
- R 1 and R 2 are each independently selected from the group consisting of H, Ci-C 6 alkyl, aryl, cyano, Ci-C 6 haloalkyl and halogen.
- R 1 and R 2 are each independently selected from the group consisting of H, methyl, f -butyl, phenyl, cyano, trifluoromethyl, chloro and bromo. In some embodiments, R 1 is H; and R 2 is cyano, chloro or bromo.
- R 1 and R 2 are both H.
- R 3 , R 4 and R 5 are each independently selected from the group consisting of H, Q-C 6 alkoxy, C 1 -C 6 alkyl, cyano, C 1 -C 6 haloalkoxy, C 1 -C 6 haloalkyl, halogen and hydroxyl.
- R 3 , R 4 and R 5 are each independently selected from the group consisting of H, C]-C 6 alkyl, C 1 -C 6 alkoxy and halogen.
- R 3 and R 5 are each independently selected from the group consisting of H, C 1 -C 6 alkyl and Q-C 6 alkoxy; and R 4 is H. In some embodiments, wherein R 3 , R 4 and R 5 are each independently selected from the group consisting of H, methyl, methoxy and bromo.
- R 3 , R 4 and R 5 are each H.
- R 6 and R 7 are each independently selected from the group consisting of H and Cj-C 3 alkyl.
- R 6 and R 7 are each independently selected from the group consisting of H and methyl.
- R 6 and R 7 are both H.
- R 8 and R 9 are each independently selected from the group consisting of H, C 1 -C 3 alkyl, aryl, C 1 -C 3 alkoxy, C 3 -C 7 cycloalkyl, Q-C 3 haloalkyl, halogen and hydroxyl; or R 8 and R 9 taken together form oxo; or
- R 8 and R 9 together with the atom to which they are both bonded form a C 3 -C 7 cycloalkyl ring.
- R 8 and R 9 are each independently selected from the group consisting of H and halogen; or R 8 and R 9 together form oxo.
- R 8 and R 9 are each independently selected from the group consisting of H and F; or
- R 8 and R 9 together form oxo.
- R 8 and R 9 are both H.
- R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, C 1 -C 6 acyloxy, Q-C 6 alkoxy, C 1 -C 6 alkyl, Q-C 6 alkylamino, C 2 -C 8 dialkylamino, C 1 -C 6 alkylcarboxamide, C 1 -C 6 alkylsulfonamide, C 1 -C 6 alkylsulfonyl, amino, carboxamide, carboxy, cyano, C 3 -C 6 cycloalkyl, C 2 -C 6 dialkylcarboxamide, C 1 -C 6 haloalkoxy, Ci-C 6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl, sulfonamide and sulfonic acid; wherein said phenyl group is optionally substituted with 1, 2 or 3 halogens.
- R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, Ci-C 6 alkoxy, C]-C 6 alkyl, C 2 -C 8 dialkylamino, C r C 6 alkylsulfonamide, Ci-C 6 alkylsulfonyl, carboxamide, carboxy, cyano, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid.
- R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, methyl, methoxy, dimethylamino, -NHSO 2 CH 3 , methylsulfonyl, carboxamide, carboxy, cyano, cyclohexyl, fluoro, chloro, trifiuoromethoxy, difluoromethoxy, trifluoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
- R 10 and R 14 are each independently selected from the group consisting of H, C 1 -C 6 alkoxy, carboxy, halogen, C 1 -C 6 haloalkoxy and C]-C 6 haloalkyl;
- R 11 and R 13 are each independently selected from the group consisting of H, C 1 -C 6 alkyl ' , Ci-C 6 alkylsulfonamide, Ci-C 6 alkoxy, carboxamide, C 1 -C 6 haloalkyl, halogen, hydroxyl and nitro; and
- R 12 is selected from the group consisting of H, Ci-C 6 alkoxy, C]-C 6 alkyl, C 2 -C 8 dialkylamino, Ci-C 6 alkylsulfonamide, Cj-C 6 alkylsulfonyl, carboxamide, cyano, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 haloalkyl, halogen, heterocyclyl, heteroaryl, hydroxyl, nitro, phenyl and sulfonic acid.
- R 10 and R 14 are each independently selected from the group consisting of H, methoxy, carboxy, fluoro, chloro and trifluoromethyl;
- R 11 and R 13 are each independently selected from the group consisting of H, methyl, methoxy, -NHSO 2 CH 3 , fluoro, chloro, carboxamide, hydroxyl, trifluoromethyl and nitro;
- R 12 is selected from the group consisting of H, methyl, methoxy, dimethylamino, - NHSO 2 CH 3 , methylsulfonyl, carboxamide, cyano, cyclohexyl, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifluoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
- R 10 , R 12 and R 14 are each independently selected from the group consisting of H and halogen; and R 11 and R 13 are both H.
- R 10 , R 12 and R 14 are each independently selected from the group consisting of H and F;
- R 11 and R 13 are both H. In some embodiments: R 10 and R 12 are both F; and
- R 11 , R 13 and R 14 are each H.
- R 1 and R 2 are each independently selected from the group consisting of H, Cj-C 6 alkyl, aryl, cyano, Q-C 6 haloalkyl and halogen;
- R 3 , R 4 and R 5 are each independently selected from the group consisting of H, C 1 -C 6 alkyl, Ci -6 alkoxy and halogen;
- R 6 and R 7 are each independently selected from the group consisting of H and C 1 -C 3 alkyl;
- R 8 and R 9 are each independently selected from the group consisting of H and halogen; or
- R 8 and R 9 together form oxo
- R 8 and R 9 together with the atom to which they are both bonded form a C 3 -C 7 cycloalkyl ring;
- R 10 , R u , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, C 1 -C 6 alkoxy, C]-C 6 alkyl, C 2 -C 8 dialkylamino, Ci-C 6 alkylsulfonamide, Ci-C 6 alkylsulfonyl, carboxamide, carboxy, cyano, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkoxy, C]-C 6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid.
- R 10 , R u , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, C 1 -C 6 alkoxy, C]-C 6 alkyl, C 2 -C 8 dialkylamino, Ci-C 6 alkylsulfonamide, Ci-C 6 alkylsul
- R 1 is selected from the group consisting of H, Q-C 6 alkyl, aryl and C 1 -C 6 haloalkyl
- R 2 is selected from the group consisting of H, cyano and halogen
- R 3 is selected from the group consisting of H and C 1 -C 6 alkyl
- R 4 is H or halogen; or R 3 and R 4 together with the atoms to which they are both bonded form a heterocyclic ring;
- R 5 is selected from the group consisting of H, C 1 -C 6 alkoxy and C 1 -C 6 alkyl; R 6 and R 7 are both H;
- R 8 and R 9 are each independently selected from the group consisting of H and halogen; or
- R 8 and R 9 together form oxo; and R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, Ci-C 6 alkoxy, Ci-C 6 alkyl, C 2 -C 8 dialkylamino, C]-C 6 alkylsulfonamide, Ci-C 6 alkylsulfonyl, carboxamide, carboxy, cyano, C 3 -C 6 cycloalkyl, Ci-C 6 haloalkoxy, C]-C 6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid.
- R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, Ci-C 6 alkoxy, Ci-C 6 alkyl, C 2 -C 8 dialkylamino, C]-C 6 alkylsulfonamide, Ci-C 6
- R 1 is selected from the group consisting of H, methyl, /-butyl, phenyl and trifluoromethyl;
- R 2 is selected from the group consisting of H, cyano, chloro and bromo;
- R 3 is selected from the group consisting of H and methyl;
- R 4 is H or bromo;
- R 5 is selected from the group consisting of H and methyl
- R 6 and R 7 are both H
- R 8 and R 9 are each independently selected from the group consisting of H and F; or
- R 8 and R 9 together form oxo; and R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of
- Some embodiments of the present invention pertain to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates or hydrates thereof:
- R 1 is selected from the group consisting of H, Ci-C 6 alkyl, aryl and Ci-C 6 haloalkyl
- R 2 is selected from the group consisting of H, cyano and halogen
- R 8 and R 9 are each independently selected from the group consisting of H and halogen; or
- R 12 and R 14 are each independently selected from the group consisting of H and halogen.
- Some embodiments of the present invention pertain to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates or hydrates thereof:
- R 1 is selected from the group consisting of H, methyl, /-butyl, phenyl and trifluoromethyl
- R 2 is selected from the group consisting of H, cyano, chloro and bromo
- R 8 and R 9 are each independently selected from the group consisting of H and F; or R 8 and R 9 together form oxo; and
- R 12 and R 14 are each independently selected from the group consisting of H, fluoro and chloro.
- R 6 and R 7 are each independently selected from the group consisting of H and Ci-C 3 alkyl
- R 8 and R 9 are each independently selected from the group consisting of H and halogen; or
- R 8 and R 9 together form oxo; and R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of
- Some embodiments of the present invention pertain to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates or hydrates thereof:
- R 6 and R 7 are both H; R 8 and R 9 are each independently selected from the group consisting of H and F; or
- R 8 and R 9 together form oxo; and R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from the group consisting of H, methyl, methoxy, dimethylamino, -NHSO 2 CH 3 , methylsulfonyl, carboxamide, carboxy, cyano, cyclohexyl, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifiuoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
- Some embodiments of the present invention include every combination of one or more compounds selected from the following group shown in TABLE A.
- individual compounds and chemical genera of the present invention encompass all pharmaceutically acceptable salts, solvates and particularly hydrates, thereof.
- the compounds of the Formula (Ia) of the present invention may be prepared according to relevant published literature procedures that are used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter in the working Examples. Protection and deprotection may be carried out by procedures generally known in the art (see, for example, Greene, T. W. and Wuts, P. G. M., Protecting Groups in Organic Synthesis, 3 rd Edition, 1999 [Wiley]; incorporated herein by reference in its entirety).
- the present invention embraces each diastereomer, each enantiomer and mixtures thereof of each compound and generic formulae disclosed herein just as if they were each individually disclosed with the specific stereochemical designation for each chiral carbon. Separation of the individual isomers (such as, by chiral HPLC, recrystallization of diastereomeric mixtures and the like) or selective synthesis (such as, by enantiomeric selective syntheses and the like) of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art.
- the normal sleep cycle and sleep architecture can be disrupted by a variety of organic causes as well as environmental influences. According to the International Classification of Sleep Disorders, there are over 80 recognized sleep disorders. Of these, compounds of the present invention are effective, for example, in any one or more of the following sleep disorders (ICSD- International Classification of Sleep Disorders: Diagnostic and Coding Manual. Diagnostic Classification Steering Committee, American Sleep Disorders Association, 1990):
- A. Dyssomnias a. Intrinsic Sleep Disorders: Psychophysiological insomnia, sleep state misperception, idiopathic insomnia, obstructive sleep apnea syndrome, central sleep apnea syndrome, central alveolar hypoventilation syndrome, periodic limb movement disorder, restless leg syndrome and intrinsic sleep disorder NOS (not otherwise specified).
- b. Extrinsic Sleep Disorders Inadequate sleep hygiene, environmental sleep disorder, altitude insomnia, adjustment sleep disorder, insufficient sleep syndrome, limit-setting sleep disorder, sleep onset association disorder, nocturnal eating (drinking) syndrome, hypnotic-dependent sleep disorder, stimulant- dependent sleep disorder, alcohol-dependent sleep disorder, toxin-induced sleep disorder and extrinsic sleep disorder NOS.
- Orcadian Rhythm Sleep Disorders a. Intrinsic Sleep Disorders: Psychological insomnia, sleep state misperception, idiopathic insomnia, obstructive sleep apnea syndrome, central sleep apnea
- Time zone change (jet lag) syndrome shift work sleep disorder, irregular sleep-wake pattern, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24-hour sleep-wake disorder and circadian rhythm sleep disorder NOS.
- Rhythmic movement disorder sleep starts, sleep talking and nocturnal leg cramps.
- Neurological Disorders Cerebral degenerative disorders, dementia, Parkinsonism, fatal familial insomnia, sleep- related epilepsy, electrical status epilepticus of sleep and sleep-related headaches, c. Associated with Other Medical Disorders:
- Sleeping sickness nocturnal cardiac ischemia, chronic obstructive pulmonary disease, sleep-related asthma, sleep-related gastroesophageal reflux, peptic ulcer disease, fibrositis syndrome, osteoarthritis, rheumatoid arthritis, fibromyalgia and post-surgical.
- benzodiazepines The most common class of medications for the maj ority of sleep disorders are the benzodiazepines, but the adverse effect profile of benzodiazepines includes daytime sedation, diminished motor coordination and cognitive impairments. Furthermore, at the National Institutes of Health Consensus Conference on Sleeping Pills and Insomnia in 1984 guidelines were developed discouraging the use of such sedative-hypnotics beyond 4-6 weeks because of concerns raised over drug misuse, dependency, withdrawal and rebound insomnia. Therefore, it is desirable to have a pharmacological agent for the treatment of insomnia, which is more effective and/or has fewer side effects than those currently used. In addition, benzodiazepines are used to induce sleep, but have little to no effect on the maintenance of sleep, sleep consolidation or slow wave sleep.
- Some sleep disorders are sometimes found in conjunction with other conditions and accordingly those conditions are treatable by compounds of Formula (Ia).
- patients suffering from mood disorders typically suffer from a sleep disorder that can be treatable by compounds of Formula (Ia).
- Having one pharmacological agent which treats two or more existing or potential conditions, as does the present invention, is more cost effective, leads to better compliance and has fewer side effects than taking two or more agents.
- NREM sleep comprises two physiological states: Non rapid eye movement (NREM) and rapid eye movement (REM) sleep.
- NREM sleep consists of four stages, each of which is characterized by progressively slower brain wave patterns, with the slower patterns indicating deeper sleep. So called delta sleep, stages 3 and 4 of NREM sleep, is the deepest and most refreshing type of sleep.
- fragmented sleep architecture means an individual, such as a sleep disorder patient, spends the majority of their sleep time in NREM sleep stages 1 and 2, lighter periods of sleep from which the individual can be easily aroused to a waking state by limited external stimuli. As a result, the individual cycles through frequent bouts of light sleep interrupted by frequent awakenings throughout the sleep period.
- Many sleep disorders are characterized by fragmented sleep architecture. For example, many elderly patients with sleep complaints have difficulty achieving long bouts of deep, refreshing sleep (NREM stages 3 and 4) and instead spend the majority of their sleep time in NREM sleep stages 1 and 2.
- the term "sleep consolidation" means a state in which the number of NREM sleep bouts, particularly stages 3 and 4 and the length of those sleep bouts are increased, while the number and length of waking bouts are decreased.
- the sleep architecture of the sleep disorder patient is consolidated to a sleeping state with increased periods of sleep and fewer awakenings during the night. More time is spent in slow wave sleep (stages 3 and 4) with fewer oscillations between stages 1 and 2.
- Compounds of the present invention can be effective in consolidating sleep patterns so that the patient with previously fragmented sleep can now achieve restorative, delta-wave sleep for longer, more consistent periods of time.
- NREM sleep makes up about 75-80% of total sleep time; stage 1 accounting for 2-5% of total sleep time, stage 2 for about 45-50%, stage 3 approximately 3-8% and stage 4 approximately 10-15%.
- stage 1 accounting for 2-5% of total sleep time
- stage 2 for about 45-50%
- stage 3 approximately 3-8%
- stage 4 approximately 10-15%.
- About 90 minutes after sleep onset NREM sleep gives way to the first REM sleep episode of the night.
- REM makes up approximately 20-25% of total sleep time.
- REM sleep is characterized by high pulse, respiration and blood pressure, as well as other physiological patterns similar to those seen in the active waking stage. Hence, REM sleep is also known as "paradoxical sleep.” Sleep onset occurs during NREM sleep and takes 10-20 minutes in healthy young adults.
- the four stages of NREM sleep together with a REM phase form one complete sleep cycle that is repeated throughout the duration of sleep, usually four or five times.
- the cyclical nature of sleep is regular and reliable: a REM period occurs about every 90 minutes during the night. However, the first REM period tends to be the shortest, often lasting less than 10 minutes, whereas the later REM periods may last up to 40 minutes.
- the time between retiring and sleep onset increases and the total amount of night-time sleep decreases because of changes in sleep architecture that impair sleep maintenance as well as sleep quality. Both NREM (particularly stages 3 and 4) and REM sleep are reduced.
- stage 1 NREM sleep which is the lightest sleep, increases with age.
- delta power means a measure of the duration of EEG activity in the 0.5 to 3.5 Hz range during NREM sleep and is thought to be a measure of deeper, more refreshing sleep.
- Delta power is hypothesized to be a measure of a theoretical process called Process S and is thought to be inversely related to the amount of sleep an individual experiences during a given sleep period. Sleep is controlled by homeostatic mechanisms; therefore, the less one sleeps the greater the drive to sleep. It is believed that Process S builds throughout the wake period and is discharged most efficiently during delta power sleep. Delta power is a measure of the magnitude of Process S prior to the sleep period. The longer one stays awake, the greater Process S or drive to sleep and thus the greater the delta power during NREM sleep.
- onset, duration or quality of sleep e.g. non-restorative or restorative sleep
- One method is a subjective determination of the patient, e.g., do they feel drowsy or rested upon waking.
- Other methods involve the observation of the patient by another during sleep, e.g., how long it takes the patient to fall asleep, how many times the patient wakes up during the night, how restless is the patient during sleep, etc.
- Another method is to measure the stages of sleep objectively using polysomnography. Polysomnography is the monitoring of multiple electrophysiological parameters during sleep and generally includes measurement of EEG activity, electrooculographic activity and electromyographic activity, as well as other measurements.
- Stage 1 NREM sleep is a transition from wakefulness to sleep and occupies about 5% of time spent asleep in healthy adults.
- Stage 2 NREM sleep which is characterized by specific EEG waveforms (sleep spindles and K complexes), occupies about 45-50% of time spent asleep.
- Stages 3 and 4 NREM sleep (also known collectively as slow-wave sleep and delta-wave sleep) are the deepest levels of sleep and occupy about 10-20% of sleep time. REM sleep, during which the majority of vivid dreams occur, occupies about 20-25% of total sleep.
- NREM stages 3 and 4 tend to occur in the first one-third to one-half of the night and increase in duration in response to sleep deprivation.
- REM sleep occurs cyclically through the night. Alternating with NREM sleep about every 80-100 minutes. REM sleep periods increase in duration toward the morning. Human sleep also varies characteristically across the life span. After relative stability with large amounts of slow-wave sleep in childhood and early adolescence, sleep continuity and depth deteriorate across the adult age range. This deterioration is reflected by increased wakefulness and stage 1 sleep and decreased stages 3 and 4 sleep.
- the compounds of the invention can be useful for the treatment of the sleep disorders characterized by excessive daytime sleepiness such as narcolepsy. Inverse agonists at the serotonin 5-HT 2A receptor improve the quality of sleep at nighttime which can decrease excessive daytime sleepiness.
- Another aspect of the present invention relates to the therapeutic use of compounds of the present invention for the treatment of sleep disorders.
- Compounds of the present invention are potent inverse agonists at the serotonin 5-HT 2A receptor and can be effective in the treatment of sleep disorders by promoting one or more of the following: reducing the sleep onset latency period (measure of sleep induction), reducing the number of nighttime awakenings and prolonging the amount of time in delta-wave sleep (measure of sleep quality enhancement and sleep consolidation) without effecting REM sleep.
- compounds of the present invention can be effective either as a monotherapy or in combination with sleep inducing agents, for example but not limited to, antihistamines.
- APD125 a potent and selective 5-HT 2A serotonin receptor inverse agonist is a member of the genus disclosed in the European Patent EP1558582.
- APD125 showed vigilance-lowering effects on waking EEG, with maximal effects at 40-80 mg; peak effects were observed at 2-4 h after dosing.
- APD 125 increased slow wave sleep and associated parameters in a dose-dependent manner, primarily during the early part of sleep. These effects occurred at the expense of REM sleep. Sleep onset latency was not decreased by APD 125.
- APD 125 decreased microarousals, the number of sleep stage shifts and number of awakenings after sleep onset.
- APD 125 a 5-HT 2A serotonin receptor inverse agonist, improved parameters of sleep consolidation and maintenance in humans.
- compounds of the present invention also highly selective 5-HT 2A serotonin receptor inverse agonists, will offer similar improvements in sleep parameters.
- Antiplatelet agents are prescribed for a variety of conditions. For example, in coronary artery disease they are used to help prevent myocardial infarction or stroke in patients who are at risk of developing obstructive blood clots (e.g., coronary thrombosis).
- obstructive blood clots e.g., coronary thrombosis
- TIA transient ischemic attack
- mini-stroke a transient ischemic attack
- Angina is a temporary and often recurring chest pain, pressure or discomfort caused by inadequate oxygen-rich blood flow (ischemia) to some parts of the heart.
- ischemia oxygen-rich blood flow
- antiplatelet therapy can reduce the effects of angina and the risk of myocardial infarction.
- Stroke is an event in which the brain does not receive enough oxygen-rich blood, usually due to blockage of a cerebral blood vessel by a blood clot.
- Angioplasty is a catheter-based technique used to open arteries obstructed by a blood clot. Whether or not stenting is performed immediately after this procedure to keep the artery open, antiplatelets can reduce the risk of forming additional blood clots following the procedure(s).
- Coronary bypass surgery is a surgical procedure in which an artery or vein is taken from elsewhere in the body and grafted to a blocked coronary artery, rerouting blood around the blockage and through the newly attached vessel. After the procedure, antiplatelets can reduce the risk of secondary blood clots. Atrial fibrillation is the most common type of sustained irregular heart rhythm
- Atrial fibrillation affects about two million Americans every year.
- the atria the heart's upper chambers
- antiplatelets can reduce the risk of blood clots forming in the heart and traveling to the brain (embolism).
- 5-HT 2A serotonin receptors are expressed on smooth muscle of blood vessels and 5-HT secreted by activated platelets causes vasoconstriction as well as activation of additional platelets during clotting.
- 5-HT 2A inverse agonist will inhibit platelet aggregation and thus be a potential treatment as an antiplatelet therapy (see Satimura, K., et al, Clin. Cardiol. 2002 Jan. 25 (l):28-32; and Wilson, H. C. et al, Thromb. Haemost. 1991 Sep 2;66(3):355-60).
- 5-HT 2A inverse agonists can be used to treat, for example, claudication or peripheral artery disease as well as cardiovascular complications (see Br. Med. J.
- tissue plasminogen activator tPA
- tPA tissue plasminogen activator
- 5-HT 2A inverse antagonists can increase circulating adiponectin in patients, suggesting that they would also be useful in protecting patients against indications that are linked to adiponectin, for example, myocardial ischemia reperfusion injury and atherosclerosis (see Nomura et al, Blood Coagulation and Fibrinolysis 2005, 16, 423-428).
- the 5-HT 2A inverse agonists disclosed herein provide beneficial improvement in microcirculation to patients in need of antiplatelet therapy by antagonizing the vasoconstrictive products of the aggregating platelets in, for example and not limited to the indications described above. Accordingly, in some embodiments, the present invention provides methods for reducing platelet aggregation in a patient in need thereof comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
- the present invention provides methods for treating coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, or a symptom of any of the foregoing in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
- the present invention provides methods for reducing risk of blood clot formation in an angioplasty or coronary bypass surgery patient, or a patient suffering from atrial fibrillation, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein at a time where such risk exists.
- the present invention provides methods for treating asthma in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
- methods for treating a symptom of asthma in a patient in need of the treatment comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
- Alzheimer's disease is a common occurrence in the elderly and is often associated with dementia such as those caused by Alzheimer's disease, Lewy Body, Parkinson's and Huntington's, which are degenerative diseases of the nervous system.
- Diseases that affect blood vessels, such as stroke, or multi-infarct dementia, which is caused by multiple strokes in the brain can also induce agitation.
- Alzheimer's disease accounts for approximately 50 to 70% of all dementias (see Koss E., et al., (1997), Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. l l(suppl 2):S45-S50).
- Alzheimer's dementia See Katz, I. R., et al., J. Clin. Psychiatry 1999 Feb., 60(2): 107-115; and Street, J. S., et al.,Arch. Gen. Psychiatry 2000 Oct., 57(10):968-976).
- the present invention provides methods for treating agitation in a patient in need of such treatment comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
- the agitation is due to a psychiatric disorder other than dementia.
- the present invention provides methods for treatment of agitation or a symptom thereof in a patient suffering from dementia comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
- the dementia is due to a degenerative disease of the nervous system, for example and without limitation, Alzheimer's disease, Lewy Body, Parkinson's disease and Huntington's disease, or dementia due to diseases that affect blood vessels, including, without limitation, stroke and multi-infarct dementia.
- methods are provided for treating agitation or a symptom thereof in a patient in need of such treatment, where the patient is a cognitively intact elderly patient, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
- Schizophrenia is a psychopathic disorder of unknown origin, which usually appears for the first time in early adulthood and is marked by a number of characteristics, psychotic symptoms, progression, phasic development and deterioration in social behavior and professional capability in the region below the highest level ever attained.
- Characteristic psychotic symptoms are disorders of thought content (multiple, fragmentary, incoherent, implausible or simply delusional contents or ideas of doctrine) and of mentality (loss of association, flight of imagination, incoherence up to incomprehensibility), as well as disorders of perceptibility (hallucinations), of emotions (superficial or inadequate emotions), of self-perception, of intentions and impulses, of interhuman relationships and finally psychomotor ⁇ disorders (such as catatonia). Other symptoms are also associated with this disorder: see, American Statistical and Diagnostic Handbook. Haloperidol (Haldol) is a potent dopamine D 2 receptor antagonist. It is widely prescribed for acute schizophrenic symptoms and is very effective for the positive symptoms of schizophrenia.
- Haldol is not effective for the negative symptoms of schizophrenia and may actually induce negative symptoms as well as cognitive dysfunction.
- administering a 5-HT 2A inverse agonist concomitantly with Haldol will provide benefits including the ability to use a lower dose of Haldol without losing its effects on positive symptoms, while reducing or eliminating its inductive effects on negative symptoms and prolonging relapse to the patient's next schizophrenic event.
- Haloperidol is used for treatment of a variety of behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorders, psychosis (organic and NOS), psychotic disorder, psychosis, schizophrenia (acute, chronic and NOS). Further uses include in the treatment of infantile autism, Huntington's chorea and nausea and vomiting from chemotherapy and chemotherapeutic antibodies. Administration of 5-HT 2A inverse agonists disclosed herein with haloperidol also will provide benefits in these indications.
- the present invention provides methods for treating a behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorders, psychosis (organic and NOS), psychotic disorder, psychosis, schizophrenia (acute, chronic and NOS) comprising administering to the patient a dopamine D 2 receptor antagonist and a 5-HT 2A inverse agonist disclosed herein.
- the present invention provides methods for treating a behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorders, psychosis (organic and NOS), psychotic disorder, psychosis, schizophrenia (acute, chronic and NOS) comprising administering to the patient haloperidol and a 5-HT 2A inverse agonist disclosed herein.
- the present invention provides methods for treating infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies comprising administering to the patient a dopamine D 2 receptor antagonist and a 5-HT 2A inverse agonist disclosed herein.
- the present invention provides methods for treating infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies comprising administering to the patient haloperidol and a 5-HT 2A inverse agonist disclosed herein.
- the present invention provides methods for treating schizophrenia in a patient in need of the treatment comprising administering to the patient a dopamine D 2 receptor antagonist and a 5-HT 2A inverse agonist disclosed herein.
- the dopamine D 2 receptor antagonist is haloperidol.
- the administration of the dopamine D 2 receptor antagonist can be concomitant with administration of the 5-HT 2A inverse agonist, or they can be administered at different times. Those of skill in the art will easily be able to determine appropriate dosing regimes for the most efficacious reduction or elimination of deleterious haloperidol effects.
- haloperidol and the 5-HT 2A inverse agonist are administered in a single dosage form and in other embodiments, they are administered in separate dosage forms.
- the present invention further provides methods of alleviating negative symptoms of schizophrenia induced by the administration of haloperidol to a patient suffering from schizophrenia, comprising administering to the patient a 5-HT 2A inverse agonist as disclosed herein.
- DPN diabetic peripheral neuropathy
- DN diabetic nephropathy
- DR diabetic retinopathy
- Serotonin is believed to play a role in vasospasm and increased platelet aggregability. Improving microvascular blood flow is beneficial to diabetic complications.
- sarpogrelate was evaluated for the prevention of the development or progression of diabetic nephropathy (Takahashi, T., et al., Diabetes. Res. Clin. Pr act. 2002 Nov; 58(2): 123-9). In the trial of 24 months of treatment, sarpogrelate significantly reduced urinary albumin excretion level.
- Topical ocular administration of 5-HT 2 receptor antagonists result in a decrease in intra ocular pressure (IOP) in monkeys (Chang et al., J. Ocul. Pharmacol. 1:137-147 (1985)) and humans (Mastropasqua et al., Acta. Ophthalmol. Scand. Suppl. 224:24-25 (1997)) indicating utility for similar compounds such as 5 -HT 2 A inverse agonists in the treatment of ocular hypertension associated with glaucoma.
- the 5-HT 2 receptor antagonist ketanserin (Mastropasqua supra) and sarpogrelate (Takenaka et al., Investig. Ophthalmol. Vis. ScL 36:S734 (1995)) have been shown to significantly lower IOP in glaucoma patients.
- Progressive multifocal leukoencephalopathy is a lethal demyelinating disease caused by an opportunistic viral infection of oligodendrocytes in immunocompromised patients.
- the causative agent is JC virus, a ubiquitous papovavirus that infects the majority of the population before adulthood and establishes a latent infection in the kidney.
- JC virus a ubiquitous papovavirus that infects the majority of the population before adulthood and establishes a latent infection in the kidney.
- the virus can reactivate and productively infect oligodendrocytes. This previously rare condition, until 1984 reported primarily in persons with underlying lymphoproliferative disorders, is now more common because it occurs in 4% of patients with AIDS.
- JC virus enters cells by receptor-mediated clathrin-dependent endocytosis. Binding of JC virus to human glial cells (e.g., oligodendrocytes) induces an intracellular signal that is critical for entry and infection by a ligand-inducible clathrin-dependent mechanism [Querbes et al., J. Virology (2004) 78:250-256]. Recently, 5-HT 2A was shown to be the receptor on human glial cells mediating infectious entry of JC virus by clathrin-dependent endocytosis [Elphick et al., Science (2004) 306:1380-1383]. 5-HT 2A antagonists, including ketanserin and ritanserin, inhibited JC virus infection of human glial cells. Ketanserin and ritanserin have inverse agonist activity at 5- HT 2A .
- 5-HT 2A antagonists including inverse agonists have been contemplated to be useful in the treatment of PML [Elphick et al, Science (2004) 306: 1380-1383].
- Prophylactic treatment of HrV-infected patients with 5-HT 2A antagonists is envisioned to prevent the spread of JC virus to the central nervous system and the development of PML.
- Aggressive therapeutic treatment of patients with PML is envisioned to reduce viral spread within the central nervous system and prevent additional episodes of demyelination.
- One aspect of the present invention encompasses methods for the treatment of progressive multifocal leukoencephalopathy in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
- the individual in need thereof has a lymphoproliferative disorder.
- the lymphoproliferative disorder is leukemia or lymphoma.
- the leukemia or lymphoma is chronic lymphocytic leukemia, Hodgkin's disease, or the like.
- the individual in need thereof has a myeloproliferative disorder.
- the individual in need thereof has carcinomatosis.
- the individual in need thereof has a granulomatous or inflammatory disease.
- the granulomatous or inflammatory disease is tuberculosis or sarcoidosis.
- the individual in need thereof is immunocompromised.
- the immunocompromised individual has impaired cellular immunity.
- the impaired cellular immunity comprises impaired T-cell immunity.
- the individual in need thereof is infected with HIV.
- the HIV-infected individual has a CD4+ cell count of ⁇ 200/mm 3 .
- the HIV-infected individual has AIDS.
- the HIV-infected individual has AIDS-related complex (ARC).
- ARC is defined as the presence of two successive CD4+ cell counts below 200/mm 3 and at least two of the following signs or symptoms: oral hairy leukoplakia, recurrent oral candidiasis, weight loss of at least 15 Ib or 10% of body weight within last six months, multidermatomal herpes zoster, temperature above 38.5 0 C for more than 14 consecutive days or more than 15 days in a 30-day period, or diarrhea with more than three liquid stools per day for at least 30 days [see, e.g., Yamada et al., Clin. Diagn. Virol. (1993) 1:245-256].
- the individual in need thereof is undergoing immunosuppressive therapy.
- the immunosuppressive therapy comprises administering an immunosuppressive agent [see, e.g., Mueller, Ann. Thorac. Surg. (2004) 77:354-362; and Krieger and Emre, Pediatr. Transplantation (2004) 8:594-599].
- the immunosuppressive therapy comprises administering an immunosuppressive agent selected from the group consisting of: corticosteroids (for example, prednisone and the like), calcineurin inhibitors (for example, cyclosporine, tacrolimus and the like), antiproliferative agents (for example, azathioprine, mycophenolate mofetil, sirolimus, everolimus and the like), T-cell depleting agents (for example, OKT ® 3 monoclonal antibody (mAb), anti-CD3 immunotoxin FN18-CRM9, Campath-1H (anti-CD52) mAb, anti-CD4 mAb, anti-T cell receptor mAb and the like), anti-DL-2 receptor (CD25) mAb (for example, basiliximab, daclizumab and the like), inhibitors of co-stimulation (for example, CTLA4-Ig, anti-CD 154 (CD40 ligand) mAb and the like), deoxyspermine, cortic
- the immunosuppressive agent and said compound or pharmaceutical composition are administered in separate dosage forms. In some embodiments, the immunosuppressive agent and said compound or pharmaceutical composition are administered in a single dosage form. In some embodiments, the individual in need thereof is undergoing immunosuppressive therapy after organ transplantation. In some embodiments, the organ is liver, kidney, lung, heart, or the like [see, e.g., Singh et al, Transplantation (2000) 69:467-472].
- the individual in need thereof is undergoing treatment for a rheumatic disease.
- the rheumatic disease is systemic lupus erythematosus or the like.
- the compound or the pharmaceutical composition inhibits JC virus infection of human glial cells
- Ketanserin a 5-HT 2A inverse agonist, have been demonstrated to protect against circulatory shocks, intracranial hypertension and cerebral ischemia during heatstroke (Chang, C. et al., Shock 24(4): 336-340 2005); and to stabilize blood pressure in spontaneously hypertensive rats (Miao, C. Clin. Exp. Pharmacol. Physiol.
- Mainserin a 5-HT 2A inverse agonist, has been shown to prevent DOCA-salt induced hypertension in rats (Silva, A. Eur, J. Pharmacol. 518(2-3): 152-7 2005).
- 5-HT 2A inverse agonists are also effective for the treatment of pain.
- Sarpogrelate has been observed to provide a significant analgesic effect both on thermal induced pain in rats after intraperitoneal administration and on inflammatory pain in rats after either intrathecal or intraperitoneal administration (Nishiyama, T. Eur. J. Pharmacol. 516: 18-22 2005).
- This same 5-HT 2A inverse agonist in humans has been shown to be an effective treatment for lower back pain, leg pain and numbness associated with sciatica brought on by lumbar disc herniation (Kanayama, M. et al., J. Neurosurg.: Spine 2:441-446 2005).
- a further aspect of the present invention pertains to pharmaceutical compositions comprising one or more compounds as described herein and one or more pharmaceutically acceptable carriers.
- Some embodiments pertain to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
- Some embodiments of the present invention include a method of producing a pharmaceutical composition comprising admixing at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.
- Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, forming the resulting mixture into a desired shape.
- Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions and syrups.
- the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives and flavorings and colorants may be added to the liquid preparations.
- Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.
- a compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art.
- Suitable pharmaceutically- acceptable carriers outside those mentioned herein, are known in the art; for example, see Remington, The Science and Practice of Pharmacy, 20 th Edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.) While it is possible that, for use in the prophylaxis or treatment, a compound of the invention may, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.
- the invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, hydrate or derivative thereof together with one or more pharmaceutically acceptable carriers thereof and/or prophylactic ingredients.
- the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
- Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation, insufflation or by a transdermal patch.
- Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in an efficient manner with a minimum of degradation of the drug.
- transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner.
- the compounds of the invention may thus be placed into the form of pharmaceutical formulations and unit dosages thereof and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
- Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid.
- the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
- dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate.
- the active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.
- active ingredient is defined in the context of a "pharmaceutical composition” and is intended to mean a component of a pharmaceutical composition that provides the primary pharmacological effect, as opposed to an "inactive ingredient” which would generally be recognized as providing no pharmaceutical benefit.
- the dose when using the compounds of the present invention can vary within wide limits and as is customary and is known to the physician, it is to be tailored to the individual conditions in each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the present invention.
- Representative doses of the present invention include, but not limited to, about 0.001 mg to about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to about 1000 mg, 0.001 mg to about 500 mg, 0.001 mg to about 250 mg, about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg and about 0.001 mg to about 25 mg.
- Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or 4 doses. Depending on the individual and as deemed appropriate from the patient's physician or caregiver it may be necessary to deviate upward or downward from the doses described herein.
- the amount of active ingredient, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician, hi general, one skilled in the art understands how to extrapolate in vivo data obtained in a model system, typically an animal model, to another, such as a human. In some circumstances, these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors.
- compositions of this invention are selected in accordance with a variety factors as cited above.
- the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
- the daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4 part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
- the compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt, solvate or hydrate of a compound of the invention.
- a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible granules.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desire shape and size.
- the powders and tablets may contain varying percentage amounts of the active compound. A representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active compound; however, an artisan would know when amounts outside of this range are necessary.
- Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter and the like.
- preparation is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
- carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets and lozenges can be used as solid forms suitable for oral administration.
- a low melting wax such as an admixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogenous mixture is then poured into convenient sized molds, allowed to cool and thereby to solidify.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Liquid form preparations include solutions, suspensions and emulsions, for example, water or water-propylene glycol solutions.
- parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
- injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- a nontoxic parenterally acceptable diluent or solvent for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di glycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the compounds according to the present invention may thus be formulated for parenteral administration (e.g.
- compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
- Aqueous formulations suitable for oral use can be prepared by dissolving or suspending the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents, as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
- viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like.
- the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
- Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
- the formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
- Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant.
- the compounds of the present invention or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler.
- Pharmaceutical forms for administration of the compounds of the present invention as an aerosol can be prepared by processes well known to the person skilled in the art.
- solutions or dispersions of the compounds of the present invention in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others and, if appropriate, customary propellants, for example include carbon dioxide, CFCs, such as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like.
- the aerosol may conveniently also contain a surfactant such as lecithin.
- the dose of drug may be controlled by provision of a metered valve.
- the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
- the active ingredients may be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrrolidone
- the powder carrier will form a gel in the nasal cavity.
- the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g. , gelatin, or blister packs from which the powder may be administered by means of an inhaler.
- the pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
- the compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
- Representative acids include, but are not limited to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippu ⁇ c, hydrobromic, hydrochloric, lsethiomc, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phospho ⁇ c, succinic, sulfi ⁇ c, tartaric, oxalic, p-toluenesulfomc and the like, such as those pharmaceutically acceptable salts listed in Journal of Pharmaceutical Sciences, 66:1-19 (1977), incorporated herein by reference in its entirety
- the acid addition salts may be obtained as the direct products of compound synthesis.
- the free base may be dissolved in a suitable solvent containing the appropnate acid and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
- the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
- Pro-drugs refers to compounds that have been modified with specific chemical groups known in the art and when administered into an individual these groups undergo biotransformation to give the parent compound. Pro-drugs can thus be viewed as compounds of the invention containing one or more specialized non-toxic protective groups used in a transient manner to alter or to eliminate a property of the compound. In one general aspect, the "pro-drug” approach is utilized to facilitate oral absorption.
- T. Higuchi and V. Stella Prodrugs as Novel Delivery Systems Vol. 14 of the A.C.S. Symposium Se ⁇ es; and m Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety
- Some embodiments of the present invention include a method of producing a pharmaceutical composition for "combination-therapy" comprising admixing at least one compound according to any of the compound embodiments disclosed herein, together with at least one known pharmaceutical agent as desc ⁇ bed herein and a pharmaceutically acceptable earner.
- 5-HT 2A serotonin receptor modulators are utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of active agents, such as 5-HT 2A serotonin receptor modulators, for the treatment of a 5-HT 2A -associated disease or disorder in companionship animals (e g , cats, dogs, etc ) and in livestock animals (e g , cows, chickens, fish, etc ) Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.
- active agents such as 5-HT 2A serotonin receptor modulators
- Another object of the present invention relates to radio-labeled compounds of the present invention that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the 5-HT 2A serotonin receptor in tissue samples, including human and for identifying 5-HT 2A serotonin receptor ligands by inhibition binding of a radio-labeled compound. It is a further object of this invention to develop novel 5-HT 2A - receptor assays of which comprise such radio-labeled compounds.
- the present invention embraces isotopically-labeled compounds of the present invention.
- Isotopically or radio-labeled compounds are those which are identical to compounds disclosed herein, but for the fact that one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature.
- Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 Cl, 75 Br, 76 Br, 77 Br, 82 Br, 123 1, 124 1, 125 I and 131 I.
- radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro 5-HT 2A serotonin receptor labeling and competition assays, compounds that incorporate 3 H, 14 C, 82 Br, 125 1, 131 I or 35 S will generally be most useful. For radio-imaging applications 11 C, 18 F, 125 1, 123 1, 124 1, 131 1, 75 Br, 76 Br or 77 Br will generally be most useful.
- a “radio-labeled” or “labeled compound” is a compound of Formula (Ia), (Ic) or (Ie) that has incorporated at least one radionuclide; in some embodiments the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1 , 35 S and 82 Br.
- isotopically-labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays.
- the radionuclide 3 H and/or 14 C isotopes are useful in these studies.
- substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Drawings and Examples infra, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art. These synthetic methods, for example, incorporating activity levels of tritium into target molecules, are as follows: A. Catalytic Reduction with Tritium Gas: This procedure normally yields high specific activity products and requires halogenated or unsaturated precursors.
- Tritium Gas Exposure Labeling This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst.
- A. Sandmeyer and like reactions This procedure transforms an aryl amine or a heteroaryl amine into a diazonium salt, such as a diazonium tetrafluoroborate salt and subsequently to 125 I labeled compound using Na 125 I.
- a represented procedure was reported by Zhu, G-D. and co-workers in J. Org. Chem., 2002, 67, 943-948.
- B. Ortho 125 Iodination of phenols This procedure allows for the incorporation of 125 I at the ortho position of a phenol as reported by Collier, T. L. and co-workers in J. Labelled Compd. Radiopharm., 1999, 42, S264-S266.
- Aryl and heteroaryl bromide exchange with 125 I This method is generally a two step process.
- the first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, a Pd catalyzed reaction [i.e. Pd(Ph 3 P) 4 ] or through an aryl or heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g., (CH 3 ) 3 SnSn(CH 3 ) 3 ].
- Pd catalyzed reaction i.e. Pd(Ph 3 P) 4
- a tri-alkyltinhalide or hexaalkylditin e.g., (CH 3 ) 3 SnSn(CH 3 ) 3 ].
- a radiolabeled 5-HT 2A serotonin receptor compound of Formula (Ia) can be used in a screening assay to identify/evaluate compounds.
- a newly synthesized or identified compound i.e., test compound
- test compound can be evaluated for its ability to reduce binding of the "radio-labeled compound of Formula (Ia)" to the 5-HT 2A -receptor.
- the ability of a test compound to compete with the "radio-labeled compound of Formula (Ia)" for the binding to the 5-HT 2A serotonin receptor directly correlates to its binding affinity.
- the labeled compounds of the present invention bind to the 5-HT 2A serotonin receptor.
- the labeled compound has an IC 50 less than about 500 ⁇ M, in another embodiment the labeled compound has an IC 50 less than about 100 ⁇ M, in yet another embodiment the labeled compound has an IC 50 less than about 10 ⁇ M, in yet another embodiment the labeled compound has an IC 50 less than about 1 ⁇ M and in still yet another embodiment the labeled inhibitor has an IC 50 less than about 0.1 ⁇ M.
- Example 1.1 Preparation of (3-Bromoimidazo[l,2- ⁇ ]pyridin-8-yl)(4-(2,4- difluorophenethyl)piperazin-l-yl)methanone (Compound 1).
- Step A Preparation of Imidazo[l,2- ⁇ ]pyridine-8-carboxylic Acid.
- Step C Preparation of (3-Bromoimidazo[l,2- ⁇ ]pyridin-8-yl)(4-(2,4- difluorophenethyl)piperazin-l-yl)methanone (Compound 9).
- l-(2,4-Difiuorophenethyl)piperazine hydrochloride (84 mg, 0.28 mmol) was added to a solution of 3-bromoimidazo[l,2- ⁇ ]pyridine-8-carboxylic acid (68 mg, 0.28 mmol), 2-(3H- [1 ,2,3]triazolo[4,5-6]pyridin-3-yl)-l , 1 ,3,3-tetramethylisouronium hexafluorophosphate ( ⁇ ATU) (138 mg, 364 ⁇ mol) and triethylamine (117 ⁇ L, 840 ⁇ mol) in T ⁇ F (2.7 mL).
- Example 1.3 Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 3).
- Step A Preparation of Imidazo[l,2- ⁇ ]pyridine-8-carboxylic Acid.
- Step B Preparation of terf-Butyl 4-(2-(2,4-difluorophenyl)acetyl)piperazine-l- carboxylate.
- 2-(2,4-Difluorophenyl)acetic acid (5.00 g, 29.1 mmol), lH-benzo[d][l,2,3]triazol-l-ol (4.46 g, 29.1 mmol), N 1 -((ethylimino)methylene)-N 3 y /V 3 -dimethylpropane-l,3-diamine hydrochloride (EDAC) (5.57 g, 29.1 mmol) and triethylamine (4.05 mL, 29.1 mmol) were stirred in DCM (30 mL) for 15 min.
- EDAC N 1 -((ethylimino)methylene)-N 3 y /V 3 -dimethylpropane-l,3-diamine hydrochloride
- Step C Preparation of tert-Butyl 4-(2,4-Difluorophenethyl)piperazine-l- carboxylate.
- tert-Butyl 4-(2-(2,4-difluorophenyl)acetyl)piperazine-l-carboxylate (1.12 g, 3.30 mmol) was dissolved in THF (8.5 mL) and borane tetrahydrofuran complex (1.0 M, 15.8 mL, 15.8 mmol) was added. The reaction was refluxed at 66 0 C. The reaction was quenched slowly with methanol (0.4 mL) dropwise.
- Step D Preparation of l-(2,4-Difluorophenethyl)piperazine.
- tert-Butyl 4-(2,4-difluorophenethyl)piperazine-l-carboxylate (0.853 g, 2.61 mmol) was dissolved in 4 M HCl in dioxane (10.0 mL) and stirred for 1 h. The reaction was concentrated to afford the hydrochloride salt of the title compound (0.718 g) as a pale solid.
- Exact mass calculated for C 12 H 16 F 2 N 2 : 226.1. Found: LCMS mlz 227.2 (M + H) + .
- Step E Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 3).
- Example 1.4 Preparation of l-(4-FIuorophenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 4).
- Step A Preparation of tert-Butyl 4-(2-(4-Fluorophenyl)-2-oxoethyl)piperazine-l- carboxylate.
- tert-Butyl piperazine-1-carboxylate (5.00 g, 26.8 mmol) and 2-bromo-l-(4- fluorophenyl)ethanone (6.99 g, 32.2 mmol) were dissolved in DMF (5 mL) and stirred for 10 min at room temperature.
- the crude material was purified by column chromatography eluting with a mixture of DCM and MeOH to afford the title compound (3.50 g) as an oil.
- Step B Preparation of l-(4-Fluorophenyl)-2-(piperazin-l-yl)ethanone.
- the oil from Step A was dissolved in 4 M HCl in dioxane (12 mL) and stirred at 45 0 C for 20 min. The solvent was removed under reduced pressure to afford the hydrochloride salt of the title compound (1.80 g) as a white solid.
- Exact mass calculated for Ci 2 H 15 FN 2 O: 222.1. Found: LCMS mlz 223.3 (M + H) + .
- Step C Preparation of l-(4-Fluorophenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 4).
- Step A Preparation of te/t-Butyl 4-(4-fluorophenethyl)piperazine-l-carboxylate.
- fert-Butyl piperazine-1 -carboxylate (1.00 g, 5.37 mmol) was dissolved in DMF (20 mL).
- l-(2-Bromoethyl)-4-fluorobenzene (2.62 g, 12.9 mmol)
- potassium carbonate 2.23 g, 16.1 mmol
- Step B Preparation of l-(4-Fluorophenethyl)piperazine. tert-Butyl 4-(4-fluorophenethyl)piperazine-l -carboxylate (1.65 g, 5.37 mmol) and 4 M HCl in dioxane (6 mL) were stirred at 43 0 C for 1 h.
- Step C Preparation of (4-(4-FluorophenethyI)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 5).
- Step B Preparation of Methyl 2-Trifluoromethyl-imidazo[l,2- ⁇ ]pyridine-8- carboxylate. To a solution of methyl 2-aminonicotinate (0.304 g) in acetonitrile (10 mL) was added
- Step C Preparation of 2-Trifluoromethyl-imidazo[l,2- ⁇ ]pyridine-8-carboxyIic Acid.
- Step D Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2- (trifluoromethyl)imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 6).
- the title compound was prepared in a manner similar to that described in Example 1.3,
- Step E using 2-trifluoromethyl-imidazo[l,2-a]pyridine-8-carboxylic acid (34.5 mg) and l-(4- fluorophenethyl)-piperazine hydrochloride (28.2 mg) as starting materials, to afford a clear oil (12.8 mg).
- Exact mass calculated for C 2I H 20 F 4 N 4 O: 420.16. Found: LCMS mlz 421.3 (M + H) + .
- Step A Preparation of Methyl 2-tert-Butyl-imidazo[l,2- ⁇ ]pyridine-8-carboxylate.
- Step B Preparation of 2-ferr-Butyl-imidazo[l,2- ⁇ ]pyridine-8-carboxylic Acid.
- Step C Preparation of (2-terf-Butylimidazo[l,2- ⁇ ]pyridin-8-yI)(4-(4- fluorophenethyl)piperazin-l-yl)methanone (Compound 7).
- the title compound was prepared in a manner similar to that described in Example 1.3,
- Step E using 2-ter/-butyl-imidazo[l,2- ⁇ ]pyridine-8-carboxylic acid (32.7 mg) and l-(4- fluorophenethyl)-piperazine hydrochloride (28.2 mg) as starting materials, to afford a clear oil (12.8 mg).
- Exact mass calculated for C 24 H 29 FN 4 O: 408.23. Found: LCMS mlz 409.5 (M + H) + .
- Example 1.8 Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2-methylimidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 8).
- Step A Preparation of Methyl 2-Methyl-imidazo[l,2- ⁇ ]pyridine-8-carboxylate.
- Step C Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2-methylimidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 8).
- Step A Preparation of Methyl 2-Phenyl-imidazo[l,2- ⁇ ]pyridine-8-carboxylate.
- Step B Preparation of 2-Phenyl-imidazo[l,2- ⁇ ]pyridine-8-carboxylic Acid, Sodium Salt.
- the title compound was prepared in a manner similar to that described in Example 1.8,
- Step B using methyl 2-phenyl-imidazo[l,2- ⁇ ]pyridine-8-carboxylate (0.310 g) as starting material, to afford a white solid (0.320 g).
- Step C Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2-phenylimidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 9).
- Example 1.10 Preparation of (4-(2-Fluoro-2-(4-fluorophenyl)ethyl)piperazin-l- yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 10).
- Step A Preparation of tert-Butyl 4-(l-Fluoro-2-(4-fluorophenyl)ethyl)piperazine-l- carboxylate.
- l-(2-Bromo-l-fluoroethyl)-4-fluorobenzene (334 mg, 1.511 mmol), prepared as described by Schlosser et al, Tetrahedron 60, 2004, 7731-7742, was dissolved in DMF (1.5 mL).
- Acetyl chloride (0.152 mL, 2.145 mmol) was added dropwise to ice cold methanol (4 mL) while stirring vigorously. After the addition was complete, the ice bath was removed and the solution was stirred at room temperature. After 15 min, the solution was transferred to a flask containing tert-buty ⁇ 4-(2-fluoro-2-(4-fluorophenyl)ethyl)piperazine-l-carboxylate (140 mg, 0.429 mmol) and the mixture was stirred at room temperature for 4 h.
- Step C Preparation of (4-(2-Fluoro-2-(4-fluorophenyl)ethyl)piperazin-l- yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 10).
- Example 1.12 Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone Hydrochloride Salt (Compound 3).
- Step A Preparation of Imidazo[l,2- ⁇ ]pyridine-8-carboxylic Acid Hydrochloride.
- Step B Preparation of Imidazo[l,2- ⁇ ]pyridine-2-carbonyl chloride Hydrochloride.
- Method 1 To imidazo[l,2- ⁇ ]pyridine-8-carboxylic acid hydrochloride (10.0 g, 50.4 mmol), thionyl chloride (98 g, 60 mL, 822 mmol) was added. To the resulting mixture N,N- dimethylformamide (1.6 mL) was added. Gas evolution was noticed and the reaction mixture was heated to 50 0 C overnight (18 h).
- Step D Preparation of l-(2,4-Difluorophenethyl)piperazine Hydrochloride.
- Step E Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone.
- l-(2,4-Difluorophenethyl) piperazine hydrochloride 13.0 g , 43.45 mmol
- acetonitrile 130 mL
- diisopropylethylamine (23.1 g, 179 mmol) was added with cooling in an ice-bath to keep the temperature below 20 0 C during addition.
- the reaction mixture slowly became homogenous.
- Step A Preparation of tert-Butyl 4-(imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazine- 1-carboxylate.
- Step B Preparation of Imidazo[l,2- ⁇ ]pyridin-8-yl(piperazin-l-yl)methanone Hydrochloride Salt.
- tert-Butyl 4-(imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazine-l-carboxylate (1.25 g, 3.78 mmol) and 4 M HCl in dioxane (15 mL) were stirred at 43 0 C for 30 min. The precipitate was filtered, washed with hexane and dried under reduced pressure to afford the HCl salt of the title compound as a solid (980 mg).
- Example 1.14 Preparation of (4-(3,4-Dimethoxyphenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 13).
- Example 1.15 Preparation of (4-(3-Fluorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 14).
- Example 1.16 Preparation of (4-(4-Chlorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl) ⁇ iethanone (Compound 15).
- Example 1.17 Preparation of (4-(3-ChIorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 16).
- Example 1.20 Preparation of (4-(2,4-Dichlorophenethyl)piperazin-l-yl)(imidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 19).
- Example 1.21 Preparation of l-(2,4-Difluorophenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 20).
- Example 1.22 Preparation of l-(Biphenyl-4-yl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 25).
- Example 1.23 Preparation of l-(4-HydroxyphenyI)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 40).
- Example 1.25 Preparation of l-(4-(Dimethylamino)phenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine- 8-carbonyl)piperazin-l-yl)ethanone (Compound 41).
- Example 1.28 Preparation of l-(4-Cyclohexylphenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 28).
- Example 1.30 Preparation of l-(4-(Difluoromethoxy)phenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 29).
- Example 1.33 Preparation of l-(4-Chloro-2-fluoro-5-methylphenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 31).
- Example 1.34 Preparation of l-(5-Chloro-2-methoxy-4-methylphenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 32).
- Example 1.36 Preparation of l-(2-Chloro-5-(trifluoromethyl)phenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 24).
- Example 1.37 Preparation of l-(3,5-Bis(trifluoromethyl)phenyl)-2-(4-(imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 33).
- Example 1.41 Preparation of l-(5-Chloro-2-methoxy-4-methyl-3-nitrophenyl)-2-(4- (imidazo[l,2- ⁇ ]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 42).
- Step A Preparation of 6-Bromoimidazo[l,2- ⁇ ]pyridine-8-carboxylic acid.
- Example 1.43 Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(5,7- dimethylimidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 27).
- Step A Preparation of 5,7-Dimethylimidazo [l,2- ⁇ ]pyridine-8-carboxylic Acid.
- Step B Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(5,7- dimethylimidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 27).
- Step A Preparation of 7-Methoxyimidazo[l,2- ⁇ ]pyridine-8-carbonitrile.
- Step C Preparation of (4-(2,4-difluorophenethyl)piperazin-l-yl)(7- methoxyimidazo[l,2- ⁇ ]pyridin-8-yl)methanone (Compound 36).
- the vector utilized be pCMV.
- This vector was deposited with the American Type Culture Collection (ATCC) on October 13, 1998 (10801 University Boulevard., Manassas, VA 20110-2209 USA) under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure. The DNA was tested by the ATCC and determined to be viable. The ATCC has assigned the following deposit number to pCMV: ATCC #203351.
- HEK293 cells were transfected while for the DOI binding assay (Example 3) COS7 cells were transfected.
- Several protocols well known in the art can be used to transfect cells. The following protocol is representative of the transfection procedures used herein for COS7 or 293 cells.
- COS-7 cells were plated onto 24 well plates, usually 1 x 10 5 cells/well or 2 x 10 5 cells/well, respectively.
- the cells were transfected by first mixing 0.25 ⁇ g cDNA in 50 ⁇ L serum-free DMEM/well and then 2 ⁇ L lipofectamine in 50 ⁇ L serum-free
- transfection media The solutions (“transfection media”) were gently mixed and incubated for 15-30 min at room temperature. The cells were washed with 0.5 mL PBS and then 400 ⁇ L of serum free medium was mixed with the transfection media and added to the cells. The cells were then incubated for 3-4 hours at 37 °C/5% CO 2 . Then the transfection medium was removed and replaced with 1 mL/well of regular growth medium.
- COS7 cells transfected with recombinant human 5-HT 2A serotonin receptors were cultured for 48 h post transfection, collected, washed with ice-cold phosphate buffered saline, pH 7.4 (PBS) and then centrifuged at 48,000 g for 20 min at 4 0 C. The cell pellet was then resuspended in wash buffer containing 20 mM HEPES, pH 7.4 and 0.1 mM EDTA, homogenized on ice using a Brinkman polytron and recentrifuged at 48,000 g for 20 min at 4 0 C.
- PBS phosphate buffered saline
- the resultant pellet was then resuspended in 20 mM HEPES, pH 7.4, homogenized on ice and centrifuged (48,000 g for 20 min at 4 0 C). Crude membrane pellets were stored at -80 0 C until used for radioligand binding assays.
- Radioligand binding assays for human 5-HT 2A serotonin receptor were conducted using the 5-HT 2 agonist [ 125 I]DOI as radioligand. To define nonspecific binding, 10 ⁇ M DOI was used for all assays. For competitive binding studies, 0.5 nM [ 125 I]DOI was used and compounds were assayed over a range of 0.01 nM to 10 ⁇ M.
- Assays were conducted in a total volume of ⁇ 200 ⁇ l in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl 2 and 10 ⁇ M pargyline). Assay incubations were performed for 60 min at room temperature and were terminated by rapid filtration under reduced pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvester. Filters were then washed several times with ice-cold wash buffer (50 mM Tris- HCl, pH 7.4). Plates were then dried at room temperature and counted in a Wallac MicroBeta scintillation counter. Certain compounds of the present invention and their corresponding activity values are shown in TABLE B.
- Certain other compounds of the invention had activity values ranging from about 10 ⁇ M to about 1 nM in this assay.
- Example 4 In vitro Human Platelet Aggregation Assays.
- Human blood (-100 mL) was collected from human donors into glass Vacutainers containing 3.8% sodium citrate (light blue tops) at room temperature.
- Platelet rich plasma PRP
- PPP platelet poor plasma
- Platelets were counted and their concentration was set to 250,000 cells/ ⁇ L by dilution with PPP. Aggregation assays were conducted according to the manufacturer's specifications.
- HEK293 cells are transiently transfected with a pCMV expression vector containing a human 5-HT 2A receptor (for the sequence of the receptor see U.S. Patent No. 6,541 ,209, SEQ TD NO:24).
- An IP accumulation assay can be performed as described in part C below.
- Compounds of the invention can be tested for their ability to inhibit a constitutively active 5-HT 2A receptor clone using an IP accumulation assay.
- 293 cells are transiently transfected with a pCMV expression vector containing a constitutively active human 5-HT 2A receptor (for the sequence of the receptor see U.S. Patent No. 6,541,209, SEQ ID NO:30).
- the constitutively active human 5-HT 2A receptor contains the human 5-HT 2A receptor described in part A except that intracellular loop 3 (IC3) and the cytoplasmic tail are replaced by the corresponding human INI 5-HT 2 c cDNA.
- An EP accumulation assay can be performed as described in part C below.
- the eluent is then transferred to 20 mL scintillation vials, 8 mL of SuperMix or Hi-Safe scintillation cocktail is added and the vials are counted for 0.5-1 5 min in a Wallac 1414 scintillation counter.
- Example 6 Efficacy of Compounds of the Invention in the Attenuation of DOI-induced Hypolocomotion in Rats.
- DOI is a potent 5-HT 2A / 2 c receptor agonist that crosses the blood-brain barrier.
- the standard protocol used is described briefly below. Animals:
- (R)-DOI HCl (C n H 16 INO 2 -HCl) was obtained from Sigma- Aldrich and was dissolved in 0.9% saline.
- Compounds of the invention were synthesized at Arena Pharmaceuticals Inc., San Diego, CA and were dissolved in 100% PEG400. DOI was injected s.c. in a volume of 1 20 mL/kg, while compounds of the invention were administered p.o. in a volume of 1 mL/kg.
- the "Motor Monitor” (Hamilton-Kinder, Poway, CA) was used for all activity measurement. This apparatus recorded rears using infrared photobeams.
- Locomotor activity testing was conducted during the light cycle between 9:00 a.m. and 25 4:00 p.m. Animals were allowed 30 min acclimation to the testing room before testing began.
- mice were first injected with vehicle or the compound of the invention (1-10 mg/kg) in their home cages. Twenty five minutes later, saline or DOI (1 mg/kg salt) was injected. Ten minutes after DOI administration, animals were placed into the activity apparatus and rearing activity 30 was measured for 10 min.
- Example 7 Serotonin 5-HT 2A Receptor Occupancy Studies in Monkey.
- the 5-HT 2A receptor occupancy of a compound of the invention can be measured.
- the study can be carried out in rhesus monkeys using PET and 18 F-altanserin.
- the PET radioligand used for the occupancy studies is 18 F-altanserin. Radiosynthesis of 18 F-altanserin is achieved in high specific activities and is suitable for radiolabeling 5-HT 2A receptors in vivo (see Staley et al, Nucl. Med. Biol, 28:271-279 (2001) and references cited therein). Quality control issues (chemical and radiochemical purity, specific activity, stability, etc.) and appropriate binding of the radioligand are verified in rat brain slices prior to use in PET experiments. Drug Doses and Formulations:
- the radiopharmaceutical is dissolved in sterile 0.9% saline, pH approx 6-7.
- the compounds of the invention are dissolved in a mixture of 60% PEG 400 and 40% sterile saline on the same day of the PET experiment.
- the monkey is anesthetized by using ketamine (10 mg/kg) and is maintained using 0.7 to 1.25% isoflurane.
- the monkey has two i.v. lines, one on each arm.
- One i.v. line is used to administer the radioligand, while the other line is used to draw blood samples for pharmacokinetic data of the radioligand as well as the unlabeled drugs.
- rapid blood samples are taken as the radioligand is administered which then taper out by the end of the scan.
- a volume of approximately 1 mL of blood is taken per time point, which is spun down and a portion of the plasma is counted for radioactivity in the blood.
- An initial control study is carried out in order to measure baseline receptor densities.
- PET scans on the monkey are separated by at least two weeks.
- Unlabeled compound of the invention is administered intravenously, dissolved in 80% PEG 400:40% sterile saline.
- PET data are analyzed by using cerebellum as the reference region and using the distribution volume region (DVR) method. This method has been applied for the analysis of 18 F-altanserin PET data in non-human primate and human studies (Smith et al., Synapse, 30:380-392, (1998)).
- DVR distribution volume region
- the effect of compounds of the invention on sleep and wakefulness can be compared to the reference drug Zolpidem. Drugs are administered during the middle of the light period (inactivity period).
- compounds of the invention are tested for their effects on sleep parameters and are compared to Zolpidem (5.0 mg/kg, Sigma, St. Louis, MO) and vehicle control (80% Tween 80, Sigma, St. Louis, MO).
- Zolpidem 5.0 mg/kg, Sigma, St. Louis, MO
- vehicle control 80% Tween 80, Sigma, St. Louis, MO.
- a repeated measures design is employed in which each rat is to receive seven separate dosings via oral gavage.
- the first and seventh dosings are vehicle and the second through sixth are the test compounds and Zolpidem given in counter-balanced order. Since all dosings are administered while the rats are connected to the recording apparatus, 60% CO 2 /40% O 2 gas is employed for light sedation during the oral gavage process. Rats are fully recovered within 60 seconds following the procedure. A minimum of three days elapses between dosings.
- dosing occurs during the middle of the rats' normal inactive period (6 hours following lights on). Dosing typically occurs between 13:15 and 13:45 using a 24 hour notation. All dosing solutions are made fresh on the day of dosing. Following each dosing, animals are continuously recorded until lights out the following day ( ⁇ 30 hours). Animal Recording and Surgical Procedures:
- Animals are housed in a temperature controlled recording room under a 12/12 light/dark cycle (lights on at 7:00 am) and have food and water available ad libitum. Room temperature (24 ⁇ 2 0 C), humidity (50 ⁇ 20% relative humidity) and lighting conditions are monitored continuously via computer. Drugs are administered via oral gavage as described above, with a minimum of three days between dosings. Animals are inspected daily in accordance with NIH guidelines.
- Wistar rats 300 ⁇ 25 g; Charles River, Wilmington, MA
- EEG electroencephalograph
- EMG electromyograph
- isoflurane anesthesia 1-4%)
- the fur is shaved from the top of the skull and the skin is disinfected with Betadine and alcohol.
- a dorsal midline incision is made, the temporalis muscle retracted and the skull cauterized and thoroughly cleaned with a 2% hydrogen peroxide solution.
- Stainless steel screws (#000) are implanted into the skull and serve as epidural electrodes.
- EEG electrodes are positioned bilaterally at +2.0 mm AP from bregma and 2.0 mm ML and at -6.0 mm AP and 3.0 mm ML.
- Multi-stranded twisted stainless steel wire electrodes are sutured bilaterally in the neck muscles for recording of the EMG.
- EMG and EEG electrodes are soldered to a head plug connector that is affixed to the skull with dental acrylic. Incisions are closed with suture (silk 4-0) and antibiotics administered topically. Pain is relieved by a long-lasting analgesic (buprenorphine) administered intramuscularly once post-operatively. Post-surgery, each animal is placed in a clean cage and observed until it is recovered. Animals are permitted a minimum of one week post-operative recovery before study.
- mice For sleep recordings, animals are connected via a cable and a counter-balanced commutator to a Neurodata model 15 data collection system (Grass-Telefactor, West Warwick, RT). The animals are allowed an acclimation period of at least 48 hours before the start of the experiment and are connected to the recording apparatus continuously throughout the experimental period except to replace damaged cables.
- the amplified EEG and EMG signals are digitized and stored on a computer using SleepSign software (Kissei Comtec, Irvine CA). Data Analysis:
- EEG and EMG data are scored visually in 10 second epochs for waking (W), REMS, NREMS. Scored data are analyzed and expressed as time spent in each state per half hour. Sleep bout length and number of bouts for each state are calculated in hourly bins. A "bout" consists of a minimum of two consecutive epochs of a given state. EEG delta power (0.5-3.5 Hz) within NREMS is also analyzed in hourly bins. The EEG spectra during NREMS are obtained offline with a fast Fourier transform algorithm on all epochs without artifact. The delta power is normalized to the average delta power in NREMS between 23:00 and 1 :00, a time when delta power is normally lowest.
- Data are analyzed using repeated measures ANOVA. Light phase and dark phase data are analyzed separately. Both the treatment effect within each rat and the time by treatment effect within each rat is analyzed. Since two comparisons are made, a minimum value of P ⁇ 0.025 is required for post hoc analysis. When statistical significance is found from the ANOVAs, t-tests are performed comparing all compounds to vehicle and the test compounds to Zolpidem.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
Description
IMIDAZO[l,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS
RELATED THERETO
FIELD OF THE INVENTION
The present invention relates to certain imidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds of Formula (Ia) and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.
The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
BACKGROUND OF THE INVENTION
Serotonin receptors
Receptors for serotonin (5-hydroxytryptamine, 5-HT) are an important class of G protein coupled receptors. Serotonin is thought to play a role in processes related to learning and memory, sleep, thermoregulation, mood, motor activity, pain, sexual and aggressive behaviors, appetite, neurodegenerative regulation and biological rhythms. Not surprisingly, serotonin is linked to pathophysiological conditions such as anxiety, depression, obsessive compulsive disorders, schizophrenia, suicide, autism, migraine, emesis, alcoholism and neurodegenerative disorders. With respect to anti-psychotic treatment approaches focused on the serotonin receptors, these types of therapeutics can generally be divided into two classes, the "typical" and the "atypical." Both have anti-psychotic effects, but the typicals also include concomitant motor-related side effects
(extra pyramidal syndromes, e.g., lip-smacking, tongue darting, locomotor movement, etc.) Such side effects are thought to be associated with the compounds interacting with other receptors, such as the human dopamine D2 receptor in the nigro-striatal pathway. Therefore, an atypical treatment is preferred. Haloperidol is considered a typical anti-psychotic and clozapine is considered an atypical anti-psychotic.
Serotonin receptors are divided into seven subfamilies, referred to as 5-HT1 through 5- HT7, inclusive. These subfamilies are further divided into subtypes. For example, the 5-HT2
subfamily is divided into three receptor subtypes: 5-HT2A, 5-HT2B and 5-HT2C- The human 5- HT2C receptor was first isolated and cloned in 1987 and the human 5-HT2A receptor was first isolated and cloned in 1990.
SUMMARY OF THE INVENTION
One aspect of the present invention encompasses certain imidazo[l,2-α]pyridine derivatives selected from compounds as shown in Formula (Ia):
(Ia) and pharmaceutically acceptable salts, solvates and hydrates thereof; wherein:
R1 and R2 are each independently selected from the group consisting of H, Ci-C6 acyl, Ci-C6 acyloxy, C]-C6 alkoxy, Ci-C6 alkoxycarbonylamino, Cj-C6 alkyl, C1-C6 alkylamino, C2-C8 dialkylamino, Ci-C6 alkylcarboxamide, Ci-C6 alkylsulfonamide, Ci-C6 alkylsulfinyl, Ci-C6 alkylsulfonyl, Ci-C6 alkylureyl, amino, aryl, aryl-Ci-C4-alkylenyl, carbo-Q-C6-alkoxy, carboxamide, carboxy, cyano, C3-C7 cycloalkyl, C2-C6 dialkylcarboxamide, Ci-C6 haloalkoxy, Cj-C6 haloalkyl, C]-C6 haloalkylsulfinyl, Cj-C6 haloalkylsulfonyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro and sulfonamide;
R3, R4 and R5 re each independently selected from the group consisting of H, Ci -C6 acyl, Ci-C6 acyloxy, Ci-C6 alkoxy, Ci-C6 alkoxycarbonylamino, Q-C6 alkyl, C]-C6 alkylamino, C2-C8 dialkylamino, Ci-C6 alkylcarboxamide, Q-C6 alkylsulfonamide, C]-C6 alkylsulfinyl, Q-C6 alkylsulfonyl, C]-C6 alkylureyl, amino, aryl, aryl-Q-C4-alkylenyl, carbo-Q-C6-alkoxy, carboxamide, carboxy, cyano, C3-C7 cycloalkyl, C2-C6 dialkylcarboxamide, C]-C6 haloalkoxy, Ci-C6 haloalkyl, C]-C6 haloalkylsulfinyl, Cj-C6 haloalkylsulfonyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro and sulfonamide;
R6 and R7 are each independently selected from the group consisting of H, Cj-C6 acyl, Cj-C3 alkyl, aryl, carboxamide, carboxy, C3-C7 cycloalkyl, Cj-C6 haloalkyl, heteroaryl and heterocyclyl;
R8 and R9 are each independently selected from the group consisting of H, Cj-C6 acyl, Cj-C3 alkyl, aryl, carboxamide, Cj-C3 alkoxy, carboxy, cyano, C3-C7 cycloalkyl, Cj-C3 haloalkyl, halogen and hydroxyl; or
R8 and R9 taken together form oxo; or
R8 and R9 together with the atom to which they are both bonded form a C3-C7 cycloalkyl ring; and
R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, Ci-C6 acyl, Ci-C6 acyloxy, Q-C6 alkoxy, Ci-C6 alkoxycarbonylamino, Q-C6 alkyl, Ci-C6 alkylamino, Ci-C6 alkylcarboxamide, Q-C6 alkylsulfinyl, Ci-C6 alkylsulfonamide, Ci-C6 alkylsulfonyl, Ci-C6 alkylureyl, amino, carbo-Ci-C6 alkoxy, carboxamide, carboxy, cyano, C3- C6 cycloalkyl, C3-C7 cycloalkylcarbonyl, C2-C8 dialkylamino, C2-C6 dialkylcarboxamide, Ci-C6 haloalkoxy, Ci-C6 haloalkyl, Q-C6 haloalkylsulfinyl, C]-C6 haloalkylsulfonyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl, sulfonamide and sulfonic acid; wherein said phenyl group is optionally substituted with 1, 2 or 3 halogens.
One aspect of the present invention pertains to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
One aspect of the present invention pertains to methods for treating 5-HT2A mediated disorders in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof. One aspect of the present invention pertains to methods for treating 5-HT2A mediated disorders selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke and atrial fibrillation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof. One aspect of the present invention pertains to methods for treating sleep disorders in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for treating dyssomnias. One aspect of the present invention pertains to methods for treating insomnia.
One aspect of the present invention pertains to methods for treating parasomnias. One aspect of the present invention pertains to methods for increasing slow wave sleep in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for improving sleep consolidation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof. One aspect of the present invention pertains to methods for improving sleep maintenance in an individual, comprising administering to said individual in need thereof a
therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for treating conditions associated with platelet aggregation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for reducing the risk of blood clot formation in an angioplasty or coronary bypass surgery individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for reducing the risk of blood clot formation in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof. One aspect of the present invention pertains to methods for reducing the risk of blood clot formation in an individual suffering from atrial fibrillation, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for treating diabetic-related disorders in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for treating progressive multifocal leukoencephalopathy in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for treating hypertension in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
One aspect of the present invention pertains to methods for treating pain in an individual, comprising administering to said individual in need thereof a therapeutically x effective amount of a compound of the present invention or a pharmaceutical composition thereof. One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a sleep disorder.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a dyssomnia.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of insomnia. One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a parasomnia.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for increasing slow wave sleep.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for improving sleep consolidation.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for improving sleep maintenance.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a 5-HT2A mediated disorder. One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke or atrial fibrillation.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a condition associated with platelet aggregation.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the reduction of the risk of blood clot formation in an angioplasty or coronary bypass surgery individual.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the reduction of the risk of blood clot formation in an individual.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the reduction of the risk of blood clot formation in an individual suffering from atrial fibrillation. One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of a diabetic-related disorder.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of progressive multifocal leukoencephalopathy. One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of hypertension.
One aspect of the present invention pertains to the use of compounds of the present invention in the manufacture of a medicament for the treatment of pain.
One aspect of the present invention pertains to compounds of the present invention for use in a method of treatment of the human or animal body by therapy. One aspect of the present invention pertains to compounds of the present invention for use in a method of treatment of the human or animal body by surgery.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a 5-HT2A mediated disorder.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke or atrial fibrillation.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a sleep disorder.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a dyssomnia.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of insomnia.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a parasomnia. One aspect of the present invention pertains to compounds of the present invention for use in a method for increasing slow wave sleep.
One aspect of the present invention pertains to compounds of the present invention for use in a method for improving sleep consolidation.
One aspect of the present invention pertains to compounds of the present invention for use in a method for improving sleep maintenance.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a condition associated with platelet aggregation.
One aspect of the present invention pertains to compounds of the present invention for use in a method of reducing the risk of blood clot formation in an angioplasty or coronary bypass surgery individual.
One aspect of the present invention pertains to compounds of the present invention for use in a method of reducing the risk of blood clot formation in an individual.
One aspect of the present invention pertains to compounds of the present invention for use in a method of reducing the risk of blood clot formation in an individual suffering from atrial fibrillation.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of a diabetic-related disorder.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of progressive multifocal leukoencephalopathy.
One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of hypertension. One aspect of the present invention pertains to compounds of the present invention for use in a method for the treatment of pain.
One aspect of the present invention pertains to processes for preparing a composition comprising admixing a compound of the present invention and a pharmaceutically acceptable carrier. These and other aspects of the invention disclosed herein will be set forth in greater detail as the patent disclosure proceeds.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a general synthetic scheme for preparation of compounds of Formula (Ia). Boc-piperazine is coupled with a phenylacetic acid derivative in the presence of a coupling agent. The resulting amide is reduced and the Boc protecting group is removed. The final step, is coupling with an imidazopyridine carboxylic acid derivative.
Figure 2 shows a second general synthetic scheme for preparation of compounds of Formula (Ia). Here the Boc-piperazine is coupled with a phenethyl halide derivative, followed by deprotection and finally coupling with an imidazopyridine carboxylic acid derivative.
Figure 3 shows synthetic schemes for preparation of certain imidazo[l,2-α]pyridines. The first synthesis involves the reaction between an acetaldehyde derivative and a 2- aminonicotinic acid derivative to produce an imidazo[l,2-α]pyridine-8 -carboxylic acid, which can then be chlorinated to form the acid chloride. Alternatively 2-aminonicotinic acids are methylated with TMS-diazomethane and reacted with disubstituted carbonyl compounds to produce certain imidazo[l,2-α]pyridine-8-carboxylic acid methyl esters, which can be subsequently demethylated.
Halogenation at the 3-position of an imidazo[l,2-α]pyridine-8-carboxylic acid derivative, by treatment with a halogenating agent, is also shown. Figure 4 shows halogenation of a compound of Formula (Ia) with a halogenating agent and cyanation of a compound of Formula (Ia) with dicyanozinc.
Figure 5 shows a third route for preparing compounds of Formula (Ia) wherein the imidazo[l,2-α]pyridine derivative is coupled first to the Boc-piperidine. After deprotection the final step is coupling with a phenethyl halide derivative. Figure 6 shows the efficacy of compound 18 in the attenuation of DOI-induced hypolocomotion in rats.
Figure 7 shows the efficacy of compound in 19 the attenuation of DOI-induced hypolocomotion in rats.
DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS
For clarity and consistency, the following definitions will be used throughout this patent document.
The term "agonists" is intended to mean moieties that interact and activate the receptor, such as the 5-HT2A serotonin receptor and initiate a physiological or pharmacological response characteristic of that receptor. For example, when moieties activate the intracellular response upon binding to the receptor, or enhance GTP binding to membranes.
The term "antagonists" is intended to mean moieties that competitively bind to the receptor at the same site as agonists (for example, the endogenous ligand), but which do not activate the intracellular response initiated by the active form of the receptor and can thereby inhibit the intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
The term "contact or contacting" is intended to mean bringing the indicated moieties together, whether in an in vitro system or an in vivo system. Thus, "contacting" a 5-HT2A serotonin receptor with a compound of the invention includes the administration of a compound of the present invention to an individual, preferably a human, having a 5-HT2A serotonin receptor, as well as, for example, introducing a compound of the invention into a sample containing a cellular or more purified preparation containing a 5-HT2A serotonin receptor.
The term "in need of treatment" and the term "in need thereof when referring to treatment are used interchangeably to mean a judgment made by a caregiver (e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of a caregiver's expertise, but that includes the knowledge that the individual or animal is ill, or will become ill, as the result of a disease, condition or disorder that is treatable by the compounds of the invention. Accordingly, the compounds of the invention can be used in a protective or preventive manner; or compounds of the invention can be used to alleviate, inhibit or ameliorate the disease, condition or disorder.
The term "individual" is intended to mean any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates and most preferably humans.
The term "inverse agonists" is intended to mean moieties that bind to the endogenous form of the receptor or to the constitutively activated form of the receptor and which inhibit the
baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of agonists or partial agonists, or decrease GTP binding to membranes. Preferably, the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50% and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist.
The term "modulate or modulating" is intended to mean an increase or decrease in the amount, quality, response or effect of a particular activity, function or molecule.
The term "pharmaceutical composition" is intended to mean a composition comprising at least one active ingredient; including but not limited to, salts, solvates and hydrates of compounds of the present invention; whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.
The term "therapeutically effective amount" is intended to mean the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician or caregiver; or by an individual, which includes one or more of the following:
(1) Preventing the disease; for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease,
(2) Inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology) and
(3) Ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
CHEMICAL GROUP, MOIETY OR RADICAL
The term "Ci-C6 acyl" is intended to mean a Q-C6 alkyl radical attached to the carbon of a carbonyl group wherein the definition of alkyl has the same definition as described herein; some examples include, but are not limited to, acetyl, propionyl, n-butanoyl, sec-butanoyl, pivaloyl, pentanoyl and the like. The term "Ci-C6 acyloxy" is intended to mean an acyl radical attached to an oxygen atom wherein acyl has the same definition has described herein; some embodiments are when acyloxy is Ci-C5 acyloxy, some embodiments are when acyloxy is Ci-C6 acyloxy. Some
examples include, but are not limited to, acetyloxy, propionyloxy, butanoyloxy, iso- butanoyloxy, pentanoyloxy, hexanoyloxy and the like.
The term "C1-C6 alkoxy" is intended to mean a Ci-C6 alkyl radical, as defined herein, attached directly to an oxygen atom, some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons. Examples include methoxy, ethoxy, rc-propoxy, /sø-propoxy, n-butoxy, /-butoxy, iso- butoxy, sec-butoxy and the like.
The term "Ci-C6 alkoxycarbonylamino" is intended to mean a single Ci-C6 alkoxy group attached to the carbon of an amide group wherein alkoxy has the same definition as found herein. The alkoxycarbonylamino group may be represented by the following:
The term "Ci-C6 alkyl" is intended to mean a straight or branched carbon radical containing 1 to 6 carbons, some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons. Examples of an alkyl include, but not limited to, methyl, ethyl, w-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, f-butyl, pentyl, iso-pentyl, ^-pentyl, neo-pentyl, 1-methylbutyl [i.e., -CH(CH3)CH2CH2CH3], 2-methylbutyl [i.e., -CH2CH(CH3)CH2CH3], rc-hexyl and the like. The term "Ci-C6 alkylcarboxamido" or "Ci-C6 alkylcarboxamide" is intended to mean a single Ci-C6 alkyl group attached to either the carbon or the nitrogen of an amide group, wherein alkyl has the same definition as found herein. The Ci-C6 alkylcarboxamido group may be represented by the following:
Examples include, but are not limited to, N-methylcarboxamide, N-ethylcarboxamide, N-n-propylcarboxamide, N- /so-propylcarboxamide, N-H-butylcarboxamide, N-sec- butylcarboxamide, N- /sø-butylcarboxamide, N-7-butylcarboxamide and the like.
The term "Ci-C6 alkylsulfinyl" is intended to mean a Ci-C6 alkyl radical attached to the sulfur of a sulfoxide radical having the formula: -S(O)- wherein the alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfinyl, ethylsulfinyl, «-propylsulfmyl, wo-propylsulfinyl, rc-butylsulfinyl, sec-butylsulfinyl, iso- butylsulfmyl, f-butylsulfinyl and the like.
The term "Ci-C6 alkylsulfonamide" is intended to mean the groups shown below:
wherein Ci-Ce alkyl has the same definition as described herein.
The term "Ci-C6 alkylsulfonyl" is intended to mean a Cj-C6 alkyl radical attached to the sulfur of a sulfone radical having the formula: -S(O)2- wherein the alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, w-propylsulfonyl, /so-propylsulfonyl, /i-butylsulfonyl, sec-butylsulfonyl, iso- butylsulfonyl, /-butylsulfonyl and the like.
The term "Ci-C6 alkylureyl" is intended to mean the group of the formula: -NC(O)N- wherein one or both of the nitrogens are substituted with the same or different Cj-C6 alkyl group wherein alkyl has the same definition as described herein. Examples of an alkylureyl include, but are not limited to, CH3NHC(O)NH-, NH2C(O)NCH3-, (CH3)2NC(O)NH-, (CH3)2NC(O)NCH3-, CH3CH2NHC(O)NH-, CH3CH2NHC(O)NCH3- and the like. The term "amino" is intended to mean the group -NH2.
The term "Ci-C6 alkylamino" is intended to mean one alkyl radical attached to a -NH- radical wherein the alkyl radical has the same meaning as described herein. Some examples include, but are not limited to, methylamino, ethylamino, «-propylamino, tso-propylamino, n- butylamino, sec-butylamino, zsø-butylamino, r-butylamino and the like. Some embodiments are "C1-C2 alkylamino."
The term "aryl" is intended to mean an aromatic ring radical containing 6 to 10 ring carbons. Examples include phenyl and naphthyl.
The term "aryl-Ci-C4-alkylenyl" is intended to mean a Ci-C4 alkylene group bonded to an aryl group, each as defined herein. In some embodiments aryl-Ci-C4-alkylenyl refers to, for example, benzyl (-CH2-phenyl), phenylethyl (-CH2CH2-phenyl) and the like
The term "carbo-Ci-C6-alkoxy" is intended to mean a Q-C6 alkyl ester of a carboxylic acid, wherein the alkyl group is as defined herein. Examples include, but are not limited to, carbomethoxy [-C(=O)OCH3], carboethoxy, carbopropoxy, carboisopropoxy, carbobutoxy, carbo-sec-butoxy, carbo-wo-butoxy, carbo-f-butoxy, carbo-n-pentoxy, carbo-zso-pentoxy, carbo- r-pentoxy, carbo-neo-pentoxy, carbo-n-hexyloxy and the like.
The term "carboxamide" is intended to mean the group -CONH2. The term "carboxy" or "carboxyl" is intended to mean the group -CO2H; also referred to as a carboxylic acid group.
The term "cyano" is intended to mean the group -CN.
The term "C3-C7 cycloalkyl" is intended to mean a saturated ring radical containing 3 to 7 carbons; some embodiments contain 3 to 6 carbons; some embodiments contain 3 to 5 carbons; some embodiments contain 5 to 7 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
The term "C3-C7 cycloalkylcarbonyl" is intended to mean a C3-C7 cycloalkyl attached to the carbon of a carbonyl group wherein C3-C7 cycloalkyl has the same definition as described herein. Examples include cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptylcarbonyl and the like. The term "C2-C8 dialkylamino" is intended to mean an amino substituted with two of the same or different Ci -C4 alkyl radicals wherein alkyl radical has the same definition as described herein. Some examples include, but are not limited to, dimethylamino, methylethylamino, diethylamino, methylpropylamino, methylisopropylamino, ethylpropylamino, ethylisopropylamino, dipropylamino, propylisopropylamino and the like. Some embodiments are "C2-C4 dialkylamino."
The term "C2-C6 dialkylcarboxamido" or "C2-C6 dialkylcarboxamide" is intended to mean two alkyl radicals, that are the same or different, attached to an amide group, wherein alkyl has the same definition as described herein. A C2-C6 dialkylcarboxamido may be represented by the following groups:
alkyl
C1-C3 alkyl C1-C3 alkyl wherein CrC3 has the same definition as described herein. Examples of a dialkylcarboxamide include, but are not limited to, N,N-dimethylcarboxamide, N-methyl-N-ethylcarboxamide, N,N- diethylcarboxamide, N-methyl-N-isopropylcarboxamide and the like.
The term "Cj-C6 haloalkoxy" is intended to mean a Ci-C6 haloalkyl, as defined herein, which is directly attached to an oxygen atom. Examples include, but are not limited to, difluoromethoxy, trifiuoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy and the like.
The term "C1-C6 haloalkyl" is intended to mean an Ci-C6 alkyl group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted and a fully substituted CrC6 haloalkyl can be represented by the formula CnL2n+I wherein L is a halogen and "n" is 1, 2, 3, 4, 5 or 6; when more than one halogen is present then they may be the same or different and selected from the group consisting of F, Cl, Br and I, preferably F, some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2- trifluoroethyl, pentafluoroethyl and the like.
The term "C1-C6 haloalkylsulfinyl" is intended to mean a Ci -C6 haloalkyl radical attached to the sulfur atom of a sulfoxide group having the formula: -S(O)- wherein the haloalkyl radical has the same definition as described herein. Examples include, but are not limited to, trifluoromethylsulfϊnyl, 2,2,2-trifluoroethylsulfmyl, 2,2-difluoroethylsulfinyl and the like.
The term "C1-C6 haloalkylsulfonyl" is intended to mean a C]-C6 haloalkyl radical attached to the sulfur atom of a sulfone group having the formula: -S(O)2- wherein haloalkyl has the same definition as described herein. Examples include, but are not limited to, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2,2-difluoroethylsulfonyl and the like. The term "halogen" or "halo" is intended to mean to a fluoro, chloro, bromo or iodo group.
The term "heteroaryl" is intended to mean an aromatic ring system containing 5 to 14 aromatic ring atoms that may be a single ring, two fused rings or three fused rings wherein at least one aromatic ring atom is a heteroatom selected from, for example, but not limited to, the group consisting of O, S and N wherein the N can be optionally substituted with H, Ci-C4 acyl or C1-C4 alkyl. Some embodiments contain 5 to 6 ring atoms for example furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl and the like. Some embodiments contain 8 to 14 ring atoms for example quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, triazinyl, indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl. phenazinyl, phenothiazinyl, phenoxazinyl, benzoxazolyl, benzothiazolyl, lH-benzimidazolyl, imidazopyridinyl, benzothienyl, benzofuranyl, and isobenzofuran and the like
The term "heterocyclic" or "heterocyclyl" is intended to mean a non-aromatic carbon ring containing 3 to 8 ring atoms wherein one, two or three ring carbons are replaced by a heteroatom selected from, for example, the group consisting of O, S, S(=O), S(=O)2 and NH, wherein the N is optionally substituted as described herein. In some embodiments, the nitrogen is optionally substituted with Ci-C4 acyl or Ci-C4 alkyl and ring carbon atoms are optionally substituted with oxo or a thiooxo thus forming a carbonyl or thiocarbonyl group. The heterocyclic group can be attached/bonded to any available ring atom, for example, ring carbon, ring nitrogen and the like. In some embodiments the heterocyclic group is a 3-, A-, 5-, 6- or 7- membered ring. Examples of a heterocyclic group include, but are not limited to, aziridin-1-yl, aziridin-2-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin- 3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, piperzin-1-yl, piperzin-2- yl, piperzin-3-yl, piperzin-4-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, [l,3]-dioxolan- 2-yl, thiomorpholin-C4-yl, [l,4]oxazepan-4-yl, l,l-dioxothiomorpholin-4-yl, azepan-1-yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl and the like. The term "hydroxyl" is intended to mean the group -OH. The term "nitro" is intended to mean the group -NO2. The term "oxo" is intended to mean the substituent =O, accordingly, as a result, when a carbon is substituted by an "oxo" group the new group resulting from the carbon and oxo together is a carbonyl group.
The term "sulfonamide" is intended to mean the group -SO2NH2. The term "sulfonic acid" is intended to mean the group -SO3H.
COMPOUNDS OF THE INVENTION:
One aspect of the present invention pertains to certain compounds as shown in Formula (Ia):
(Ia) and pharmaceutically acceptable salts, solvates and hydrates thereof; wherein:
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 have the same definitions as described herein , supra and infra.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. AU combinations of the embodiments pertaining to the chemical groups represented by the variables (e.g., R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14) contained within the generic chemical formulae described herein, for example, (Ia, Ic and Ie) are specifically embraced by the present invention just as if each and every combination was individually explicitly recited, to the extent that such combinations embrace compounds that result in stable compounds {i.e., compounds that can be isolated, characterized and tested for biological activity). In addition, all subcombinations of the chemical groups listed in the embodiments describing such variables, as well as all subcombinations of uses and medical indications described herein, are also specifically embraced by the present invention just as if each and every subcombination of chemical groups and subcombination of uses and medical indications was individually and explicitly recited herein.
As used herein, "substituted" indicates that at least one hydrogen atom of the chemical group is replaced by a non-hydrogen substituent or group, the non-hydrogen substituent or group can be monovalent or divalent. When the substituent or group is divalent, then it is understood that this group is further substituted with another substituent or group. When a chemical group herein is "substituted" it may have up to the full valance of substitution; for example, a methyl group can be substituted by 1, 2, or 3 substituents, a methylene group can be substituted by 1 or 2 substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5
substituents, a naphthyl group can be substituted by 1, 2, 3, 4, 5, 6, or 7 substituents and the like. Likewise, "substituted with one or more substituents" refers to the substitution of a group with one substituent up to the total number of substituents physically allowed by the group. Further, when a group is substituted with more than one group they can be identical or they can be different.
Compounds of the invention can also include tautomeric forms, such as keto-enol tautomers and the like. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is understood that the various tautomeric forms are within the scope of the compounds of the present invention. Compounds of the invention can also include all isotopes of atoms occurring in the intermediates and/or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include deuterium and tritium.
It is understood and appreciated that compounds of Formula (Ia) and formulae related thereto may have one or more chiral centers and therefore can exist as enantiomers and/or diastereomers. The invention is understood to extend to and embrace all such enantiomers, diastereomers and mixtures thereof, including but not limited to racemates. It is understood that compounds of Formula (Ia) and formulae used throughout this disclosure are intended to represent all individual enantiomers and mixtures thereof, unless stated or shown otherwise.
The Groups R1 and R2
In some embodiments, R1 and R2 are each independently selected from the group consisting of H, Ci-C6 acyloxy, C1-C6 alkoxy, C]-C6 alkyl, CrC6 alkylsulfonyl, aryl, aryl-Ci-C4- alkylenyl, carbo-CrC6 alkoxy, carboxy, cyano, C3-C7 cycloalkyl, C1-C6 haloalkoxy, C]-C6 haloalkyl, halogen, heteroaryl, heterocyclyl and hydroxyl.
In some embodiments, R1 and R2 are each independently selected from the group consisting of H, Ci-C6 alkyl, aryl, cyano, Ci-C6 haloalkyl and halogen.
In some embodiments, R1 and R2 are each independently selected from the group consisting of H, methyl, f -butyl, phenyl, cyano, trifluoromethyl, chloro and bromo. In some embodiments, R1 is H; and R2 is cyano, chloro or bromo.
In some embodiments, wherein R1 and R2 are both H.
The Groups R3. R4 and R5
In some embodiments, wherein R3, R4 and R5 are each independently selected from the group consisting of H, Q-C6 alkoxy, C1-C6 alkyl, cyano, C1-C6 haloalkoxy, C1-C6 haloalkyl, halogen and hydroxyl.
In some embodiments, R3, R4 and R5 are each independently selected from the group consisting of H, C]-C6 alkyl, C1-C6 alkoxy and halogen.
In some embodiments, R3 and R5 are each independently selected from the group consisting of H, C1-C6 alkyl and Q-C6 alkoxy; and R4 is H. In some embodiments, wherein R3, R4 and R5 are each independently selected from the group consisting of H, methyl, methoxy and bromo.
In some embodiments, R3, R4 and R5 are each H.
The Groups R6 and R7 In some embodiments, R6 and R7 are each independently selected from the group consisting of H and Cj-C3 alkyl.
In some embodiments, wherein R6 and R7 are each independently selected from the group consisting of H and methyl.
In some embodiments, wherein R6 and R7 are both H.
The Groups R8 and R9
In some embodiments, R8 and R9 are each independently selected from the group consisting of H, C1-C3 alkyl, aryl, C1-C3 alkoxy, C3-C7 cycloalkyl, Q-C3 haloalkyl, halogen and hydroxyl; or R8 and R9 taken together form oxo; or
R8 and R9 together with the atom to which they are both bonded form a C3-C7 cycloalkyl ring.
In some embodiments, R8 and R9 are each independently selected from the group consisting of H and halogen; or R8 and R9 together form oxo.
In some embodiments, R8 and R9 are each independently selected from the group consisting of H and F; or
R8 and R9 together form oxo. In some embodiments, R8 and R9 are both H. In some embodiments, wherein R8 and R9 together form oxo.
The Groups R10. R". R12. R13 and R14
In some embodiments, R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, C1-C6 acyloxy, Q-C6 alkoxy, C1-C6 alkyl, Q-C6 alkylamino, C2-C8 dialkylamino, C1-C6 alkylcarboxamide, C1-C6 alkylsulfonamide, C1-C6 alkylsulfonyl, amino, carboxamide, carboxy, cyano, C3-C6 cycloalkyl, C2-C6 dialkylcarboxamide, C1-C6 haloalkoxy,
Ci-C6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl, sulfonamide and sulfonic acid; wherein said phenyl group is optionally substituted with 1, 2 or 3 halogens.
In some embodiments, R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, Ci-C6 alkoxy, C]-C6 alkyl, C2-C8 dialkylamino, CrC6 alkylsulfonamide, Ci-C6 alkylsulfonyl, carboxamide, carboxy, cyano, C3-C6 cycloalkyl, C1-C6 haloalkoxy, C1-C6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid.
In some embodiments, R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, methyl, methoxy, dimethylamino, -NHSO2CH3, methylsulfonyl, carboxamide, carboxy, cyano, cyclohexyl, fluoro, chloro, trifiuoromethoxy, difluoromethoxy, trifluoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
In some embodiments:
R10 and R14 are each independently selected from the group consisting of H, C1-C6 alkoxy, carboxy, halogen, C1-C6 haloalkoxy and C]-C6 haloalkyl;
R11 and R13 are each independently selected from the group consisting of H, C1-C6 alkyl', Ci-C6 alkylsulfonamide, Ci-C6 alkoxy, carboxamide, C1-C6 haloalkyl, halogen, hydroxyl and nitro; and
R12 is selected from the group consisting of H, Ci-C6 alkoxy, C]-C6 alkyl, C2-C8 dialkylamino, Ci-C6 alkylsulfonamide, Cj-C6 alkylsulfonyl, carboxamide, cyano, C3-C6 cycloalkyl, C1-C6 haloalkoxy, C1-C6 haloalkyl, halogen, heterocyclyl, heteroaryl, hydroxyl, nitro, phenyl and sulfonic acid.
In some embodiments:
R10 and R14 are each independently selected from the group consisting of H, methoxy, carboxy, fluoro, chloro and trifluoromethyl;
R11 and R13 are each independently selected from the group consisting of H, methyl, methoxy, -NHSO2CH3, fluoro, chloro, carboxamide, hydroxyl, trifluoromethyl and nitro; and
R12 is selected from the group consisting of H, methyl, methoxy, dimethylamino, - NHSO2CH3, methylsulfonyl, carboxamide, cyano, cyclohexyl, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifluoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
In some embodiments:
R10, R12 and R14 are each independently selected from the group consisting of H and halogen; and R11 and R13 are both H.
In some embodiments:
R10, R12 and R14 are each independently selected from the group consisting of H and F; and
R11 and R13 are both H. In some embodiments: R10 and R12 are both F; and
R11, R13 and R14 are each H.
Some Preferred Combinations: In some embodiments: R1 and R2 are each independently selected from the group consisting of H, Cj-C6 alkyl, aryl, cyano, Q-C6 haloalkyl and halogen;
R3, R4 and R5 are each independently selected from the group consisting of H, C1-C6 alkyl, Ci-6 alkoxy and halogen;
R6 and R7 are each independently selected from the group consisting of H and C1-C3 alkyl;
R8 and R9 are each independently selected from the group consisting of H and halogen; or
R8 and R9 together form oxo; or
R8 and R9 together with the atom to which they are both bonded form a C3-C7 cycloalkyl ring; and
R10, Ru, R12, R13 and R14 are each independently selected from the group consisting of H, C1-C6 alkoxy, C]-C6 alkyl, C2-C8 dialkylamino, Ci-C6 alkylsulfonamide, Ci-C6 alkylsulfonyl, carboxamide, carboxy, cyano, C3-C6 cycloalkyl, C1-C6 haloalkoxy, C]-C6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid. In some embodiments:
R1 is selected from the group consisting of H, Q-C6 alkyl, aryl and C1-C6 haloalkyl; R2 is selected from the group consisting of H, cyano and halogen; R3 is selected from the group consisting of H and C1-C6 alkyl; and R4 is H or halogen; or R3 and R4 together with the atoms to which they are both bonded form a heterocyclic ring;
R5 is selected from the group consisting of H, C1-C6 alkoxy and C1-C6 alkyl; R6 and R7 are both H;
R8 and R9 are each independently selected from the group consisting of H and halogen; or
R8 and R9 together form oxo; and
R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, Ci-C6 alkoxy, Ci-C6 alkyl, C2-C8 dialkylamino, C]-C6 alkylsulfonamide, Ci-C6 alkylsulfonyl, carboxamide, carboxy, cyano, C3-C6 cycloalkyl, Ci-C6 haloalkoxy, C]-C6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid. In some embodiments:
R1 is selected from the group consisting of H, methyl, /-butyl, phenyl and trifluoromethyl;
R2 is selected from the group consisting of H, cyano, chloro and bromo;
R3 is selected from the group consisting of H and methyl; R4 is H or bromo;
R5 is selected from the group consisting of H and methyl;
R6 and R7 are both H;
R8 and R9 are each independently selected from the group consisting of H and F; or
R8 and R9 together form oxo; and R10, R11, R12, R13 and R14 are each independently selected from the group consisting of
H, methyl, methoxy, dimethylamino, -NHSO2CH3, methylsulfonyl, carboxamide, carboxy, cyano, cyclohexyl, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifluoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
Some embodiments of the present invention pertain to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates or hydrates thereof:
(Ic) wherein:
R1 is selected from the group consisting of H, Ci-C6 alkyl, aryl and Ci-C6 haloalkyl; R2 is selected from the group consisting of H, cyano and halogen;
R8 and R9 are each independently selected from the group consisting of H and halogen; or
R8 and R9 together form oxo; and
R12 and R14 are each independently selected from the group consisting of H and halogen. Some embodiments of the present invention pertain to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates or hydrates thereof:
R1 is selected from the group consisting of H, methyl, /-butyl, phenyl and trifluoromethyl; R2 is selected from the group consisting of H, cyano, chloro and bromo;
R8 and R9 are each independently selected from the group consisting of H and F; or R8 and R9 together form oxo; and
R12 and R14 are each independently selected from the group consisting of H, fluoro and chloro. Some embodiments of the present invention pertain to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates or hydrates thereof:
(Ie) wherein: R6 and R7 are each independently selected from the group consisting of H and Ci-C3 alkyl;
R8 and R9 are each independently selected from the group consisting of H and halogen; or
R8 and R9 together form oxo; and R10, R11, R12, R13 and R14 are each independently selected from the group consisting of
H, Ci-C6 alkoxy, Ci-C6 alkyl, C2-C8 dialkylamino, Ci-C6 alkylsulfonamide, Ci-C6 alkylsulfonyl, carboxamide, carboxy, cyano, C3-C6 cycloalkyl, C]-C6 haloalkoxy, Ci-C6 haloalkyl, heteroaryl, halogen, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid.
Some embodiments of the present invention pertain to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates or hydrates thereof:
R6 and R7 are both H; R8 and R9 are each independently selected from the group consisting of H and F; or
R8 and R9 together form oxo; and
R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, methyl, methoxy, dimethylamino, -NHSO2CH3, methylsulfonyl, carboxamide, carboxy, cyano, cyclohexyl, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifiuoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
Some embodiments of the present invention include every combination of one or more compounds selected from the following group shown in TABLE A.
TABLE A
,2- -
-
-
1 -
Chemical Structure Chemical Name No.
2-(4-(imidazo[l,2-a]pyridine-8-
34 carbonyl)piperazin- 1 -yl)- 1 -(4-
(trifluoromethyl)phenyl)ethanone
2-(4-(imidazo[ 1 ,2-a]pyridine-8-
(4-(2,4-difluorophenethyl)piperazin-
36 1 -yl)(7-methoxyimidazo[ 1 ,2- a]pyridin-8-yl)methanone
2-hydroxy-5-(2-(4-(imidazo[l ,2-
37 a]pyridine-8 -carbonyl)piperazin- 1 - yl)acetyl)benzamide
2-(4-(imidazo[l ,2-a]pyridine-8-
38 carbonyl)piperazin- 1 -yl)- 1 -(2-
(trifluoromethyl)phenyl)ethanone
4-(2-(4-(imidazo[l,2-a]pyridine-8-
1 -(4-hydroxyphenyl)-2-(4-
l-(4-(dimethylamino)phenyl)-2-(4-
-
-
Additionally, individual compounds and chemical genera of the present invention, for example those compounds found in TABLE A including diastereomers and enantiomers thereof, encompass all pharmaceutically acceptable salts, solvates and particularly hydrates, thereof.
The compounds of the Formula (Ia) of the present invention may be prepared according to relevant published literature procedures that are used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter in the working Examples. Protection and deprotection may be carried out by procedures generally known in the art (see, for example, Greene, T. W. and Wuts, P. G. M., Protecting Groups in Organic Synthesis, 3rd Edition, 1999 [Wiley]; incorporated herein by reference in its entirety).
It is understood that the present invention embraces each diastereomer, each enantiomer and mixtures thereof of each compound and generic formulae disclosed herein just as if they were each individually disclosed with the specific stereochemical designation for each chiral carbon. Separation of the individual isomers (such as, by chiral HPLC, recrystallization of diastereomeric mixtures and the like) or selective synthesis (such as, by enantiomeric selective syntheses and the like) of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art.
INDICATIONS AND METHODS OF TREATMENT In addition to the foregoing beneficial uses for the modulators of 5-HT2A serotonin receptor activity disclosed herein, the compounds disclosed herein are believed to be useful in the treatment of several additional diseases and disorders and in the amelioration of symptoms thereof. Without limitation, these include the following:
1. Sleep disorders
It is reported in the National Sleep Foundation's 2002 Sleep In America Poll, 58% of the adults surveyed report having experienced one or more symptoms of insomnia at least a few nights a week in the past year. Additionally, 35% of the adults surveyed say they have experienced insomnia-like symptoms every night or almost every night.
The normal sleep cycle and sleep architecture can be disrupted by a variety of organic causes as well as environmental influences. According to the International Classification of Sleep Disorders, there are over 80 recognized sleep disorders. Of these, compounds of the present invention are effective, for example, in any one or more of the following sleep disorders (ICSD- International Classification of Sleep Disorders: Diagnostic and Coding Manual. Diagnostic Classification Steering Committee, American Sleep Disorders Association, 1990):
A. Dyssomnias a. Intrinsic Sleep Disorders: Psychophysiological insomnia, sleep state misperception, idiopathic insomnia, obstructive sleep apnea syndrome, central sleep apnea syndrome, central alveolar hypoventilation syndrome, periodic limb movement disorder, restless leg syndrome and intrinsic sleep disorder NOS (not otherwise specified). b. Extrinsic Sleep Disorders: Inadequate sleep hygiene, environmental sleep disorder, altitude insomnia, adjustment sleep disorder, insufficient sleep syndrome, limit-setting sleep disorder, sleep onset association disorder, nocturnal eating (drinking) syndrome, hypnotic-dependent sleep disorder, stimulant- dependent sleep disorder, alcohol-dependent sleep disorder, toxin-induced sleep disorder and extrinsic sleep disorder NOS. c. Orcadian Rhythm Sleep Disorders:
Time zone change (jet lag) syndrome, shift work sleep disorder, irregular sleep-wake pattern, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24-hour sleep-wake disorder and circadian rhythm sleep disorder NOS.
B. Parasomnias a. Arousal Disorders:
Confusional arousals, sleepwalking and sleep terrors. b. Sleep-Wake Transition Disorders:
Rhythmic movement disorder, sleep starts, sleep talking and nocturnal leg cramps.
C. Sleep Disorders Associated With Medical/Psychiatric Disorders a. Associated with Mental Disorders:
Psychoses, mood disorders, anxiety disorders, panic disorders and alcoholism, b. Associated with Neurological Disorders:
Cerebral degenerative disorders, dementia, Parkinsonism, fatal familial insomnia, sleep- related epilepsy, electrical status epilepticus of sleep and sleep-related headaches, c. Associated with Other Medical Disorders:
Sleeping sickness, nocturnal cardiac ischemia, chronic obstructive pulmonary disease, sleep-related asthma, sleep-related gastroesophageal reflux, peptic ulcer disease, fibrositis syndrome, osteoarthritis, rheumatoid arthritis, fibromyalgia and post-surgical.
The effects of sleep deprivation are more than excessive daytime sleepiness. Chronic insomniacs report elevated levels of stress, anxiety, depression and medical illnesses (National Institutes of Health, National Heart, Lung and Blood Institute, Insomnia Facts Sheet, Oct. 1995). Preliminary evidence suggests that having a sleep disorder that causes significant loss of sleep may contribute to increased susceptibility to infections due to immunosuppression, cardiovascular complications such as hypertension, cardiac arrhythmias, stroke and myocardial infarction, compromised glucose tolerance, increased obesity and metabolic syndrome. Compounds of the present invention are useful to prevent or alleviate these complications by improving sleep quality. The most common class of medications for the maj ority of sleep disorders are the benzodiazepines, but the adverse effect profile of benzodiazepines includes daytime sedation, diminished motor coordination and cognitive impairments. Furthermore, at the National Institutes of Health Consensus Conference on Sleeping Pills and Insomnia in 1984 guidelines were developed discouraging the use of such sedative-hypnotics beyond 4-6 weeks because of concerns raised over drug misuse, dependency, withdrawal and rebound insomnia. Therefore, it is desirable to have a pharmacological agent for the treatment of insomnia, which is more effective and/or has fewer side effects than those currently used. In addition, benzodiazepines are used to induce sleep, but have little to no effect on the maintenance of sleep, sleep consolidation or slow wave sleep. Therefore, sleep maintenance disorders are not currently well treated. Clinical studies with agents of a similar mechanism of action as compounds of the present invention have demonstrated significant improvements on objective and subjective sleep parameters in normal, healthy volunteers as well as patients with sleep disorders and mood disorders [Sharpley A. L., et al., Slow Wave Sleep in Humans: Role of 5-HT2A and 5HT2c Receptors. Neuropharmacology, 1994, Vol. 33(3/4):467-71; Winokur A., et al., Acute Effects of Mirtazapine on Sleep Continuity and Sleep Architecture in Depressed Patients: A Pilot Study. Soc. of Biol. Psych., 2000, Vol. 48:75-78; and Landolt H. P., et al., Serotonin-2 Receptors and Human Sleep: Effect of Selective Antagonist on EEG Power Spectra. Neuropsychopharmacology, 1999, Vol. 21(3):455-66].
Some sleep disorders are sometimes found in conjunction with other conditions and accordingly those conditions are treatable by compounds of Formula (Ia). For example, but not limited to, patients suffering from mood disorders typically suffer from a sleep disorder that can be treatable by compounds of Formula (Ia). Having one pharmacological agent which treats two or
more existing or potential conditions, as does the present invention, is more cost effective, leads to better compliance and has fewer side effects than taking two or more agents.
It is an object of the present invention to provide a therapeutic agent for the use in treating sleep disorders. It is another object of the present invention to provide one pharmaceutical agent, which may be useful in treating two or more conditions wherein one of the conditions is a sleep disorder. Compounds of the present invention described herein may be used alone or in combination with a mild sleep inducer (i.e. antihistamine). Sleep Architecture: Sleep comprises two physiological states: Non rapid eye movement (NREM) and rapid eye movement (REM) sleep. NREM sleep consists of four stages, each of which is characterized by progressively slower brain wave patterns, with the slower patterns indicating deeper sleep. So called delta sleep, stages 3 and 4 of NREM sleep, is the deepest and most refreshing type of sleep. Many patients with sleep disorders are unable to adequately achieve the restorative sleep of stages 3 and 4. In clinical terms, patients' sleep patterns are described as fragmented, meaning patients spend a lot of time alternating between stages 1 and 2 (semi-wakefulness) and being awake and very little time in deep sleep. As used herein, the term "fragmented sleep architecture" means an individual, such as a sleep disorder patient, spends the majority of their sleep time in NREM sleep stages 1 and 2, lighter periods of sleep from which the individual can be easily aroused to a waking state by limited external stimuli. As a result, the individual cycles through frequent bouts of light sleep interrupted by frequent awakenings throughout the sleep period. Many sleep disorders are characterized by fragmented sleep architecture. For example, many elderly patients with sleep complaints have difficulty achieving long bouts of deep, refreshing sleep (NREM stages 3 and 4) and instead spend the majority of their sleep time in NREM sleep stages 1 and 2.
In contrast to fragmented sleep architecture, as used herein the term "sleep consolidation" means a state in which the number of NREM sleep bouts, particularly stages 3 and 4 and the length of those sleep bouts are increased, while the number and length of waking bouts are decreased. In essence, the sleep architecture of the sleep disorder patient is consolidated to a sleeping state with increased periods of sleep and fewer awakenings during the night. More time is spent in slow wave sleep (stages 3 and 4) with fewer oscillations between stages 1 and 2. Compounds of the present invention can be effective in consolidating sleep patterns so that the patient with previously fragmented sleep can now achieve restorative, delta-wave sleep for longer, more consistent periods of time.
As sleep moves from stage 1 into later stages, heart rate and blood pressure drop, metabolic rate and glucose consumption fall and muscles relax. In normal sleep architecture, NREM sleep makes up about 75-80% of total sleep time; stage 1 accounting for 2-5% of total sleep time, stage 2 for about 45-50%, stage 3 approximately 3-8% and stage 4 approximately 10-15%. About 90 minutes after sleep onset, NREM sleep gives way to the first REM sleep episode of the night. REM
makes up approximately 20-25% of total sleep time. In contrast to NREM sleep, REM sleep is characterized by high pulse, respiration and blood pressure, as well as other physiological patterns similar to those seen in the active waking stage. Hence, REM sleep is also known as "paradoxical sleep." Sleep onset occurs during NREM sleep and takes 10-20 minutes in healthy young adults. The four stages of NREM sleep together with a REM phase form one complete sleep cycle that is repeated throughout the duration of sleep, usually four or five times. The cyclical nature of sleep is regular and reliable: a REM period occurs about every 90 minutes during the night. However, the first REM period tends to be the shortest, often lasting less than 10 minutes, whereas the later REM periods may last up to 40 minutes. With aging, the time between retiring and sleep onset increases and the total amount of night-time sleep decreases because of changes in sleep architecture that impair sleep maintenance as well as sleep quality. Both NREM (particularly stages 3 and 4) and REM sleep are reduced. However, stage 1 NREM sleep, which is the lightest sleep, increases with age. As used herein, the term "delta power" means a measure of the duration of EEG activity in the 0.5 to 3.5 Hz range during NREM sleep and is thought to be a measure of deeper, more refreshing sleep. Delta power is hypothesized to be a measure of a theoretical process called Process S and is thought to be inversely related to the amount of sleep an individual experiences during a given sleep period. Sleep is controlled by homeostatic mechanisms; therefore, the less one sleeps the greater the drive to sleep. It is believed that Process S builds throughout the wake period and is discharged most efficiently during delta power sleep. Delta power is a measure of the magnitude of Process S prior to the sleep period. The longer one stays awake, the greater Process S or drive to sleep and thus the greater the delta power during NREM sleep. However, individuals with sleep disorders have difficulty achieving and maintaining delta wave sleep and thus have a large build-up of Process S with limited ability to discharge this buildup during sleep. 5-HT2A agonists tested preclinically and clinically mimic the effect of sleep deprivation on delta power, suggesting that subjects with sleep disorders treated with a 5-HT2A inverse agonist or antagonist will be able to achieve deeper sleep that is more refreshing. These same effects have not been observed with currently marketed pharmacotherapies. In addition, currently marketed pharmacotherapies for sleep have side effects such as hangover effects or addiction that are associated with the GABA receptor. 5-HT2A inverse agonists do not target the GABA receptor and so these side effects are not a concern.
Subjective and objective determinations of sleep disorders:
There are a number of ways to determine whether the onset, duration or quality of sleep (e.g. non-restorative or restorative sleep) is impaired or improved. One method is a subjective determination of the patient, e.g., do they feel drowsy or rested upon waking. Other methods involve the observation of the patient by another during sleep, e.g., how long it takes the patient to
fall asleep, how many times the patient wakes up during the night, how restless is the patient during sleep, etc. Another method is to measure the stages of sleep objectively using polysomnography. Polysomnography is the monitoring of multiple electrophysiological parameters during sleep and generally includes measurement of EEG activity, electrooculographic activity and electromyographic activity, as well as other measurements. These results, along with observations, can measure not only sleep latency (the amount of time required to fall asleep), but also sleep continuity (overall balance of sleep and wakefulness) and sleep consolidation (percent of sleeping time spent in delta-wave or restorative sleep) which may be an indication of the quality of sleep.
There are five distinct sleep stages, which can be measured by polysomnography: rapid eye movement (REM) sleep and four stages of non-rapid eye movement (NREM) sleep (stages 1 , 2, 3 and 4). Stage 1 NREM sleep is a transition from wakefulness to sleep and occupies about 5% of time spent asleep in healthy adults. Stage 2 NREM sleep, which is characterized by specific EEG waveforms (sleep spindles and K complexes), occupies about 45-50% of time spent asleep. Stages 3 and 4 NREM sleep (also known collectively as slow-wave sleep and delta-wave sleep) are the deepest levels of sleep and occupy about 10-20% of sleep time. REM sleep, during which the majority of vivid dreams occur, occupies about 20-25% of total sleep.
These sleep stages have a characteristic temporal organization across the night. NREM stages 3 and 4 tend to occur in the first one-third to one-half of the night and increase in duration in response to sleep deprivation. REM sleep occurs cyclically through the night. Alternating with NREM sleep about every 80-100 minutes. REM sleep periods increase in duration toward the morning. Human sleep also varies characteristically across the life span. After relative stability with large amounts of slow-wave sleep in childhood and early adolescence, sleep continuity and depth deteriorate across the adult age range. This deterioration is reflected by increased wakefulness and stage 1 sleep and decreased stages 3 and 4 sleep. In addition, the compounds of the invention can be useful for the treatment of the sleep disorders characterized by excessive daytime sleepiness such as narcolepsy. Inverse agonists at the serotonin 5-HT2A receptor improve the quality of sleep at nighttime which can decrease excessive daytime sleepiness.
Accordingly, another aspect of the present invention relates to the therapeutic use of compounds of the present invention for the treatment of sleep disorders. Compounds of the present invention are potent inverse agonists at the serotonin 5-HT2A receptor and can be effective in the treatment of sleep disorders by promoting one or more of the following: reducing the sleep onset latency period (measure of sleep induction), reducing the number of nighttime awakenings and prolonging the amount of time in delta-wave sleep (measure of sleep quality enhancement and sleep consolidation) without effecting REM sleep. In addition, compounds of the present invention can be effective either as a monotherapy or in combination with sleep inducing agents, for example but not limited to, antihistamines.
Pharmacodynamic Effects of the Selective 5-HT2A Inverse Agonist APD125 in Healthy Adults:
APD125, a potent and selective 5-HT2A serotonin receptor inverse agonist is a member of the genus disclosed in the European Patent EP1558582. In Phase 1 trials, APD125 showed vigilance-lowering effects on waking EEG, with maximal effects at 40-80 mg; peak effects were observed at 2-4 h after dosing. In the afternoon nap model of insomnia in normal volunteers, APD 125 increased slow wave sleep and associated parameters in a dose-dependent manner, primarily during the early part of sleep. These effects occurred at the expense of REM sleep. Sleep onset latency was not decreased by APD 125. In the afternoon nap model, APD 125 decreased microarousals, the number of sleep stage shifts and number of awakenings after sleep onset.
In conclusion, APD 125, a 5-HT2A serotonin receptor inverse agonist, improved parameters of sleep consolidation and maintenance in humans. Thus, compounds of the present invention, also highly selective 5-HT2A serotonin receptor inverse agonists, will offer similar improvements in sleep parameters.
2. Antiplatelet Therapies (Conditions Related to Platelet Aggregation):
Antiplatelet agents (antiplatelets) are prescribed for a variety of conditions. For example, in coronary artery disease they are used to help prevent myocardial infarction or stroke in patients who are at risk of developing obstructive blood clots (e.g., coronary thrombosis).
In a myocardial infarction (heart attack), the heart muscle does not receive enough oxygen- rich blood because of a blockage in the coronary blood vessels. If taken while an attack is in progress or immediately afterward (preferably within 30 minutes), antiplatelets can reduce the damage to the heart. A transient ischemic attack ("TIA" or "mini-stroke") is a brief interruption of oxygen flow to the brain due to decreased blood flow through arteries, usually due to an obstructing blood clot. Antiplatelet drugs have been found to be effective in preventing TIAs.
Angina is a temporary and often recurring chest pain, pressure or discomfort caused by inadequate oxygen-rich blood flow (ischemia) to some parts of the heart. In patients with angina, antiplatelet therapy can reduce the effects of angina and the risk of myocardial infarction.
Stroke is an event in which the brain does not receive enough oxygen-rich blood, usually due to blockage of a cerebral blood vessel by a blood clot. In high-risk patients, taking antiplatelets regularly has been found to prevent the formation of blood clots that cause first or second strokes. Angioplasty is a catheter-based technique used to open arteries obstructed by a blood clot. Whether or not stenting is performed immediately after this procedure to keep the artery open, antiplatelets can reduce the risk of forming additional blood clots following the procedure(s).
Coronary bypass surgery is a surgical procedure in which an artery or vein is taken from elsewhere in the body and grafted to a blocked coronary artery, rerouting blood around the blockage and through the newly attached vessel. After the procedure, antiplatelets can reduce the risk of secondary blood clots. Atrial fibrillation is the most common type of sustained irregular heart rhythm
(arrhythmia). Atrial fibrillation affects about two million Americans every year. In atrial fibrillation, the atria (the heart's upper chambers) rapidly fire electrical signals that cause them to quiver rather than contract normally. The result is an abnormally fast and highly irregular heartbeat. When given after an episode of atrial fibrillation, antiplatelets can reduce the risk of blood clots forming in the heart and traveling to the brain (embolism).
5-HT2A serotonin receptors are expressed on smooth muscle of blood vessels and 5-HT secreted by activated platelets causes vasoconstriction as well as activation of additional platelets during clotting. There is evidence that a 5-HT2A inverse agonist will inhibit platelet aggregation and thus be a potential treatment as an antiplatelet therapy (see Satimura, K., et al, Clin. Cardiol. 2002 Jan. 25 (l):28-32; and Wilson, H. C. et al, Thromb. Haemost. 1991 Sep 2;66(3):355-60). 5-HT2A inverse agonists can be used to treat, for example, claudication or peripheral artery disease as well as cardiovascular complications (see Br. Med. J. 298: 424-430, 1989), arterial thrombosis (see, Pawlak, D. et al, Thrombosis Research 90: 259-270, 1998), atherosclerosis (see, Hayashi, T. et al, Atherosclerosis 168: 23-31, 2003), vasoconstriction caused by serotonin (see, Fujiwara, T. and Chiba, S. Journal of Cardiovascular Pharmacology 26: 503-510, 1995), restenosis of arteries following angioplasty or stent placement (see, Fujita, M. et al., Am. Heart J. 145:el6, 2003). It can also be used alone or in combination with thrombolytic therapy, for example, tissue plasminogen activator (tPA) (see, Yamashita, T. et al , Haemostasis 30:321-332, 2000), to provide cardioprotection following MI or pόstischemic myocardial dysfunction (see, Muto, T. et al, MoI Cell. Biochem. 272: 119-132, 2005) or protection from ischemic injury during percutaneous coronary intervention (see, Horibe, E. Circulation Research 68: 68-72, 2004) and the like, including complications resulting therefrom.
5-HT2A inverse antagonists can increase circulating adiponectin in patients, suggesting that they would also be useful in protecting patients against indications that are linked to adiponectin, for example, myocardial ischemia reperfusion injury and atherosclerosis (see Nomura et al, Blood Coagulation and Fibrinolysis 2005, 16, 423-428).
The 5-HT2A inverse agonists disclosed herein provide beneficial improvement in microcirculation to patients in need of antiplatelet therapy by antagonizing the vasoconstrictive products of the aggregating platelets in, for example and not limited to the indications described above. Accordingly, in some embodiments, the present invention provides methods for reducing platelet aggregation in a patient in need thereof comprising administering to the patient a
composition comprising a 5-HT2A inverse agonist disclosed herein. In further embodiments, the present invention provides methods for treating coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, or a symptom of any of the foregoing in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT2A inverse agonist disclosed herein.
In further embodiments, the present invention provides methods for reducing risk of blood clot formation in an angioplasty or coronary bypass surgery patient, or a patient suffering from atrial fibrillation, comprising administering to the patient a composition comprising a 5-HT2A inverse agonist disclosed herein at a time where such risk exists.
3. Asthma
5-HT has been linked to the pathophysiology of acute asthma (see Cazzola, M. and Matera, M. G., Trends Pharmacol Sd. 21: 201-202, 2000; and De Bie, J. J. et al, British J. Pharm., 1998, 124, 857-864). The compounds of the present invention disclosed herein are useful in the treatment of asthma and the treatment of the symptoms thereof. Accordingly, in some embodiments, the present invention provides methods for treating asthma in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT2A inverse agonist disclosed herein. In further embodiments, methods are provided for treating a symptom of asthma in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT2A inverse agonist disclosed herein.
4. Agitation
Agitation is a well-recognized behavioral syndrome with a range of symptoms, including hostility, extreme excitement, poor impulse control, tension and uncooperativeness (see Cohen- Mansfield J. and Billig, N., (1986), Agitated Behaviors in the Elderly. I. A Conceptual Review. J. Am. Geriatr. Soc. 34(10): 711-721).
Agitation is a common occurrence in the elderly and is often associated with dementia such as those caused by Alzheimer's disease, Lewy Body, Parkinson's and Huntington's, which are degenerative diseases of the nervous system. Diseases that affect blood vessels, such as stroke, or multi-infarct dementia, which is caused by multiple strokes in the brain can also induce agitation. Alzheimer's disease accounts for approximately 50 to 70% of all dementias (see Koss E., et al., (1997), Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. l l(suppl 2):S45-S50). An estimated 5% of people aged 65 and older and up to 20% of those aged 80 and older are affected by dementia; of these sufferers, nearly half exhibit behavioral disturbances, such as agitation, wandering and violent outbursts.
Agitated behaviors can also be manifested in cognitively intact elderly people and by those with psychiatric disorders other than dementia.
Agitation is often treated with antipsychotic medications such as haloperidol in nursing home and other assisted care settings. There is emerging evidence that agents acting at the 5-HT2A serotonin receptors in the brain have the effects of reducing agitation in patients, including
Alzheimer's dementia (See Katz, I. R., et al., J. Clin. Psychiatry 1999 Feb., 60(2): 107-115; and Street, J. S., et al.,Arch. Gen. Psychiatry 2000 Oct., 57(10):968-976).
The compounds of the invention disclosed herein are useful for treating agitation and symptoms thereof. Thus, in some embodiments, the present invention provides methods for treating agitation in a patient in need of such treatment comprising administering to the patient a composition comprising a 5-HT2A inverse agonist disclosed herein. In some embodiments, the agitation is due to a psychiatric disorder other than dementia. In some embodiments, the present invention provides methods for treatment of agitation or a symptom thereof in a patient suffering from dementia comprising administering to the patient a composition comprising a 5-HT2A inverse agonist disclosed herein. In some embodiments of such methods, the dementia is due to a degenerative disease of the nervous system, for example and without limitation, Alzheimer's disease, Lewy Body, Parkinson's disease and Huntington's disease, or dementia due to diseases that affect blood vessels, including, without limitation, stroke and multi-infarct dementia. In some embodiments, methods are provided for treating agitation or a symptom thereof in a patient in need of such treatment, where the patient is a cognitively intact elderly patient, comprising administering to the patient a composition comprising a 5-HT2A inverse agonist disclosed herein.
5. Add-On therapy to Haloperidol in the treatment of schizophrenia and other disorders: Schizophrenia is a psychopathic disorder of unknown origin, which usually appears for the first time in early adulthood and is marked by a number of characteristics, psychotic symptoms, progression, phasic development and deterioration in social behavior and professional capability in the region below the highest level ever attained. Characteristic psychotic symptoms are disorders of thought content (multiple, fragmentary, incoherent, implausible or simply delusional contents or ideas of persecution) and of mentality (loss of association, flight of imagination, incoherence up to incomprehensibility), as well as disorders of perceptibility (hallucinations), of emotions (superficial or inadequate emotions), of self-perception, of intentions and impulses, of interhuman relationships and finally psychomotor^ disorders (such as catatonia). Other symptoms are also associated with this disorder: see, American Statistical and Diagnostic Handbook. Haloperidol (Haldol) is a potent dopamine D2 receptor antagonist. It is widely prescribed for acute schizophrenic symptoms and is very effective for the positive symptoms of schizophrenia. However, Haldol is not effective for the negative symptoms of schizophrenia and may actually
induce negative symptoms as well as cognitive dysfunction. In accordance with some methods of the invention, administering a 5-HT2A inverse agonist concomitantly with Haldol will provide benefits including the ability to use a lower dose of Haldol without losing its effects on positive symptoms, while reducing or eliminating its inductive effects on negative symptoms and prolonging relapse to the patient's next schizophrenic event.
Haloperidol is used for treatment of a variety of behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorders, psychosis (organic and NOS), psychotic disorder, psychosis, schizophrenia (acute, chronic and NOS). Further uses include in the treatment of infantile autism, Huntington's chorea and nausea and vomiting from chemotherapy and chemotherapeutic antibodies. Administration of 5-HT2A inverse agonists disclosed herein with haloperidol also will provide benefits in these indications.
Li some embodiments, the present invention provides methods for treating a behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorders, psychosis (organic and NOS), psychotic disorder, psychosis, schizophrenia (acute, chronic and NOS) comprising administering to the patient a dopamine D2 receptor antagonist and a 5-HT2A inverse agonist disclosed herein.
In some embodiments, the present invention provides methods for treating a behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorders, psychosis (organic and NOS), psychotic disorder, psychosis, schizophrenia (acute, chronic and NOS) comprising administering to the patient haloperidol and a 5-HT2A inverse agonist disclosed herein.
In some embodiments, the present invention provides methods for treating infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies comprising administering to the patient a dopamine D2 receptor antagonist and a 5-HT2A inverse agonist disclosed herein.
In some embodiments, the present invention provides methods for treating infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies comprising administering to the patient haloperidol and a 5-HT2A inverse agonist disclosed herein. In further embodiments, the present invention provides methods for treating schizophrenia in a patient in need of the treatment comprising administering to the patient a dopamine D2 receptor antagonist and a 5-HT2A inverse agonist disclosed herein. Preferably, the dopamine D2 receptor antagonist is haloperidol.
The administration of the dopamine D2 receptor antagonist can be concomitant with administration of the 5-HT2A inverse agonist, or they can be administered at different times. Those of skill in the art will easily be able to determine appropriate dosing regimes for the most efficacious reduction or elimination of deleterious haloperidol effects. In some embodiments,
haloperidol and the 5-HT2A inverse agonist are administered in a single dosage form and in other embodiments, they are administered in separate dosage forms.
The present invention further provides methods of alleviating negative symptoms of schizophrenia induced by the administration of haloperidol to a patient suffering from schizophrenia, comprising administering to the patient a 5-HT2A inverse agonist as disclosed herein.
6. Diabetic-Related Pathologies:
Although hyperglycemia is the major cause for the pathogenesis of diabetic complications such as diabetic peripheral neuropathy (DPN), diabetic nephropathy (DN) and diabetic retinopathy (DR), some clinical work has implicated that increased plasma serotonin concentration in diabetic patients plays a role in disease progression (Pietraszek, M. H., et al., Thrombosis Res. 1992, 66(6), 765-74; and Andrzejewska-Buczko J., et al, Klin. Oczna. 1996; 98(2), 101-4). Serotonin is believed to play a role in vasospasm and increased platelet aggregability. Improving microvascular blood flow is beneficial to diabetic complications. A recent study by Cameron and Cotter in Naunyn Schmiedebergs Arch. Pharmacol.
2003 Jun; 367(6):607-14, used a 5-HT2A antagonist experimental drug AT-1015 and other non- specific 5-HT2A antagonists including ritanserin and sarpogrelate. These studies found that all three drugs were able to produce a marked correction (82.6-99.7%) of a 19.8% sciatic motor conduction deficit in diabetic rats. Similarly, 44.7% and 14.9% reductions in sciatic endoneurial blood flow and saphenous sensory conduction velocity were completely reversed.
In a separate patient study, sarpogrelate was evaluated for the prevention of the development or progression of diabetic nephropathy (Takahashi, T., et al., Diabetes. Res. Clin. Pr act. 2002 Nov; 58(2): 123-9). In the trial of 24 months of treatment, sarpogrelate significantly reduced urinary albumin excretion level.
7. Glaucoma
Topical ocular administration of 5-HT2 receptor antagonists result in a decrease in intra ocular pressure (IOP) in monkeys (Chang et al., J. Ocul. Pharmacol. 1:137-147 (1985)) and humans (Mastropasqua et al., Acta. Ophthalmol. Scand. Suppl. 224:24-25 (1997)) indicating utility for similar compounds such as 5 -HT2 A inverse agonists in the treatment of ocular hypertension associated with glaucoma. The 5-HT2 receptor antagonist ketanserin (Mastropasqua supra) and sarpogrelate (Takenaka et al., Investig. Ophthalmol. Vis. ScL 36:S734 (1995)) have been shown to significantly lower IOP in glaucoma patients.
8. Progressive Multifocal Leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a lethal demyelinating disease caused by an opportunistic viral infection of oligodendrocytes in immunocompromised patients.
The causative agent is JC virus, a ubiquitous papovavirus that infects the majority of the population before adulthood and establishes a latent infection in the kidney. In immunocompromised hosts, the virus can reactivate and productively infect oligodendrocytes. This previously rare condition, until 1984 reported primarily in persons with underlying lymphoproliferative disorders, is now more common because it occurs in 4% of patients with AIDS. Patients usually present with relentlessly progressive focal neurologic defects, such as hemiparesis or visual field deficits, or with alterations in mental status. On brain MRI, one or more white matter lesions are present; they are hyperintense on T2-weighted images and hypointense on Tl-weighted images. There is no mass effect and contrast enhancement is rare. Diagnosis can be confirmed by brain biopsy, with demonstration of virus by in situ hybridization or immunocytochemistry. Polymerase chain reaction amplification of JC virus sequences from the CSF can confirm diagnosis without the need for biopsy [Antinori et al., Neurology (1997) 48:687-694; Berger and Major, Seminars in Neurology (1999) 19:193-200; and Portegies, et al., Eur. J. Neurol. (2004) 11:297-304]. Currently, there is no effective therapy. Survival after diagnosis is about 3 to 5 months in AIDS patients.
JC virus enters cells by receptor-mediated clathrin-dependent endocytosis. Binding of JC virus to human glial cells (e.g., oligodendrocytes) induces an intracellular signal that is critical for entry and infection by a ligand-inducible clathrin-dependent mechanism [Querbes et al., J. Virology (2004) 78:250-256]. Recently, 5-HT2A was shown to be the receptor on human glial cells mediating infectious entry of JC virus by clathrin-dependent endocytosis [Elphick et al., Science (2004) 306:1380-1383]. 5-HT2A antagonists, including ketanserin and ritanserin, inhibited JC virus infection of human glial cells. Ketanserin and ritanserin have inverse agonist activity at 5- HT2A.
5-HT2A antagonists including inverse agonists have been contemplated to be useful in the treatment of PML [Elphick et al, Science (2004) 306: 1380-1383]. Prophylactic treatment of HrV-infected patients with 5-HT2A antagonists is envisioned to prevent the spread of JC virus to the central nervous system and the development of PML. Aggressive therapeutic treatment of patients with PML is envisioned to reduce viral spread within the central nervous system and prevent additional episodes of demyelination. One aspect of the present invention encompasses methods for the treatment of progressive multifocal leukoencephalopathy in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
In some embodiments, the individual in need thereof has a lymphoproliferative disorder. In some embodiments, the lymphoproliferative disorder is leukemia or lymphoma. In some embodiments, the leukemia or lymphoma is chronic lymphocytic leukemia, Hodgkin's disease, or the like.
In some embodiments, the individual in need thereof has a myeloproliferative disorder. In some embodiments, the individual in need thereof has carcinomatosis. In some embodiments, the individual in need thereof has a granulomatous or inflammatory disease. In some embodiments, the granulomatous or inflammatory disease is tuberculosis or sarcoidosis.
In some embodiments, the individual in need thereof is immunocompromised. In some embodiments, the immunocompromised individual has impaired cellular immunity. In some embodiments, the impaired cellular immunity comprises impaired T-cell immunity.
In some embodiments, the individual in need thereof is infected with HIV. In some embodiments, the HIV-infected individual has a CD4+ cell count of < 200/mm3. In some embodiments, the HIV-infected individual has AIDS. In some embodiments, the HIV-infected individual has AIDS-related complex (ARC). In certain embodiments, ARC is defined as the presence of two successive CD4+ cell counts below 200/mm3 and at least two of the following signs or symptoms: oral hairy leukoplakia, recurrent oral candidiasis, weight loss of at least 15 Ib or 10% of body weight within last six months, multidermatomal herpes zoster, temperature above 38.5 0C for more than 14 consecutive days or more than 15 days in a 30-day period, or diarrhea with more than three liquid stools per day for at least 30 days [see, e.g., Yamada et al., Clin. Diagn. Virol. (1993) 1:245-256].
In some embodiments, the individual in need thereof is undergoing immunosuppressive therapy. In some embodiments, the immunosuppressive therapy comprises administering an immunosuppressive agent [see, e.g., Mueller, Ann. Thorac. Surg. (2004) 77:354-362; and Krieger and Emre, Pediatr. Transplantation (2004) 8:594-599]. In some embodiments, the immunosuppressive therapy comprises administering an immunosuppressive agent selected from the group consisting of: corticosteroids (for example, prednisone and the like), calcineurin inhibitors (for example, cyclosporine, tacrolimus and the like), antiproliferative agents (for example, azathioprine, mycophenolate mofetil, sirolimus, everolimus and the like), T-cell depleting agents (for example, OKT®3 monoclonal antibody (mAb), anti-CD3 immunotoxin FN18-CRM9, Campath-1H (anti-CD52) mAb, anti-CD4 mAb, anti-T cell receptor mAb and the like), anti-DL-2 receptor (CD25) mAb (for example, basiliximab, daclizumab and the like), inhibitors of co-stimulation (for example, CTLA4-Ig, anti-CD 154 (CD40 ligand) mAb and the like), deoxyspergualin and analogs thereof (for example, 15-DSG, LF-08-0299, LF14-0195 and the like), leflunomide and analogs thereof (for example, leflunomide, FK778, FK779 and the like), FTY720, anti-alpha-4-integrin monoclonal antibody and anti-CD45 RB monoclonal antibody. In some embodiments, the immunosuppressive agent and said compound or pharmaceutical composition are administered in separate dosage forms. In some embodiments, the immunosuppressive agent and said compound or pharmaceutical composition are administered in a single dosage form.
In some embodiments, the individual in need thereof is undergoing immunosuppressive therapy after organ transplantation. In some embodiments, the organ is liver, kidney, lung, heart, or the like [see, e.g., Singh et al, Transplantation (2000) 69:467-472].
In some embodiments, the individual in need thereof is undergoing treatment for a rheumatic disease. In some embodiments, the rheumatic disease is systemic lupus erythematosus or the like.
In some embodiments, the compound or the pharmaceutical composition inhibits JC virus infection of human glial cells
9. Hypertension
Serotonin has been observed to play an important role in the regulation of vascular tone, vasoconstriction and pulmonary hypertension (Deuchar, G. et al., PuIm. Pharmacol. Ther. 18(1):23-31. 2005; and Marcos, E. et al, Ore. Res. 94(9):1263-70 2004). Ketanserin, a 5-HT2A inverse agonist, have been demonstrated to protect against circulatory shocks, intracranial hypertension and cerebral ischemia during heatstroke (Chang, C. et al., Shock 24(4): 336-340 2005); and to stabilize blood pressure in spontaneously hypertensive rats (Miao, C. Clin. Exp. Pharmacol. Physiol. 30(3): 189-193). Mainserin, a 5-HT2A inverse agonist, has been shown to prevent DOCA-salt induced hypertension in rats (Silva, A. Eur, J. Pharmacol. 518(2-3): 152-7 2005).
10. Pain
5-HT2A inverse agonists are also effective for the treatment of pain. Sarpogrelate has been observed to provide a significant analgesic effect both on thermal induced pain in rats after intraperitoneal administration and on inflammatory pain in rats after either intrathecal or intraperitoneal administration (Nishiyama, T. Eur. J. Pharmacol. 516: 18-22 2005). This same 5-HT2A inverse agonist in humans has been shown to be an effective treatment for lower back pain, leg pain and numbness associated with sciatica brought on by lumbar disc herniation (Kanayama, M. et al., J. Neurosurg.: Spine 2:441-446 2005).
PHARMACEUTICAL COMPOSITIONS
A further aspect of the present invention pertains to pharmaceutical compositions comprising one or more compounds as described herein and one or more pharmaceutically acceptable carriers. Some embodiments pertain to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier. Some embodiments of the present invention include a method of producing a pharmaceutical composition comprising admixing at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.
Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, forming the resulting mixture into a desired shape.
Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tabletting lubricants and disintegrants may be used in tablets and capsules for oral administration. Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions and syrups. Alternatively, the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives and flavorings and colorants may be added to the liquid preparations. Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms. A compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically- acceptable carriers, outside those mentioned herein, are known in the art; for example, see Remington, The Science and Practice of Pharmacy, 20th Edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.) While it is possible that, for use in the prophylaxis or treatment, a compound of the invention may, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.
The invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, hydrate or derivative thereof together with one or more pharmaceutically acceptable carriers thereof and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof. Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation, insufflation or by a transdermal patch. Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in an efficient manner with a minimum of degradation of the drug. Typically, transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner. One of ordinary skill in the art will understand and appreciate the techniques appropriate for manufacturing a desired efficacious transdermal patch based upon the needs of the artisan.
The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical formulations and unit dosages thereof and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.
Compounds of the present invention or a solvate or physiologically functional derivative thereof can be used as active ingredients in pharmaceutical compositions, specifically as 5-HT2A serotonin receptor modulators. By the term "active ingredient" is defined in the context of a "pharmaceutical composition" and is intended to mean a component of a pharmaceutical composition that provides the primary pharmacological effect, as opposed to an "inactive ingredient" which would generally be recognized as providing no pharmaceutical benefit.
The dose when using the compounds of the present invention can vary within wide limits and as is customary and is known to the physician, it is to be tailored to the individual conditions in each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the present invention. Representative doses of the present invention include, but not limited to, about 0.001 mg to about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to about 1000 mg, 0.001 mg to about 500 mg, 0.001 mg to about 250 mg, about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg and about 0.001 mg to about 25 mg. Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or
4 doses. Depending on the individual and as deemed appropriate from the patient's physician or caregiver it may be necessary to deviate upward or downward from the doses described herein. The amount of active ingredient, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician, hi general, one skilled in the art understands how to extrapolate in vivo data obtained in a model system, typically an animal model, to another, such as a human. In some circumstances, these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors. Representative factors include the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, on whether an acute or chronic disease state is being treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the present invention and as part of a drug combination. The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety factors as cited above. Thus, the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations. The daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4 part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated. The compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt, solvate or hydrate of a compound of the invention.
For preparing pharmaceutical compositions from the compounds of the present invention, the selection of a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible granules. A solid carrier can be one or more substances
which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desire shape and size. The powders and tablets may contain varying percentage amounts of the active compound. A representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active compound; however, an artisan would know when amounts outside of this range are necessary. Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets and lozenges can be used as solid forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as an admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool and thereby to solidify.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Liquid form preparations include solutions, suspensions and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. Aqueous formulations suitable for oral use can be prepared by dissolving or suspending the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents, as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like.
For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump. Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable
propellant. If the compounds of the present invention or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler. Pharmaceutical forms for administration of the compounds of the present invention as an aerosol can be prepared by processes well known to the person skilled in the art. For their preparation, for example, solutions or dispersions of the compounds of the present invention in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others and, if appropriate, customary propellants, for example include carbon dioxide, CFCs, such as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.
In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
Alternatively the active ingredients may be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g. , gelatin, or blister packs from which the powder may be administered by means of an inhaler. The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
The compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Representative acids include, but are not limited to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic,
hippuπc, hydrobromic, hydrochloric, lsethiomc, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoπc, succinic, sulfiπc, tartaric, oxalic, p-toluenesulfomc and the like, such as those pharmaceutically acceptable salts listed in Journal of Pharmaceutical Sciences, 66:1-19 (1977), incorporated herein by reference in its entirety.
The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropnate acid and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
Compounds of the present invention can be converted to "pro-drugs." The term "prodrugs" refers to compounds that have been modified with specific chemical groups known in the art and when administered into an individual these groups undergo biotransformation to give the parent compound. Pro-drugs can thus be viewed as compounds of the invention containing one or more specialized non-toxic protective groups used in a transient manner to alter or to eliminate a property of the compound. In one general aspect, the "pro-drug" approach is utilized to facilitate oral absorption. A thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems Vol. 14 of the A.C.S. Symposium Seπes; and m Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety
Some embodiments of the present invention include a method of producing a pharmaceutical composition for "combination-therapy" comprising admixing at least one compound according to any of the compound embodiments disclosed herein, together with at least one known pharmaceutical agent as descπbed herein and a pharmaceutically acceptable earner.
It is noted that when the 5-HT2A serotonin receptor modulators are utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of active agents, such as 5-HT2A serotonin receptor modulators, for the treatment of a 5-HT2A-associated disease or disorder in companionship animals (e g , cats, dogs, etc ) and in livestock animals (e g , cows, chickens, fish, etc ) Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.
OTHER UTILITIES
Another object of the present invention relates to radio-labeled compounds of the present invention that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the 5-HT2A serotonin receptor in tissue samples, including human and for identifying 5-HT2A serotonin receptor ligands by inhibition binding of a radio-labeled compound. It is a further object of this invention to develop novel 5-HT2A- receptor assays of which comprise such radio-labeled compounds.
The present invention embraces isotopically-labeled compounds of the present invention. Isotopically or radio-labeled compounds are those which are identical to compounds disclosed herein, but for the fact that one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature. Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), 11C, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36Cl, 75Br, 76Br, 77Br, 82Br, 1231, 1241, 125I and 131I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro 5-HT2A serotonin receptor labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, 1251, 131I or 35S will generally be most useful. For radio-imaging applications 11C, 18F, 1251, 1231, 1241, 1311, 75Br, 76Br or 77Br will generally be most useful. It is understood that a "radio-labeled " or "labeled compound" is a compound of Formula (Ia), (Ic) or (Ie) that has incorporated at least one radionuclide; in some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 1251 , 35S and 82Br.
Certain isotopically-labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays. In some embodiments the radionuclide 3H and/or 14C isotopes are useful in these studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Drawings and Examples infra, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. Other synthetic methods that are useful are discussed infra. Moreover, it should be understood that all of the atoms represented in the compounds of the invention can be either the most commonly occurring isotope of such atoms or the scarcer radio-isotope or nonradioactive isotope.
Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art. These synthetic methods, for example, incorporating activity levels of tritium into target molecules, are as follows:
A. Catalytic Reduction with Tritium Gas: This procedure normally yields high specific activity products and requires halogenated or unsaturated precursors.
B. Reduction with Sodium Borohydride [3H]: This procedure is rather inexpensive and requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters and the like.
C. Reduction with Lithium Aluminum Hydride [3H]: This procedure offers products at almost theoretical specific activities. It also requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters and the like.
D. Tritium Gas Exposure Labeling: This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst.
E. N-Methylation using Methyl Iodide [3H]: This procedure is usually employed to prepare 0-methyl or N-methyl (3H) products by treating appropriate precursors with high specific activity methyl iodide (3H). This method in general allows for higher specific activity, such as for example, about 70-90 Ci/mmol. Synthetic methods for incorporating activity levels of 125I into target molecules include:
A. Sandmeyer and like reactions: This procedure transforms an aryl amine or a heteroaryl amine into a diazonium salt, such as a diazonium tetrafluoroborate salt and subsequently to 125I labeled compound using Na125I. A represented procedure was reported by Zhu, G-D. and co-workers in J. Org. Chem., 2002, 67, 943-948. B. Ortho 125Iodination of phenols: This procedure allows for the incorporation of 125I at the ortho position of a phenol as reported by Collier, T. L. and co-workers in J. Labelled Compd. Radiopharm., 1999, 42, S264-S266.
C. Aryl and heteroaryl bromide exchange with 125I: This method is generally a two step process. The first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, a Pd catalyzed reaction [i.e. Pd(Ph3P)4] or through an aryl or heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g., (CH3)3SnSn(CH3)3]. A representative procedure was reported by Le Bas, M.-D. and co-workers in J. Labelled Compd. Radiopharm. 2001, 44, S280-S282.
A radiolabeled 5-HT2A serotonin receptor compound of Formula (Ia) can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the "radio-labeled compound of Formula (Ia)" to the 5-HT2A-receptor. Accordingly, the ability of a test compound to compete with the "radio-labeled compound of Formula (Ia)" for the binding to the 5-HT2A serotonin receptor directly correlates to its binding affinity. The labeled compounds of the present invention bind to the 5-HT2A serotonin receptor.
In one embodiment the labeled compound has an IC50 less than about 500 μM, in another embodiment the labeled compound has an IC50 less than about 100 μM, in yet another
embodiment the labeled compound has an IC50 less than about 10 μM, in yet another embodiment the labeled compound has an IC50 less than about 1 μM and in still yet another embodiment the labeled inhibitor has an IC50 less than about 0.1 μM.
Other uses of the disclosed receptors and methods will become apparent to those in the art based upon, inter alia, a review of this disclosure.
As will be recognized, the steps of the methods of the present invention need not be performed any particular number of times or in any particular sequence. Additional objects, advantages and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are intended to be illustrative and not intended to be limiting.
EXAMPLES Example 1 : Syntheses of compounds of the present invention.
Illustrated syntheses for compounds of the present invention are shown in Figures 1 through 5 where the symbols have the same definitions as used throughout this disclosure.
The compounds of the invention and their syntheses are further illustrated by the following examples. The following examples are provided to further define the invention without, however, limiting the invention to the particulars of these examples. The compounds described herein, supra and infra, are named according to the CS ChemDraw Ultra Version 7.0.1, AutoNom version 2.2, or CS ChemDraw Ultra Version 9.0.7. In certain instances common names are used and it is understood that these common names would be recognized by those skilled in the art.
Chemistry: Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker Avance-400 equipped with a QNP (Quad Nucleus Probe) or a BBI (Broad Band Inverse) and z-gradient. Chemical shifts are given in parts per million (ppm) with the residual solvent signal used as reference. NMR abbreviations are used as follows: s = singlet, d = doublet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dt = doublet of triplets, t = triplet, td = triplet of doublets, tt = triplet of triplets, q = quartet, m = multiplet, bs = broad singlet, bt = broad triplet. Microwave irradiations were carried out using a Smith Synthesizer™ or an Emrys Optimizer™ (Biotage). Thin-layer chromatography (TLC) was performed on silica gel 60 F254 (Merck), preparatory thin-layer chromatography (prep TLC) was preformed on PK6F silica gel 60 A 1 mm plates (Whatman) and column chromatography was carried out on a silica gel column using Kieselgel 60, 0.063-0.200 mm (Merck). Evaporation was done under reduced pressure on a Bϋchi rotary evaporator. LCMS spec: HPLC-pumps: LC-IOAD VP, Shimadzu Inc.; HPLC system controller:
SCL-IOA VP, Shimadzu Inc; UV-Detector: SPD-IOA VP, Shimadzu Inc; Autosampler: CTC
HTS, PAL, Leap Scientific; Mass spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex; Software: Analyst 1.2.
Example 1.1: Preparation of (3-Bromoimidazo[l,2-α]pyridin-8-yl)(4-(2,4- difluorophenethyl)piperazin-l-yl)methanone (Compound 1).
Step A: Preparation of Imidazo[l,2-α]pyridine-8-carboxylic Acid.
2-Aminonicotinic acid (2.0 g, 14.48 mmol) and 2-bromo-l,l-diethoxyethane (2.247 mL, 14.48 mmol) in acetonitrile (10 mL) were heated at 150 0C for 2 h under microwave irradiation. The resulting precipitate was filtered off and washed with acetonitrile and hexane to afford the title compound (2.783 g) as a solid. Exact mass calculated for C8H6N2O2: 162.0. Found: LCMS mlz = 163.1 (M + H)+. 1H NMR (400 MHz, Methanol-^) δ 7.62 (dd, J = 6.82, 7.33 Hz, IH), 8.06 (d, J = 2.27 Hz, IH), 8.36 (d, J = 2.02 Hz, IH), 8.62 (d, J = 7.33 Hz, IH), 9.04 (d, J = 6.82 Hz, IH). Step B: Preparation of 3-Bromoimidazo[l,2-α]pyridine-8-carboxylic Acid.
Imidazo[l,2-α]pyridine-8-carboxylic acid (100 mg, 617 μmol), l-bromopyrrolidine-2,5- dione (110 mg, 617 μmol) and N,N-dimethylformamide (1.5 mL) were stirred at room temperature for 1 h. The resulting precipitate was filtered off and washed with acetonitrile and hexane to afford the title compound as a solid (68 mg). Exact mass calculated for C8H5BrN2O2: 239.95. Found: LCMS mlz (%) = 241.2 ((M + H)+, 79Br, 100%), 243.2 ((M + H)+, 81Br, 97%). 1H NMR (400 MHz, Methanol-^) δ 7.58 (t, J = 7.07 Hz, IH), 8.13 (s, IH), 8.50 (d, J = 7.58 Hz, IH), 8.84 (d, J = 7.07 Hz, IH).
Step C: Preparation of (3-Bromoimidazo[l,2-α]pyridin-8-yl)(4-(2,4- difluorophenethyl)piperazin-l-yl)methanone (Compound 9). l-(2,4-Difiuorophenethyl)piperazine hydrochloride (84 mg, 0.28 mmol) was added to a solution of 3-bromoimidazo[l,2-α]pyridine-8-carboxylic acid (68 mg, 0.28 mmol), 2-(3H- [1 ,2,3]triazolo[4,5-6]pyridin-3-yl)-l , 1 ,3,3-tetramethylisouronium hexafluorophosphate (ΗATU) (138 mg, 364 μmol) and triethylamine (117 μL, 840 μmol) in TΗF (2.7 mL). The reaction mixture was heated at 100 0C under microwave irradiation for 20 min. The solvent was removed under reduced pressure and the residue was purified by preparative ΗPLC to afford the TFA salt of the title compound as a solid (162 mg). Exact mass calculated for C20H19BrF2N4O: 448.1. Found: LCMS mlz (%) = 449.1 ((M + H)+, 79Br, 100%), 451.1 ((M + H)+, 81Br, 97%). 1H NMR (400 MHz,
δ 3.01-3.14 (m, 2H), 3.14-3.91 (m, 10H), 6.93-7.01 (m, 2H), 7.34 (dd, J = 8.59, 15.16 Hz, IH), 7.50 (t, J = 7.07 Hz, IH), 7.85 (d, J= 7.33 Hz, IH), 8.02 (s, IH), 8.56 (d, / = 7.07 Hz, IH).
Example 1.2: Preparation of 8-(4-(2,4-Difluorophenethyl)piperazine-l- carbonyl)imidazo[l,2-α]pyridine-3-carbonitrile (Compound 2).
(3-Bromoimidazo[l,2-α]pyridin-8-yl)(4-(2,4-difluorophenethyl)piperazm-l- yl)methanone (26 mg, 58 μmol ) was added to a solution of dicyanozinc (6.8 mg, 58 μmol), tetrakis(triphenylphosphine)palladium(0) (2.0 mg, 1.736 μmol) and triethylamine (8.1 μL, 58 μmol) in DMF (1.0 mL). The reaction mixture was heated at 120 0C under microwave irradiation for 20 min. The crude mixture was purified by preparative HPLC to afford the TFA salt of the title compound as a solid (5.3 mg). Exact mass calculated for C2IH19F2N5O: 395.2.
Found: LCMS mlz = 396.3 (M + H)+. 1H NMR (400 MHz,
δ 3.10-3.17 (m, 2H), 3.38-3.45 (m, 2H), 3.46-3.58 (m, 4H), 3.72-4.24 (m, 4H), 6.93-6.99 (m, 2H), 7.26 (t, J = 7.07 Hz, IH), 7.31-7.37 (m, IH), 7.60 (d, J = 7.07 Hz, IH), 8.24 (s, IH), 8.53 (d, J = 7.07 Hz, IH).
Example 1.3: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 3).
Step A: Preparation of Imidazo[l,2-α]pyridine-8-carboxylic Acid.
To a mixture of 2-aminonicotinic acid (0.6906 g, 5.00 mmol) in acetonitrile (20 mL) was added bromoacetaldehyde dimethyl acetal (0.591 mL, 5.00 mmol). The resulting slurry was heated at 150 0C under microwave irradiation for 2 h. The resulting precipitate was filtered off and washed with acetonitrile and hexane to afford the title compound (0.924 g) as a grey solid. Exact mass calculated for C8H6N2O2: 162.04. Found: LCMS mlz = 163.3 (M + H)+. 1H NMR (400 MHz, DMSO-<4) δ 7.58-7.69 (m, IH), 8.15 (d, J= 2.27 Hz, IH), 8.50 (dd, J= 7.45, 1.14 Hz, IH), 8.56 (d, J= 2.02 Hz, IH), 9.20 (dd, J= 6.69, 1.14 Hz, IH).
Step B: Preparation of terf-Butyl 4-(2-(2,4-difluorophenyl)acetyl)piperazine-l- carboxylate.
2-(2,4-Difluorophenyl)acetic acid (5.00 g, 29.1 mmol), lH-benzo[d][l,2,3]triazol-l-ol (4.46 g, 29.1 mmol), N1-((ethylimino)methylene)-N3 y/V3-dimethylpropane-l,3-diamine hydrochloride (EDAC) (5.57 g, 29.1 mmol) and triethylamine (4.05 mL, 29.1 mmol) were stirred in DCM (30 mL) for 15 min. /erf-Butyl piperazine-1-carboxylate (2.71 g, 14.5 mmol) was added and the mixture was stirred at room temperature for 8 h. The reaction was diluted
with DCM (10 mL), washed with 1 N NaOH (5 mL) followed by 1 M citric acid (5 mL). The organic extracts were dried over Na2SO4, filtered and concentrated. The oily residue was purified by preparative HPLC. The fractions containing the desired product were lyophilized to afford material that was neutralized with NaHCO3 (75 mL) and extracted with EtOAc (2 x 200 mL). The organic extracts were dried over Na2SO4, filtered and concentrated to afford the title compound (1.68 g) as a yellow solid. Exact mass calculated for C17H22F2N2O3: 340.2. Found: LCMS mlz = 341.3 (M + H)+. 1H NMR (400 MHz, DMSO-^5) δ 1.42 (s, 9H), 3.25-3.39 (m, 4H), 3.42-3.48 (m, 2H), 3.49-3.56 (m, 2H), 3.74 (s, 2H), 7.02 (dt, J= 2.7, 8.5 Hz, IH), 7.18 (dt, J= 2.6, 9.7 Hz, IH), 7.25-7.33 (m, IH). Step C: Preparation of tert-Butyl 4-(2,4-Difluorophenethyl)piperazine-l- carboxylate. tert-Butyl 4-(2-(2,4-difluorophenyl)acetyl)piperazine-l-carboxylate (1.12 g, 3.30 mmol) was dissolved in THF (8.5 mL) and borane tetrahydrofuran complex (1.0 M, 15.8 mL, 15.8 mmol) was added. The reaction was refluxed at 66 0C. The reaction was quenched slowly with methanol (0.4 mL) dropwise. Then, 0.5 M HCl (10.0 mL) was added and the mixture was extracted with EtOAc (2 x 100 mL). The organic extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC. The fractions containing the desired product were added to NaHCO3 (20 mL) and extracted with EtOAc (2 x 100 mL). The organic extracts were dried over Na2SO4, filtered and concentrated to yield the title compound (1.08 g) as a white solid. Exact mass calculated for CnH24F2N2O2: 326.2. Found: LCMS mlz = 327.1 (M + H)+. 1H NMR (400 MHz, DMSO-<2tf) δ 1.41 (s, 9H), 2.80-2.96 (m, 6H), 3.10-3.03 (m, 2H), 3.50-3.60 (m, 4H), 7.06 (dt, J= 2.6, 8.5 Hz, IH), 7.22 (dt, J= 2.6, 9.6 Hz, IH), 7.38- 7.46 (m, IH).
Step D: Preparation of l-(2,4-Difluorophenethyl)piperazine. tert-Butyl 4-(2,4-difluorophenethyl)piperazine-l-carboxylate (0.853 g, 2.61 mmol) was dissolved in 4 M HCl in dioxane (10.0 mL) and stirred for 1 h. The reaction was concentrated to afford the hydrochloride salt of the title compound (0.718 g) as a pale solid. Exact mass calculated for C12H16F2N2: 226.1. Found: LCMS mlz = 227.2 (M + H)+. 1H NMR (400 MHz, DMSO-40 δ 2.95-3.75 (m, 12H), 6.03-6.80 (bs, IH), 7.04-7.12 (m, IH), 7.24 (dt, J= 2.6, 9.6 Hz, IH), 7.39-7.50 (m, IH).
Step E: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 3).
To a solution of imidazo[l,2-α]pyridine-8-carboxylic acid (36.6 mg, 226 μmol), l-(2,4- difluorophenethyl)piperazine hydrochloride (45.0 mg, 150 μmol) and triethylamine (210 μl, 1504 μmol) in DMF (0.75 mL) was added 1-propylphosphonic acid anhydride solution (50% in ethyl acetate, 183 μL, 0.301 mmol). The mixture was stirred for 2 h, quenched with water and purified by preparative HPLC/MS. The resultant lyophilate was dissolved in DCM, treated with
MP-carbonate resin (-200 mg). The mixture was stirred for 30 min and filtered to remove the resin. The solvent was removed under reduced pressure to afford the title compound as a white solid (33.0 mg). Exact mass calculated for C20H20F2N4O: 370.16. Found: LCMS mlz = 371.4 (M + H)+. 1H NMR (400 MHz, CDCl3) δ 2.45-2.53 (m, 2H), 2.57-2.64 (m, 2H), 2.64-2.71 (m, 2H), 2.74-2.84 (m, 2H), 3.29-3.43 (m, 2H), 3.85-3.98 (m, 2H), 6.69-6.92 (m, 3H), 7.10-7.21 (m, IH), 7.23-7.28 (m, IH), 7.64 (d, J= 1.26 Hz, IH), 7.69 (d, J= 1.26 Hz, IH), 8.18 (dd, J = 6.82, 1.26 Hz3 IH).
Example 1.4: Preparation of l-(4-FIuorophenyl)-2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 4).
Step A: Preparation of tert-Butyl 4-(2-(4-Fluorophenyl)-2-oxoethyl)piperazine-l- carboxylate. tert-Butyl piperazine-1-carboxylate (5.00 g, 26.8 mmol) and 2-bromo-l-(4- fluorophenyl)ethanone (6.99 g, 32.2 mmol) were dissolved in DMF (5 mL) and stirred for 10 min at room temperature. The crude material was purified by column chromatography eluting with a mixture of DCM and MeOH to afford the title compound (3.50 g) as an oil. Exact mass calculated for C17H23FN2O3: 322.2. Found: LCMS mlz = 323.4 (M + H)+. 1H NMR (400 MHz, Acetonitrile-έ/j) δ 1.42 (s, 9H) 2.47 (t, J = 5.0 Hz, 4H), 3.36 (t, J = 5.0 Hz, 4H), 3.77 (s, 2H), 7.20 (t, J = 8.8, 2H), 8.07 (td, J = 2.0, 8.8 Hz, 2H).
Step B: Preparation of l-(4-Fluorophenyl)-2-(piperazin-l-yl)ethanone. The oil from Step A was dissolved in 4 M HCl in dioxane (12 mL) and stirred at 45 0C for 20 min. The solvent was removed under reduced pressure to afford the hydrochloride salt of the title compound (1.80 g) as a white solid. Exact mass calculated for Ci2H15FN2O: 222.1. Found: LCMS mlz = 223.3 (M + H)+. 1H NMR (400 MHz, Acetonitrile-rfj) δ 3.56 (s, 8H), 5.05 (s, 2H), 7.46 (t, J = 8.8, 2H), 8.10 (td, J = 2.1, 8.8 Hz, 2H).
Step C: Preparation of l-(4-Fluorophenyl)-2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 4).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using imidazo[l,2-α]pyridme-8-carboxylic acid (24.3 mg) and l-(4-fluorophenyl)-2- (piperazin-l-yl)ethanone hydrochloride (29.5 mg) as starting materials, to afford a brown oil (28.2 mg). Exact mass calculated for C20H19FN4O2: 366.15. Found: LCMS mlz = 367.3 (M + H)+.
Example 1.5: Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(imidazo[l,2-α]pyridin- 8-yl)methanone (Compound 5).
Step A: Preparation of te/t-Butyl 4-(4-fluorophenethyl)piperazine-l-carboxylate. fert-Butyl piperazine-1 -carboxylate (1.00 g, 5.37 mmol) was dissolved in DMF (20 mL). l-(2-Bromoethyl)-4-fluorobenzene (2.62 g, 12.9 mmol) and potassium carbonate (2.23 g, 16.1 mmol) were then added to the solution. The reaction was heated for 1 h at 120 0C under microwave irradiation in a heavy- walled sealed tube. The product was purified by HPLC (5- 95% acetonitrile/water) to afford the TFA salt of the title compound (1.65 g) as an oil. Exact mass calculated for C17H25FN2O2: 308.2. Found: LCMS mlz = 309.4 (M + H)+. Step B: Preparation of l-(4-Fluorophenethyl)piperazine. tert-Butyl 4-(4-fluorophenethyl)piperazine-l -carboxylate (1.65 g, 5.37 mmol) and 4 M HCl in dioxane (6 mL) were stirred at 43 0C for 1 h. The product was purified by HPLC (5- 50% acetonitrile/water) to afford the TFA salt of the title compound (510 mg) as a solid. Exact mass calculated for C12HnFN2: 208.1. Found: LCMS mlz = 209.0 (M + H)+.
Step C: Preparation of (4-(4-FluorophenethyI)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 5).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using imidazo[l,2-α]pyridine-8-carboxylic acid (24.3 mg) and l-(4-fluorophenethyl)- piperazine hydrochloride (28.1 mg) as starting materials, to afford an orange solid (34.2 mg).
Exact mass calculated for C20H21FN4O: 352.17. Found: LCMS mlz = 353.4 (M + H)+. 1H NMR (400 MHz, CDCl3) δ 2.43-2.54 (m, 2H), 2.65-2.70 (m, 2H), 2.73-2.81 (m, 2H), 3.36 (t, J = 4.80 Hz, 3H), 3.90-3.97 (m, 3H), 6.84 (t, J= 6.82 Hz, IH), 6.92-7.00 (m, 2H), 7.15 (dd, J = 8.59, 5.56 Hz, 2H), 7.23-7.26 (m, IH), 7.63 (d, J = 1.01 Hz, IH), 7.68 (d, J= 1.01 Hz, IH), 8.13-8.22 (m, IH).
Example 1.6: Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2- (trifluoromethyl)imidazo[l,2-α]pyridin-8-yI)methanone (Compound 6).
To a slurry of 2-aminonicotinic acid (2.07 g, 15 mmol) in methanol (45 mL) was added 2.0 M TMS-diazomethane in hexane (15 mL, 30 mmol) and the mixture was stirred for 30 min.
The resulting yellow solution was quenched with acetic acid (10 mL) and concentrated under reduced pressure and azeotroped with hexane. The residue was taken up in MeOH and treated with MP-carbonate resin (1O g, -30 mmol) for 30 min. The mixture was filtered to remove the resin and the filtrate was concentrated under vacuum. The residue was purified via column chromatography (1 :9-l :2 EtOAc/hexane) to afford the title compound as a white solid (1.63 g). 1H NMR (400 MHz, DMSO-J6) δ 3.81 (s, 3H), 6.62 (dd, J = 7.83, 4.55 Hz, IH), 7.17 (bs, 2H), 8.05 (dd, J= 7.83, 2.02 Hz, IH), 8.21 (dd, J= 4.55, 2.02 Hz, IH).
Step B: Preparation of Methyl 2-Trifluoromethyl-imidazo[l,2-α]pyridine-8- carboxylate. To a solution of methyl 2-aminonicotinate (0.304 g) in acetonitrile (10 mL) was added
3-bromo-l,l,l-trifluoroacetone (0.230 mL). The resulting solution was heated to 80 0C for 18 h. The solution was cooled to room temperature and concentrated under reduced pressure. The residue was taken up in water, K2CO3 (0.691 g, 5 mmol) was added and the mixture was extracted 3 times with EtOAc. The combined extracts were washed with brine, dried over MgSO4 and concentrated. The residue was purified via column chromatography (1:5-1:1
EtOAc/hexane) to afford the title compound as a white solid (0.148 g). 1H NMR (400 MHz, CDCl3) δ 4.05 (s, 3H), 7.03 (t, J= 7.07 Hz, IH), 7.99 (s, IH), 8.10 (dd, J= 7.07, 1.26 Hz, IH), 8.35 (dd, J= 6.82, 1.26 Hz, IH).
Step C: Preparation of 2-Trifluoromethyl-imidazo[l,2-α]pyridine-8-carboxyIic Acid.
To a solution of methyl 2-trifluoromethyl-imidazo[l,2-α]pyridine-8-carboxylate (0.148 g, 0.606 mmol) in 5 mL of H2O/EtOH (1:2) was added 5 M NaOH (0.195 mL, 0.975 mmol). The solution was heated to reflux for 2 h. After neutralization with 1 M HCl (1.0 mL, 1.0 mmol), the solution was cooled in a freezer overnight. The resulting precipitate was filtered off and washed with EtOH to afford the title compound as a white solid (0.0676 g). 1H NMR (400 MHz, DMSO-J6) δ 7.18 (t, J= 6.95 Hz, IH), 8.03 (dd, J= 7.20, 1.14 Hz, IH), 8.66 (s, IH), 8.81 (dd, J= 6.82, 1.01 Hz, IH), 13.34 (bs, IH).
Step D: Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2- (trifluoromethyl)imidazo[l,2-α]pyridin-8-yl)methanone (Compound 6). The title compound was prepared in a manner similar to that described in Example 1.3,
Step E, using 2-trifluoromethyl-imidazo[l,2-a]pyridine-8-carboxylic acid (34.5 mg) and l-(4- fluorophenethyl)-piperazine hydrochloride (28.2 mg) as starting materials, to afford a clear oil (12.8 mg). Exact mass calculated for C2IH20F4N4O: 420.16. Found: LCMS mlz = 421.3 (M + H)+.
Example 1.7: Preparation of (2-tert-Butylimidazo[l,2-α]pyridin-8-yl)(4-(4- fluorophenethyl)piperazin-l-yl)methanone (Compound 7).
Step A: Preparation of Methyl 2-tert-Butyl-imidazo[l,2-α]pyridine-8-carboxylate.
The title compound was prepared in a manner similar to that described in Example 1.6, Step B, using l-bromo-3,3-dimethylbutan-2-one (90%, 0.4439 mL) and methyl 2- aminonicotinate (0.304 g) as starting materials, to afford a white solid (0.303 g). 1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 4.01 (s, 3H), 6.78 (t, J = 6.95 Hz, IH), 7.42 (s, IH), 7.90 (d, J = 7.33 Hz, IH), 8.22 (d, J= 6.82 Hz, IH).
Step B: Preparation of 2-ferr-Butyl-imidazo[l,2-α]pyridine-8-carboxylic Acid.
The title compound was prepared in a manner similar to that described in Example 1.4, Step C, using methyl 2-tert-butyl-imidazo[l,2-α]pyridine-8-carboxylate (0.303 g) as starting material, to afford a white solid (0.0911 g). 1H NMR (400 MHz, DMSO-J6) δ 1.40 (s, 9H), 7.36 (t, J= 6.95 Hz, IH), 8.14 (s, IH), 8.21 (d, J= 7.07 Hz, IH), 8.91 (dd, J= 6.82, 1.01 Hz, IH).
Step C: Preparation of (2-terf-Butylimidazo[l,2-α]pyridin-8-yI)(4-(4- fluorophenethyl)piperazin-l-yl)methanone (Compound 7). The title compound was prepared in a manner similar to that described in Example 1.3,
Step E, using 2-ter/-butyl-imidazo[l,2-α]pyridine-8-carboxylic acid (32.7 mg) and l-(4- fluorophenethyl)-piperazine hydrochloride (28.2 mg) as starting materials, to afford a clear oil (12.8 mg). Exact mass calculated for C24H29FN4O: 408.23. Found: LCMS mlz = 409.5 (M + H)+. 1H NMR (400 MHz, CDCl3) δ 1.36 (s, 9H), 2.57 (bs, 2H), 2.59-2.66 (m, 2H), 2.70 (t, J = 4.93 Hz, 2H), 2.76-2.84 (m, 2H), 3.30-3.38 (m, 2H), 3.93 (bs, 2H), 6.74 (t, J= 6.95 Hz, IH), 6.93-7.02 (m, 2H), 7.10-7.20 (m, 2H), 7.20-7.25 (m, IH), 7.36 (s, IH), 8.08 (dd, J= 6.69, 1.14 Hz, IH).
Example 1.8: Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2-methylimidazo[l,2- α]pyridin-8-yl)methanone (Compound 8).
Step A: Preparation of Methyl 2-Methyl-imidazo[l,2-α]pyridine-8-carboxylate.
The title compound was prepared in a manner similar to that described in Example 1.6, Step B, using l-bromo-2,2-dimethoxypropane (0.271 mL) and methyl 2 -aminonicotinate (0.304 g) as starting materials, to afford a beige solid (0.102 g). 1H NMR (400 MHz, CDCl3) δ 2.54 (s, 3H), 4.04 (s, 3H), 6.82 (t, J= 6.95 Hz, IH), 7.43 (s, IH), 7.93 (dd, J= 7.33, 1.26 Hz, IH), 8.22 (dd, J= 6.57, 1.26 Hz, IH).
Step B: Preparation of 2-MethyI-imidazo[l,2-α]pyridine-8-carboxylic Acid, Sodium Salt.
To a solution of methyl 2 -methyl -imidazo[l,2-α]pyridine-8-carboxylate (0.100 g, 0.525 mmol) in 6 mL of H2O/EtOH (1 :2) was added 1 M NaOH (578 μl, 578 μmol). The solution was heated to reflux for 1 h. The solution was cooled to room temperature and concentrated under reduced pressure to afford the title compound as a white solid (0.104 g). 1H NMR (400 MHz, DMSO-^6) δ 2.33 (s, 3H), 4.14 (bs, IH), 6.77 (t, J= 6.82 Hz, IH), 7.56 (dd, J = 7.07, 1.52 Hz, IH), 7.62 (s, IH), 8.38 (dd, J = 6.57, 1.26 Hz, IH).
Step C: Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2-methylimidazo[l,2- α]pyridin-8-yl)methanone (Compound 8).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using 2-methyl-imidazo[l,2-α]pyridine-8-carboxylic acid, sodium salt (26.4 mg) and 1- (4-fluorophenethyl)-piperazine hydrochloride (28.1 mg) as starting materials, to afford a white solid (27.9 mg). Exact mass calculated for C2IH23FN4O: 366.19. Found: LCMS mlz = 367.5 (M + H)+. 1H NMR (400 MHz, CDCl3) δ 2.46 (s, 3H), 2.58-2.64 (m, 4H), 2.67 (bs, 2H), 2.73-2.82 (m, 2H), 3.38 (t, J= 4.80 Hz, 2H), 3.93 (bs, 2H), 6.77 (t, J= 6.82 Hz, IH), 6.92-7.01 (m, 2H), 7.10-7.21 (m, 3H), 7.38 (s, IH), 8.07 (dd, J= 6.69, 1.14 Hz, IH).
Example 1.9: Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2-phenylimidazo[l,2- α]pyridin-8-yl)methanone (Compound 9).
Step A: Preparation of Methyl 2-Phenyl-imidazo[l,2-α]pyridine-8-carboxylate.
The title compound was prepared in a manner similar to that described in Example 1.6, Step B, using bromoacetophenone (0.398 g) and methyl 2-aminonicotinate (0.304 g) as starting materials, to afford a white solid (0.310 g). 1H NMR (400 MHz, CDCl3) δ 4.08 (s, 3H), 6.88 (t, J= 6.95 Hz, IH), 7.32-7.38 (m, IH), 7.41-7.48 (m, 2H), 7.96 (s, IH), 7.99 (dd, J= 7.07, 1.26 Hz, IH), 8.01-8.05 (m, 2H), 8.32 (dd, J= 6.57, 1.26 Hz, IH).
Step B: Preparation of 2-Phenyl-imidazo[l,2-α]pyridine-8-carboxylic Acid, Sodium Salt. The title compound was prepared in a manner similar to that described in Example 1.8,
Step B, using methyl 2-phenyl-imidazo[l,2-α]pyridine-8-carboxylate (0.310 g) as starting material, to afford a white solid (0.320 g). 1H NMR (400 MHz, DMSO-rftf) δ 7.13 (t, J= 6.95 Hz, IH), 7.34-7.42 (m, IH), 7.50 (t, J= 7.58 Hz, 2H), 7.93-8.03 (m, 3H), 8.61 (s, IH), 8.82 (dd, J= 6.69, 1.14 Hz, IH).
Step C: Preparation of (4-(4-Fluorophenethyl)piperazin-l-yl)(2-phenylimidazo[l,2- α]pyridin-8-yl)methanone (Compound 9).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using 2-phenyl-H -imidazo[l,2-α]pyridine-8-carboxylic acid, sodium salt (28.6 mg) and l-(4-fluorophenethyl)-piperazine hydrochloride (28.1 mg) as starting materials, to afford a white solid (37.8 mg). Exact mass calculated for C26H25FN4O: 428.20. Found: LCMS mlz = 429.3 (M + H)+. 1H NMR (400 MHz, CDCl3) δ 2.58 (bs, 2H), 2.63-2.69 (m, J= 8.34 Hz, 2H), 2.74 (bs, 2H), 2.77-2.85 (m, 2H), 3.44 (bs, 2H), 3.97 (bs, 2H), 6.84 (t, J= 6.82 Hz, IH), 6.93-7.03 (m, 2H), 7.10-7.20 (m, 2H), 7.29-7.37 (m, 2H), 7.39-7.47 (m, 2H), 7.92 (s, IH), 7.96-8.02 (m, 2H), 8.18 (dd, J= 6.82, 1.26 Hz, IH).
Example 1.10: Preparation of (4-(2-Fluoro-2-(4-fluorophenyl)ethyl)piperazin-l- yl)(imidazo[l,2-α]pyridin-8-yl)methanone (Compound 10).
Step A: Preparation of tert-Butyl 4-(l-Fluoro-2-(4-fluorophenyl)ethyl)piperazine-l- carboxylate. l-(2-Bromo-l-fluoroethyl)-4-fluorobenzene (334 mg, 1.511 mmol), prepared as described by Schlosser et al, Tetrahedron 60, 2004, 7731-7742, was dissolved in DMF (1.5 mL). tert-Buty\ piperazine-1-carboxylate (310 mg, 1.662 mmol), potassium hydrogen carbonate (151 mg, 1.511 mmol) and potassium iodide (25.08 mg, 0.151 mmol) were added and the mixture was stirred at 80 0C overnight. The reaction mixture was cooled to room temperature, diluted with water and extracted twice with dichloromethane. The combined extracts were dried with sodium sulfate, filtered and concentrated to dryness. The crude product was purified by flash chromatography on silica gel (ethyl acetate:hexanes, 1:1) to afford the title compound as a white solid (142 mg, 28.8%). Exact mass calculated for CnH24F2N2O2: 326.18. Found: LCMS mlz = 327.4 (M + H)+. 1H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 2.62 (ddd, J= 33.3, 14.3, 2.8 Hz, IH) 2.62-2.45 (m, 4H), 2.90 (ddd, J= 17.3, 14.3, 8.6 Hz, IH), 3.46 (t, J= 4.8 Hz, 4H), 5.63 (ddd, J= 40.5, 8.6, 2.5 Hz, IH), 7.07 (t, J= 8.6 Hz, 2H), 7.32 (dd, J= 8.5, 5.6 Hz, 2H). Step B: Preparation of l-(2-Fluoro-2-(4-fluorophenyl)ethyl)piperazine Dihydrochloride Salt.
Acetyl chloride (0.152 mL, 2.145 mmol) was added dropwise to ice cold methanol (4 mL) while stirring vigorously. After the addition was complete, the ice bath was removed and the solution was stirred at room temperature. After 15 min, the solution was transferred to a flask containing tert-buty\ 4-(2-fluoro-2-(4-fluorophenyl)ethyl)piperazine-l-carboxylate (140 mg, 0.429 mmol) and the mixture was stirred at room temperature for 4 h. The precipitate was
isolated by filtration, washed with ice-cold methanol and ether and dried under reduced presure over KOH to afford the title compound as a white solid (104 mg, 81%). Exact mass calculated for C12H16F2N2: 226.13. Found: LCMS mlz = 227.4 (M + H)+. 1H NMR (400 MHz, D2O) δ 3.35 (ddd, J= 35.6, 14.3, 2.2 Hz, IH), 3.56-343 (m, 8H), 3.65 (ddd, J= 14.3, 13.3, 10.3 Hz, IH), 5.99 (ddd, J = 49.1, 10.3, 1.8 Hz, IH), 7.08 (t, J= 8.9 Hz, 2H), 7.35 (dd, J= 7.7, 5.5 Hz, 2H).
Step C: Preparation of (4-(2-Fluoro-2-(4-fluorophenyl)ethyl)piperazin-l- yl)(imidazo[l,2-α]pyridin-8-yl)methanone (Compound 10).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using imidazo[l,2-α]pyridine-8-carboxylic acid (24.3 mg) and 1 -(2-fluoro-2-(4- fluorophenyl)ethyl)piperazine hydrochloride (29.9 mg) to afford a white solid (31.0 mg). Exact mass calculated for C20H20F2N4O: 370.16. Found: LCMS mlz = 370.9 (M + H)+.
Example 1.11: Preparation of (3-Chloroimidazo[l,2-α]pyridin-8-yl)(4-(2,4- difluorophenethyl)piperazin-l-yl)methanone (Compound 11).
(4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2-α]pyridin-8-yl)methanone (500 mg, 1.350 mmol), l-chloropyrrolidine-2,5-dione (216 mg, 1.620 mmol) and 2-propanol (10 mL) were stirred at room temperature for 1 h. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC to afford the TFA salt of the title compound as a solid (348 mg). Exact mass calculated for C20H19ClF2N4O: 404.1. Found: LCMS mlz (%) = 405.3 ((M + H)+, 35Cl, 100%), 407.3 ((M + H)+, 37Cl, 32%). 1H NMR (400 MHz, Acetonitrile- d3) δ 3.10-3.17 (m, 2H), 3.38-3.45 (m, 2H), 3.46-3.58 (m, 4H), 3.72-4.24 (m, 4H), 6.93-7.00 (m, 2H), 7.30-7.36 (m, IH), 7.37-7.41 (m, IH), 7.71 (d, J= 7.07 Hz, IH), 7.89 (s, IH), 8.47 (d, J = 7.07 Hz, IH).
Example 1.12: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone Hydrochloride Salt (Compound 3).
To a mixture of 2-aminonicotinic acid, (152.19 g, 1.102 mol) was added chloroacetaldehyde (45 wt % in water, 230 mL and 1.31 mol). The resulting slurry was heated
to 60 0C in an oil bath with efficient stirring. The slurry gradually became homogenous and a strong exothermic reaction increasing the temperature by 20-22 0C was noticed. The heating was discontinued and the reaction mixture was allowed to cool to room temperature. Solids started separating out, the resulting slurry was diluted with isopropanol (870 mL) and the mixture was stirred at room temperature for 1 h followed by cooling to 0-10 0C for an additional 1 h. The solids were filtered off and washed with isopropanol (435 mL) and heptanes (2 x 140 mL) and dried at 40 °C in vacuum oven to afford the title compound (200.3 g, 92%) as a pale tan solid. Exact mass calculated for C8H6N2O2: 162.04. Found: LCMS mlz = 163.0 (M + H)+. 1H NMR (400 MHz, D2O) δ 7.53 (t, J = 7.0 Hz, IH), 7.96 (d, J = 1 Hz, IH), 8.25 (d, J = 1 Hz, IH), 8.45 (d, J= IA Hz, IH), 8.93 (d, J= 6.7 Hz, IH).
Step B: Preparation of Imidazo[l,2-α]pyridine-2-carbonyl chloride Hydrochloride. Method 1: To imidazo[l,2-α]pyridine-8-carboxylic acid hydrochloride (10.0 g, 50.4 mmol), thionyl chloride (98 g, 60 mL, 822 mmol) was added. To the resulting mixture N,N- dimethylformamide (1.6 mL) was added. Gas evolution was noticed and the reaction mixture was heated to 50 0C overnight (18 h). The reaction mixture was then cooled to room temperature and the product was filtered and washed with isopropyl acetate (40 mL) followed by 10% isopropanol in isopropyl acetate (40 mL). The white solid thus obtained was dried under reduced pressure to afford the title compound (10.2 g, 93%). The compound was used without further purification in Step E. Method 2: To imidazo[l,2-α]pyridine-8-carboxylic acid hydrochloride (15.0 g, 76 mmol), toluene (80 mL) was added followed by thionyl chloride (17.4 g, 146 mmol). To the resulting mixture, N^N-dimethylformamide (1.15 mL) was added. Gas evolution was noticed and the mixture was stirred at ambient temperature for 30 min and then was heated to 50 0C overnight (18 h). The reaction mixture was then cooled to room temperature for 30 min and the product was filtered and washed with isopropyl acetate (40 mL) followed by ethyl acetate (40 mL). The white solid was dried under reduced pressure to afford the title compound (13.4 g, 82%). The compound was used without further purification in step E. 1H ΝMR (400 MHz, DMSO-<4) δ 7.69 (t, J= 6.98 Hz, IH), 8.18 (d, J= 1 Hz, IH), 8.53 (m, IH), 8.65 (d, J= IHz, IH), 9.27 (d, J= 6.7 Hz, IH), 13.9-14.4 (br, IH). Step C: Preparation of tert-Butyl 4-(2-(2,4-Difluorophenyl) acetyl)piperazine-l- carboxylate.
Method 1: 2-(2,4-Difluorophenyl)acetic acid (100 g, 0.58 mol), boric acid (3.63g, 58.7 mmol) and phenylboronic acid (3.58 g, 29.36 mmol) were dissolved in toluene (700 mL). After 15 min, tert-butyl piperazine-1-carboxylate (121 g, 0.65 mol) was added portionwise and the resulting mixture was heated to 110 0C with stirring. The reaction flask was equipped with a Dean-Stark apparatus to remove water. The mixture was maintained under gentle reflux for 48 h until the theoretical amount of water was collected. After completion of reaction, the mixture
was cooled to 20-25 0C and concentrated using a rotary evaporator. The residue was diluted with ethyl acetate (500 mL) and washed with water (75 mL). The organic extracts were dried over sodium sulfate (Na2SO4), filtered and concentrated to afford a sticky solid, which was triturated with ethyl acetate/heptanes (2: 1, 350 mL). The solid thus formed was filtered and dried to afford the title compound (146.5 g, 74%) as a pale yellow solid. Exact mass calculated for C17H22F2N2O3: 340.16; Found: LCMS mlz = 341.3 (M + H)+. 1H NMR (400 MHz, DMSO- d6) δ 1.42 (s, 9H), 3.25-3.39 (m, 4H), 3.42-3.48 (m, 2H), 3.49-3.56 (m, 2H), 3.74 (s, 2H), 7.02 (dt, J = 2.7, 8.5 Hz, IH), 7.18 (dt, J= 2.6, 9.7 Hz, IH), 7.25-7.33 (m, IH).
Method 2: 2-(2,4-Difluorophenyl)acetic acid (202.6 g, 1.18 mol), was dissolved in acetonitrile (1.8 L). Carbonyldiimidazole (188.4 g, 1.16 mol) was added portionwise at room temperature. There was gas evolution due to the liberation of carbon dioxide. After the addition was completed, the mixture was heated to 60 0C with stirring for 4 h. The active intermediate thus formed was cooled to room temperature. tert-Butyl piperazine-1-carboxylate (219 g, 1.175 mol) was added and the mixture heated to 60 0C with stirring for 4 h. The reaction was monitored by LC/MS for consumption of the starting material. The crude reaction mixture was cooled to 20-25 °C and the solvent was removed using a rotary evaporator. The pale yellow solid residue was suspended in 5% sodium hydroxide (1 L), mixed well for 20 min and filtered. The solid collected was then washed with water (1 L) and dried in a vacuum oven at 50-55 0C overnight to afford the title compound (329 g, 82%). Step D: Preparation of l-(2,4-Difluorophenethyl)piperazine Hydrochloride. tert-Butyl 4-(2-(2,4-difluorophenyl)acetyl)piperazine-l-carboxylate (101.2 g, 297 mmol) was dissolved in THF (800 mL) and borane tetrahydrofuran complex (1.0 M, 666 mL, 666 mmol) was added. The addition was carried out carefully while keeping the temperature below 20 0C. The reaction mixture was then heated to 50-55 0C for 2 h. The reaction was monitored by LC/MS for consumption of the starting material. The crude mixture was quenched carefully over 1 h with ethyl acetate (150 mL) followed by addition of methanol (150 mL). After the gas evolution had subsided, about two thirds of the solvent was removed using a rotary evaporator and the remaining solution was diluted with isopropyl acetate (800 mL). Sodium hydroxide (25% solution, 160 g) was added dropwise while the temperature was maintained below 25 0C. After the addition was complete the reaction mixture was then heated to 55-60 0C for 2 h and then gradually cooled to room temperature. The layers were separated and the basic aqueous layer was discarded. The organic layer was dried over sodium sulfate (50 g) and filtered. The solvent was removed using a rotary evaporator. The residual oil was dissolved in isopropanol (800 mL) and HCl (-10-11 N, 79 mL) was added slowly over a period of 30 minutes. After completion of the addition, the mixture was heated to 65-70 0C for 4 h and was then cooled to 0-10 0C in an ice-bath for 2 h. The precipitate was filtered, washed with isopropanol (100 ml) and dried to afford the title compound as a white solid (75.6 g, 85%).
Exact mass calculated for C12H16F2N2: 226.13; Found: LCMS m/z = 227.2 (M + H)+. 1H NMR (400 MHz, DMSO-^5) δ 2.95-3.75 (m, 12H), 6.03-6.80 (br, IH), 7.04-7.12 (m, IH), 7.24 (dt, J = 2.6, 9.6 Hz, IH), 7.39-7.50 (m, IH).
Step E: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone. l-(2,4-Difluorophenethyl) piperazine hydrochloride (13.0 g , 43.45 mmol), was suspended in acetonitrile (130 mL). To this solution diisopropylethylamine (23.1 g, 179 mmol) was added with cooling in an ice-bath to keep the temperature below 20 0C during addition. The reaction mixture slowly became homogenous. To the reaction mixture, imidazo[l,2- α]pyridine-8-carbonyl chloride hydrochloride (10.2 g, 47.0 mmol) was added. The mixture was stirred and the progress of the reaction was monitored by LC/MS. A solid precipitate was formed quickly. The mixture was stirred at ambient for 30 min, slowly heated to 45-50 0C and then stirred for 3 h. LC/MS of the reaction mixture showed that the reaction was 80% complete and therefore additional portions of the acid chloride (2.9 g, 9.2 mmol) were added. The mixture was stirred at 45-50 0C overnight (18 h). The solvent was removed using a rotary evaporator and the residue was dissolved in water (75 mL). The pH of the solution was adjusted to 10-11 with 25% sodium hydroxide. An oil layer was separated and extracted with isopropyl acetate (2 x 40 mL). The combined organic phases were washed with water (25 mL), dried over sodium sulfate (10 g) and filtered. The filtrate was concentrated to afford the crude freebase of the title compound (13.7 g, 85% yield) as a tan solid. Exact mass calculated for C20H20F2N4O: 370.16; Found: LCMS m/z = 370.9 (M + H)+. 1H NMR (400 MHz, DMSO-^6) δ ppm 2.38 (t, J = 1 Hz, 2H), 2.52 (m, 4H), 2.74 (t, J= 1 Hz, 2H), 3.13 (t, J= 1 Hz, 2H), 3.67 (t, J= 1 Hz, 2H), 6.93 (t, J= 7Hz, IH) , 6.99 (dt, J= 7Hz,lHz, IH), 7.14(dt, J= 6Hz, IHz, IH), 7.21 (d, J= 6Hz, IH), 7.38 (q, J = 6Hz, 1 H), 7.61 (m, , 1 H), 7.95 (m, 1 H), 8.62 (d, J = 6Hz, 1 H). Step F: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yI)(imidazo[l,2- α]pyridin-8-yl)methanone Hydrochloride.
(4-(2,4-Difluorophenethyl)piperazin-l-yl)(imidazo[l,2-a]pyridin-8-yl)methanone (10.2 g, 27.5 mmol) prepared in step E was dissolved in isopropanol (110 mL). Hydrochloric acid (10 N, 6.05 mL) was added, the mixture was heated to 40 0C and stirred for 1 h. A solid precipitate was formed. The mixture was allowed to cool to room temperature and stirred at 20-25 0C overnight. The solid was filtered, washed with isopropanol (30 mL) and dried in a vacuum oven at 60 0C overnight to afford the title compound (10.6 g, 86%). Exact mass calculated for C20H20F2N4O: 370.16; Found: LCMS m/z = 371.4 (M + H)+. 1H NMR (400 MHz, DMSO-^6) δ 3.14 (m, 2H), 3.22 (m, 2H), 3.69-3.78 (br, 8H), 4.45-4.77 (br, IH), 7.09 (dt, J= 1, 8 Hz, IH), 7.25 (dt, J= 1, 8 Hz, IH), 7.44 (q, J= 8 Hz, IH), 7.55 (t, J= 8 Hz, IH), 7.99 (d, J= 7 Hz, IH), 8.21 (s, IH), 8.50 (d, J= 1 Hz, IH), 9.01 (d, J= 8 Hz, IH), 12.05-12.25 (br s, IH).
Example 1.13: Preparation of Imidazo[l,2-α]pyridin-8-yl(4-(4- methoxyphenethyl)piperazin-l-yl)methanone (Compound 12).
Step A: Preparation of tert-Butyl 4-(imidazo[l,2-α]pyridine-8-carbonyl)piperazine- 1-carboxylate.
Imidazo[l,2-α]pyridine-8-carbonyl chloride (2.00 g, 11.07 mmol) was added to a solution of tert-buty\ piperazine- 1-carboxylate (2.269 g, 12.18 mmol) and triethylamine (5.40 mL, 38.8 mmol) in THF (15 mL). The solution was stirred at room temperature for 30 min. The solvent was removed under reduced pressure to afford the title compound (1.25 g) as a solid. Exact mass calculated for CnH22N4O3 330.2, found 331.2 (M + H)+.
Step B: Preparation of Imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone Hydrochloride Salt. tert-Butyl 4-(imidazo[l,2-α]pyridine-8-carbonyl)piperazine-l-carboxylate (1.25 g, 3.78 mmol) and 4 M HCl in dioxane (15 mL) were stirred at 43 0C for 30 min. The precipitate was filtered, washed with hexane and dried under reduced pressure to afford the HCl salt of the title compound as a solid (980 mg). Exact mass calculated for Ci2H14N4O 230.1. Found 231.1 (M + H)+. 1H NMR (400 MHz, DMSO-^6) δ 3.02-3.15 (m, 2H) 3.57-3.71 (m, 2H), 3.88-4.03 (m, 2H), 4.15-4.68 (m, 2H), 7.56 (t, J = 7.07 Hz, IH), 8.03 (d, J= 7.07 Hz, IH), 8.25 (d, J= 2.02 Hz, IH), 8.50 (d, J= 2.0 Hz, IH), 9.02 (d, J= 6.57 Hz, IH). Step C: Preparation of Imidazo[l,2-α]pyridin-8-yl(4-(4- methoxyphenethyl)piperazin-l-yl)methanone (Compound 12). l-(2-Bromoethyl)-4-methoxybenzene (48 mg, 187 μmol) was added to a solution of imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (50 mg, 187 μmol) and potassium carbonate (78 mg, 562 μmol) in DMF (3.0 mL). The mixture was heated at 120 0C for 20 min under microwave irradiation. The residue was purified by preparative HPLC to give a solid (TFA salt) in 15.7% yield (14.1 mg). Exact mass calculated for C2]H24N4O2: 364.2. Found: LCMS m/z = 365.4 (M + H)+. 1H NMR (400 MHz, Acetonitrile-J,) δ 2.97-3.02 (m, 2H) 3.23-3.29 (m, 2H), 3.30-3.75 (m, 8H), 3.76 (s, 3H), 6.86-6.90 (m, 2H), 7.15-7.19 (m, 2H), 7.43 (t, J= 7.1 Hz, IH), 7.84 (d, J= 7.1 Hz, IH), 7.93 (d, J= 2.0 Hz, IH), 8.06 (d, J= 2.0 Hz, IH), 8.64 (dd, J = 0.6, 6.8 Hz, IH).
Example 1.14: Preparation of (4-(3,4-Dimethoxyphenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 13).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-<2]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (50 mg, 187μmol) and 4-(2-bromoethyl)-l,2-dimethoxybenzene (55 mg, 225 μmol) as starting materials, to afford the TFA salt as a solid (8.7 mg). Exact mass calculated for C22H26N4O3: 394.2. Found: LCMS mlz = 395.4 (M + H)+. 1H NMR (400 MHz, Acetonitrile-^) δ 2.97-3.02 (m, 2H), 3.26- 3.31 (m, 2H), 3.30-3.75 (m, 8H), 3.76 (s, 3H), 3.79 (s, 3H), 6.75-6.79 (dd, / = 2.0, 8.1 Hz, IH), 6.84-6.89 (m, 2H), 7.41 (t, J = 7.0 Hz, IH), 7.82 (d, J= 13 Hz, IH), 7.93 (d, J= 2.0 Hz, IH), 8.05 (d, J= 2.0 Hz, IH), 8.64 (d, J= 6.8 Hz, IH).
Example 1.15: Preparation of (4-(3-Fluorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 14).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (50 mg, 187μmol) and l-(2-bromoethyl)-3-fluorobenzene (46 mg, 225 μmol) as starting materials, to afford the TFA salt as a solid (10.5 mg). Exact mass calculated for C2oH2iFN40: 352.2. Found: LCMS mlz = 353.4 (M + H)+. 1H NMR (400 MHz, Acetonitrile-Jj) δ 3.07-3.12 (m, 2H) 3.28- 3.33 (m, 2H), 3.35-3.75 (m, 8H), 6.98-7.11 (m, 3H), 7.34 (t, / = 8.1 Hz, IH), 7.40 (X, J= 8.1 Hz, IH), 7.80 (dd, J= 1.0 Hz, 7.2 Hz, IH), 7.92 (d, J= 2.0 Hz, IH), 8.05 (d, J= 2.0 Hz, IH), 8.64 (dd, J= 1.0 Hz, 6.8 Hz, IH).
Example 1.16: Preparation of (4-(4-Chlorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)πiethanone (Compound 15).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (50 mg, 187μmol) and l-(2-bromoethyl)-4-chlorobenzene (49 mg, 225 μmol) as starting materials, to afford the TFA salt as a solid (14.9 mg). Exact mass calculated for C20H2IClN4O: 368.1.
Found: LCMS mlz (%) = 369.1 ((M + H)+, 35Cl, 100%), 371.1 ((M + H)+, 37Cl, 33%). 1H NMR (400 MHz, Acetonitrile-rfj) δ 3.06-3.12 (m, 2H) 3.25-3.31 (m, 2H), 3.35-3.80 (m, 8H), 7.24-7.28 (m, 2H), 7.32-7.36 (m, 2H), 7.41 (t, J= 7.1 Hz, IH), 7.81 (dd, J= 1.0 Hz, 7.2 Hz, IH), 7.92 (d, J= 2.0 Hz, IH), 8.05 (d, J= 2.0 Hz, IH), 8.63 (dd, J= 1.0 Hz, 6.8 Hz, IH).
Example 1.17: Preparation of (4-(3-ChIorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 16).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (50 mg,
187μmol) and l-(2-bromoethyl)-3-chlorobenzene (49 mg, 225 μmol) as starting materials, to afford the TFA salt as a solid (12.6 mg). Exact mass calculated for C20H21CIN4O: 368.1. Found: LCMS mlz (%) = 369.1 ((M + H)+, 35Cl, 100%), 371.1 ((M + H)+, 37Cl, 33%). 1H NMR (400 MHz, Acetonitrile-^) δ 3.06-3.11 (m, 2H) 3.28-3.34 (m, 2H), 3.35-3.90 (m, 8H), 7.19-7.23 (m, IH), 7.26-7.35 (m, 3H), 7.42 (t, J=6.9 Hz, IH), 7.84 (dd, J= 1.0 Hz, 7.2 Hz, IH), 7.93 (d, J = 2.0 Hz, IH), 8.06 (d, J= 2.0 Hz, IH), 8.64 (dd, J= 1.0, 6.8 Hz, IH).
Example 1.18: Preparation of (4-(2-Chlorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 17).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (50 mg, 187 μmol) and l-(2-bromoethyl)-2-chlorobenzene (49 mg, 225 μmol) as starting materials, to afford the TFA salt as a solid (11.8 mg). Exact mass calculated for C20H2IClN4O: 368.1. Found: LCMS mlz (%) = 369.1 ((M + H)+, 35Cl, 100%), 371.1 ((M + H)+, 37Cl, 33%). 1H NMR (400
MHz,
δ 3.25 (m, 4H), 3.30-3.90 (m, 8H), 7.26-7.31 (m, 2H), 7.33-7.37 (m, IH), 7.39.7.44 (m; 2H), 7.81 (dd, J= 1.0, 7.2 Hz, IH), 7.93 (d, J= 2.0 Hz, IH), 8.05 (d, J= 2.0 Hz, IH), 8.64 (dd, J= 1.0, 6.8 Hz, IH).
Example 1.19: Preparation of (4-(2-Fluorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 18).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (65 mg, 244 μmol) and l-(2-bromoethyl)-2-fluorobenzene (59 mg, 292 μmol) as starting materials, to afford the TFA salt as a solid (38 mg). Exact mass calculated for C20H2IFN4O: 352.2. Found: LCMS m/z = 353.4 (M + H)+. 1H NMR (400 MHz, Acetonitrile-dj) δ 3.09-3.16 (m, 2H) 3.24-3.34 (m, 2H), 3.35-3.55 (m, 8H), 7.07-7.19 (m, 2H), 7.27-7.35 (m, 2H), 7.41-7.47 (m, IH), 7.83-7.87 (m, IH), 7.91-7.94 (m, IH), 8.05-8.08 (m, IH), 8.65 (d, J= 6.8 Hz, IH).
Example 1.20: Preparation of (4-(2,4-Dichlorophenethyl)piperazin-l-yl)(imidazo[l,2- α]pyridin-8-yl)methanone (Compound 19).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (65 mg, 244 μmol) and l-(2-bromoethyl)-2,4-dichlorobenzene (74 mg, 292 μmol) as starting materials, to afford the TFA salt as a solid (41.0 mg). Exact mass calculated for C20H20Cl2N4O: 402.1. Found: LCMS m/z (%) = 403.4 ((M + H)+, 35Cl, 35Cl, 100%), 405.2 ((M + H)+, 35Cl, 37Cl, 64%). 1H NMR (400 MHz, Acetanitrile-d,) δ 3.16-3.29 (m, 4H) 3.30-3.90 (m, 8H), 7.30-7.36 (m, 2H), 7.38-7.45 (m, IH), 7.50 (s, IH), 7.80-7.86 (m, IH), 7.92 (s, IH), 8.05 (d, J= 2.0 Hz, IH), 8.64 (d, J= 7.1Hz, IH).
Example 1.21: Preparation of l-(2,4-Difluorophenyl)-2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 20).
The title compound was prepared in a manner similar to that described in Example 1.13, step C, using imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone hydrochloride (100 mg, 375 μmol) and 2-bromo-l-(2,4-difluorophenyl)ethanone (106 mg, 450 μmol) as starting materials, to afford the TFA salt of the title compound as a solid (96.2 mg). Exact mass calculated for
C20H18F2N4O2: 384.1. Found: LCMS mlz = 385.4 (M + H)+. 1H NMR (400 MHz, Acetonitrile- d3) δ 3.30-4.30 (m, 8H), 4.65 (d, J= 2.2 Hz, 2H), 7.11-7.19 (m, 2H), 7.45 (t, J= 7.1 Hz, IH), 7.87 (dd, J = 1.0, 7.2 Hz, IH), 7.92 (d, J = 2.0 Hz, IH), 8.01-8.04 (m, IH), 8.05 (d, J= 2.0 Hz, IH), 8.66 (dd, J= 1.0, 7.2 Hz, IH).
Example 1.22: Preparation of l-(Biphenyl-4-yl)-2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 25).
l-(Biphenyl-4-yl)-2-bromoethanone (57 mg, 208 μmol) was added to a solution of imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) and potassium carbonate (72 mg, 521 μmol) in DMSO (1.0 mL). The mixture was stirred at 28 0C for 1 hour. The residue was purified by preparative LCMS to afford the TFA salt of the title compound (23 mg) as a solid. Exact mass calculated for C26H24N4O2: 424.2; found: LCMS mlz = 425.0 (M+H)+. 1H NMR (400 MHz, Acetonitrile-rf,) δ 3.34-3.50 (m, 2H), 3.50-3.70 (m, 2H), 3.70- 3.94 (m, 2H), 3.94-4.23 (m, 2H), 4.77 (s, 2H), 7.39 (t, J= 7.07 Hz, IH), 7.43-7.48 (m, IH),
7.49-7.54 (m, 2H), 7.73 (d, J= 8.08 Hz, 2H), 7.78-7.85 (m, 3H), 7.90 (d, J= 2.02 Hz, IH), 8.01- 8.05 (m, 3H), 8.62 (d, J = 7.07 Hz, IH).
Example 1.23: Preparation of l-(4-HydroxyphenyI)-2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 40).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-hydroxyphenyl)ethanone (45 mg, 208 μmol), and imidazo[l,2-α]pyridin-8- yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (21 mg) as a solid. Exact mass calculated for C20H20N4O3: 364.2; found: LCMS mlz = 365.1
(M+H)+. 1H NMR (400 MHz,
δ 2.81-3.30 (m, 4H), 3.47 (bs, 2H), 3.94 (bs, 2H), 4.77 (s, 2H), 6.94 (d, J = 8.59 Hz, 2H), 7.45-7.50 (m, IH), 7.85 (d, J = 8.59 Hz, 2H), 7.90-7.95 (m, 2H), 8.10-8.14 (m, IH), 8.69-8.74 (m, IH).
Example 1.24: Preparation of JV-(2-Hydroxy-5-(2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)acetyl)phenyl)methanesuifonamide (Compound 23).
The title compound was prepared in a manner similar to that described in Example 1.22, using N-(5-(2-bromoacetyl)-2-hydroxyphenyl)methanesulfonamide (64 mg, 208 μmol), and imidazo[l,2-α]pyridm-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (18 mg) as a solid. Exact mass calculated for C2IH23N5O5S: 457.1; found: LCMS mlz = 458.2 (M+H)+. 1H NMR (400 MHz, D2O) δ 2.90 (s, 3H), 3.80 (bs, 4H), 4.23 (bs, 4H), 5.19 (s, 2H), 7.31 (d, J = 8.59 Hz, IH), 7.74 (t, J = 7.07 Hz, IH), 8.03 (d, J = 8.59 Hz, IH), 8.13 (s, IH), 8.18 (s, IH), 8.27 (d, J = 7.07 Hz, IH), 8.39 (s, IH), 9.02 (d, J= 7.07 Hz, IH).
Example 1.25: Preparation of l-(4-(Dimethylamino)phenyl)-2-(4-(imidazo[l,2-α]pyridine- 8-carbonyl)piperazin-l-yl)ethanone (Compound 41).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-(dimethylamino)phenyl)ethanone (50 mg, 208 μmol), and imidazo[l,2- α]pyridin-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (33 mg) as a solid. Exact mass calculated for C22H25N5O2: 391.2; found: LCMS mlz = 392.5 (M+H)+. 1H NMR (400 MHz, Acetonitrile-J,) δ 3.07 (s, 6H), 3.33-3.50 (m, 2H), 3.56- 3.71 (m, 2H), 3.71-3.90 (m, 2H), 4.03-4.22 (m, 2H), 4.65 (s, 2H), 6.75 (d, J = 9.09 Hz, 2H), 7.39 (t, J = 7.07 Hz, IH), 7.77-7.81 (m, 3H), 7.91 (d, J = 1.77 Hz, IH), 8.04 (d, J = 1.77 Hz, IH), 8.63 (d, J = 6.82 Hz, IH).
Example 1.26: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- (2-(trifluoromethyl)phenyl)ethanone (Compound 38).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(2-(trifluoromethyl)phenyl)ethanone (56 mg, 208 μmol), and imidazo[l,2- α]pyridin-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the
TFA salt (5.7 mg) as a solid. Exact mass calculated for C2IH19F3N4O2: 416.2; found: LCMS mlz = 417.2 (M+H)+.
Example 1.27: Preparation of 2-Hydroxy-5-(2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)acetyl)benzamide (Compound 37).
The title compound was prepared in a manner similar to that described in Example 1.22, using 5-(2-bromoacetyl)-2-hydroxybenzamide (54 mg, 208 μmol), and imidazo[l,2-α]pyridin-8- yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (25 mg) as a solid. Exact mass calculated for C21H21N5O4: 407.2; found: LCMS mlz = 408.2
(M+H)+. 1H NMR (400 MHz,
S 2.74-4.26 (m, 8H), 4.90 (s, 2H), 6.56 (bs, IH), 7.05 (d, J = 8.84 Hz, IH), 7.45 (t, J = 7.07 Hz, IH), 7.85-7.89 (m, 2H), 7.98-8.10 (bs, IH), 8.02 (d, J = 8.84 Hz, IH), 8.07 (d, J = 1.77 Hz, IH), 8.51 (s, IH), 8.66 (d, J = 6.57 Hz, IH).
Example 1.28: Preparation of l-(4-Cyclohexylphenyl)-2-(4-(imidazo[l,2-α]pyridine-8- carbonyl)piperazin-l-yl)ethanone (Compound 28).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-cyclohexylphenyl)ethanone (59 mg, 208 μmol), and imidazo[l,2-α]pyridin- 8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (13 mg) as a solid. Exact mass calculated for C26H30N4O2: 430.2; found: LCMS mlz = 431.0 (M+H)+.
Example 1.29: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- " (4-(thiophen-2-yl)phenyl)ethanone (Compound 35).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-(thiophen-2-yl)phenyl)ethanone (59 mg, 208 μmol), and imidazo[l,2-
β]pyridin-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (17 mg) as a solid. Exact mass calculated for C24H22N4O2S: 430.2; found: LCMS mlz = 431.1 (M+H)+.
Example 1.30: Preparation of l-(4-(Difluoromethoxy)phenyl)-2-(4-(imidazo[l,2- α]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 29).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-(difluoromethoxy)phenyl)ethanone (55 mg, 208 μmol), and imidazo[l,2- α]pyridin-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (5 mg) as a solid. Exact mass calculated for C2IH20F2N4O3: 414.2; found: LCMS mlz = 414.9 (M+H)+.
Example 1.31: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- (4-morpholinophenyl)ethanone (Compound 43).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-morpholinophenyl)ethanone (59 mg, 208 μmol), and imidazo[l,2-α]pyridin- 8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (32 mg) as a solid. Exact mass calculated for C24H27N5O3: 433.2; found: LCMS mlz = 434.2 (M+H)+. 1H NMR (400 MHz,
δ 3.36 (bt, J = 4.80 Hz, 4H), 3.39-4.38 (m, 8H), 3.77 (bt, J = 4.80 Hz, 4H), 4.70 (s, 2H), 6.96 (d, J = 8.84 Hz, 2H), 7.44 (t, J = 7.07 Hz, IH), 7.82 (d, J = 8.84 Hz, 2H), 7.85 (d, J = 7.33 Hz, IH), 7.92 (d, J = 1.77 Hz, IH), 8.06 (d, J = 1.77 Hz, IH), 8.65 (d, J = 6.82 Hz, IH).
Example 1.32: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- (4-(pyrrolidin-l-yl)phenyl)ethanone (Compound 21).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-(pyrrolidin-l-yl)phenyl)ethanone (56 mg, 208 μmol), and imidazo[l,2- α]pyridin-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (31 mg) as a solid. Exact mass calculated for C24H27N5O2: 417.2; found: LCMS mlz = 418.4 (M+H)+.
Example 1.33: Preparation of l-(4-Chloro-2-fluoro-5-methylphenyl)-2-(4-(imidazo[l,2- α]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 31).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-chloro-2-fluoro-5-methylphenyl)ethanone (55 mg, 208 μmol), and imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (1.6 mg) as a solid. Exact mass calculated for C2IH2OClFN4O2: 414.1; found: LCMS mlz (%) = 415.1 ((M+H)+ 35Cl, 100%), 417.2 ((M+H)+ 37Cl, 32%).
Example 1.34: Preparation of l-(5-Chloro-2-methoxy-4-methylphenyl)-2-(4-(imidazo[l,2- α]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 32).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(5-chloro-2-methoxy-4-methylphenyl)ethanone (58 mg, 208 μmol), and imidazo[l,2-α]pyridin-8-yl(piperazm-l-yl)methanone (40 mg, 174 μmol) as starting materials, to afford the TFA salt (29 mg) as a solid. Exact mass calculated for C22H23ClN4O3: 426.1; found: LCMS mlz (%) = 427.1 ((M+H)+ 35Cl, 100%), 429.1 ((M+H)+ 37Cl, 32%). 1H NMR (400
MHz, Acetonitrile-d,) δ 2.43 (s, 3H), 3.28-4.46 (m, 8H), 3.96 (s, 3H), 4.62 (s, 2H), 7.14 (s, IH), 7.42 (t, J = 7.07 Hz, IH), 7.81-7.85 (m, 2H), 7.93 (s, IH), 8.06 (s, IH), 8.64 (d, J = 7.07 Hz, IH).
Example 1.35: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- (4-(trifluoromethyl)phenyl)ethanone (Compound 34).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-(trifluoromethyl)phenyl)ethanone (42 mg, 156 μmol), and imidazo[l,2- α]pyridin-8-yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (48 mg) as a solid. Exact mass calculated for C2IH)9F3N4O2: 416.2; found: LCMS mlz = 417.5 (M+H)+.
Example 1.36: Preparation of l-(2-Chloro-5-(trifluoromethyl)phenyl)-2-(4-(imidazo[l,2- α]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 24).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(2-chloro-5-(trifluoromethyl)phenyl)ethanone (47 mg, 156 μmol), and imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (54 mg) as a solid. Exact mass calculated for C2IHi8ClF3N4O2: 450.1; found: LCMS mlz (%) = 451.3 ((M+H)+ 35Cl, 100%), 453.3 ((M+H)+ 37Cl, 32%). 1H NMR (400 MHz, Acetonitrile-4,) δ 3.50 (bs, 4H), 3.95 (bs, 4H), 4.70 (s, 2H), 7.46 (t, J = 7.07 Hz, IH), 7.76 (d, J = 8.59 Hz, IH), 7.86-7.92 (m, 3H), 8.07 (d, J= 6.57 Hz, 2H), 8.66 (d, J = 7.07 Hz, IH).
Example 1.37: Preparation of l-(3,5-Bis(trifluoromethyl)phenyl)-2-(4-(imidazo[l,2- α]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 33).
The title compound was prepared in a manner similar to that described in Example 1.22, using l-(3,5-bis(trifluoromethyl)phenyl)-2-bromoethanone (52 mg, 156 μmol), and imidazo[l,2- α]pyridin-8-yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (30 mg) as a solid. Exact mass calculated for C22Hi8F6N4O2: 484.1; found: LCMS mlz = 485.4 (M+H)+. 1H NMR (400 MHz,
δ 3.52 (bs, 4H), 3.98 (bs, 4H), 4.87 (s, 2H), 7.47 (t, / = 7.07 Hz, IH), 7.89-7.92 (m, 2H), 8.08 (d, J = 1.52 Hz, IH), 8.33 (s, IH), 8.46 (s, 2H), 8.67 (d, J = 7.07 Hz, IH).
Example 1.38: Preparation of 4-(2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l- yl)acetyl)benzonitrile (Compound 39).
The title compound was prepared in a manner similar to that described in Example 1.22, using 4-(2-bromoacetyl)benzonitrile (35 mg, 156 μmol), and imidazo[l,2-α]pyridin-8- yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (23 mg) as a solid. Exact mass calculated for C2IH19N5O2: 373.2; found: LCMS mlz = 374.3 (M+H)+.
Example 1.39: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- (4-(trifluoromethoxy)phenyl)ethanone (Compound 22).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-(trifluoromethoxy)phenyl)ethanone (44 mg, 156 μmol), and imidazo[l,2- <z]pyridin-8-yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (22 mg) as a solid. Exact mass calculated for C21Hi9F3N4O3: 432.1 ; found: LCMS mlz = 433.2 (M+H)+.
Example 1.40: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- phenylpropan-l-one(Compound 30).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-phenylpropan-l-one (33 mg, 156 μmol), and imidazo[l,2-α]pyridin-8- yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (29 mg) as a solid. Exact mass calculated for C21H22N4O2: 362.2; found: LCMS mlz = 363.5 (M+H)+.
Example 1.41: Preparation of l-(5-Chloro-2-methoxy-4-methyl-3-nitrophenyl)-2-(4- (imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)ethanone (Compound 42).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(5-chloro-2-methoxy-4-methyl-3-nitrophenyl)ethanone (50 mg, 156 μmol), and imidazo[l,2-α]pyridin-8-yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (14 mg) as a solid. Exact mass calculated for C22H22CIN5O5: 471.1; found: LCMS mlz (%) = 472.5 ((M+H)+ 35Cl, 100%), 474.6 ((M+H)+ 37Cl, 32%).
Example 1.42: Preparation of (6-Bromoimidazo[l,2-α]pyridin-8-yl)(4-(2,4- difluorophenethyl)piperazin-l-yl)methanone (Compound 44).
Step A: Preparation of 6-Bromoimidazo[l,2-α]pyridine-8-carboxylic acid.
The title compound was prepared in a manner similar to that described in Example 1.3, Step A, using 5-bromo-2-aminonicotinic acid (0.109 g) and chloroacetaldehyde (7.75 M, 0.077 mL, 0.600 mmol) as starting materials (heated 30 minutes at 150 0C under microwave) to afford a grey solid (0.067 g). 1H NMR (400 MHz, DMSOd6) δ 7.98 (d, J=I .52 Hz, 1 H), 8.22 (d, J=I.77 Hz, 1 H), 8.25 (s, 1 H), 9.37 (d, J=I .52 Hz, 1 H).
Step B: Preparation of (6-Bromoimidazo[l,2-α]pyridin-8-yl)(4-(2,4- difluorophenethyl)piperazin-l-yl)methanone (Compound 44).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using 6-bromoimidazo[l,2-α]pyridine-8-carboxylic acid (36.2 mg, 0.150 mmol), l-(2,4- difluorophenethyl)piperazine dihydrochloride (29.9 mg, 0.100 mmol) as starting materials to afford a white solid (24.3 mg). Exact mass for C20Hi9BrF2N4O: 448.1; found: LCMS mlz = 449.1((M+H)+ 79Br, 100%), 451.1 ((M+H)+ 81Br, 80). 1H NMR (400 MHz, CDCl3) δ 2.50 (tar s, 2H), 2.57-2.64 (m, 2H), 2.67 (br s, 2H), 2.75-2.84 (m, 2H), 3.30-3.39 (m, 2H), 3.85-3.96 (m, J = 4.29 Hz, 2H), 6.73-6.83 (m, 2H), 7.11-7.20 (m, IH), 7.33 (d, J= 1.77 Hz, IH), 7.61 (d, J= 1.01 Hz, IH), 7.68 (d, J= 1.01 Hz, IH), 8.33 (d, J = 1.77 Hz, IH).
Example 1.43: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(5,7- dimethylimidazo[l,2-α]pyridin-8-yl)methanone (Compound 27). Step A: Preparation of 5,7-Dimethylimidazo [l,2-α]pyridine-8-carboxylic Acid.
To a mixture of 2-amino-4,6-dimethylnicotinic acid hydrochloride salt (0.101 g, 0.500 mmol) in water (2.5 mL) was added NaOH (1.0 M, 0.5 mL) and chloroacetaldehyde (7.75 M, 0.077 mL, 0.600 mmol). The resulting slurry was heated to 150 0C under microwave irradiation for 30 min. The crude mixture was purified via preparative HPLC/MS. The resultant TFA salt obtained was taken up in ACN and treated with 4.0 M HCl in dioxane (1.25 mL) and reduced under reduced pressure to afford the title compound (0.108 g) as a white solid. 1H NMR (400 MHz, DMSO-^6) δ 2.75 (s, 3H) 2.78 (s, 3H), 7.46 (s, IH), 8.17 (d, J= 2.27 Hz, IH), 8.39 (d, J = 2.27 Hz, IH). Step B: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(5,7- dimethylimidazo[l,2-α]pyridin-8-yl)methanone (Compound 27).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using 5,7-dimethylimidazo[l,2-α]pyridine-8-carboxylic acid (34.0 mg, 0.150 mmol), 1- (2,4-difluorophenethyl)piperazine dihydrochloride (29.9 mg, 0.100 mmol) as starting materials to afford a white solid (31.6 mg). Exact mass for C22H24F2N4O: 398.2; found: LCMS mlz = 399.1 (M+H)+. 1H NMR (400 MHz, CDCl3) δ 2.35 (s, 3H) 2.56 (s, 3H), 2.57-2.63 (m, 4H),
2.74-2.80 (m, 4H), 3.19-3.27 (m, IH), 3.30-3.37 (m, IH), 3.84-3.93 (m, IH), 3.96-4.07 (m, IH), 6.51 (s, IH), 6.72-6.84 (m, 2H), 7.11-7.19 (m, IH), 7.42 (s, IH), 7.65 (s, IH).
Example 1.44: Preparation of (4-(2,4-Difluorophenethyl)piperazin-l-yl)(7- methoxyimidazo[l,2-α]pyridin-8-yl)methanone (Compound 36).
Step A: Preparation of 7-Methoxyimidazo[l,2-α]pyridine-8-carbonitrile.
To a solution of 2-amino-4-methoxynicotinonitrile (1.491 g, 10.0 mmol) in water (20.00 ml) was added 2-chloroacetaldehyde (1.548 mL, 12.00 mmol) and the reaction was heated to 80 0C in an oil bath overnight. The reaction was cooled to room temperature, NaOH (10.00 ml, 10.00 mmol) was added and the resulting precipitate was filtered off and washed with water to afford the title compound (1.621 g) as a tan solid. 1H NMR (400 MHz, DMSO-O δ 4.05 (s, 3H), 7.13 (d, J= 7.70 Hz, IH), 7.52 (d, J= 1.35 Hz, IH), 7.92 (d, /= 1.35Hz, IH), 8.84 (d, J = 7.70 Hz, IH). Step B: Preparation of 7-Methoxyimidazo[l,2-α]pyridine-8-carboxylic Acid.
To a mixture of 7-methoxyimidazo[l,2-α]pyridine-8-carbonitrile (0.173 g, 1.00 mmol) and water (1.000 ml) was added 3.75 M NaOH (0.400 ml, 1.500 mmol), the resulting mixture was heated to 160 0C under microwave irradiation for 30 min. The reaction was treated with 1.0 M HCl (1.000 ml, 1.000 mmol), the resulting precipitate was filtered off and washed with water. The mother liquor was reduced under reduced pressure to afford a crude mixture (76.0%) of the title compound (0.117 g) as a tan solid. Exact mass for C9H8N2O3: 192.1; found: LCMS mlz = 193.2 (M+H)+.
Step C: Preparation of (4-(2,4-difluorophenethyl)piperazin-l-yl)(7- methoxyimidazo[l,2-α]pyridin-8-yl)methanone (Compound 36).
The title compound was prepared in a manner similar to that described in Example 1.3, Step E, using 7-methoxyimidazo[l,2-α]pyridine-8-carboxylic acid (28.8 mg, 0.150 mmol), 1- (2,4-difluorophenethyl)piperazine dihydrochloride (29.9 mg, 0.100 mmol) as starting materials to afford a white solid (13.9 mg). Exact mass for C2]H22F2N4O2: 400.2; found: LCMS mlz = 401.3 (M+H)+. 1H NMR (400 MHz, CDCl3) δ 2.55-2.65 (m, 6H), 2.77-2.81 (m, 2H), 3.33-3.39 (m, 2H), 3.93 (s, 3H), 3.91-3.97 (m, 2H), 6.70 (d, J= 7.54 Hz, IH), 6.74-6.82 (m, 2H), 7.13- 7.19 (m, IH), 7.48 (d, J= 1.25 Hz, IH), 7.56 (d, J=1.25 Hz, IH), 8.92 (d, J=7.54 Hz, IH).
Example 1.45: Preparation of 2-(4-(Imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l-yl)-l- (4-(methylsulfonyl)phenyl)ethanone (Compound 26).
The title compound was prepared in a manner similar to that described in Example 1.22, using 2-bromo-l-(4-(methylsulfonyl)phenyl)ethanone (43 mg, 156 μmol), and imidazo[l,2- α]pyridin-8-yl(piperazin-l-yl)methanone (30 mg, 130 μmol) as starting materials, to afford the TFA salt (13 mg) as a solid. Exact mass calculated for C2IH22N4O4S: 426.1; found: LCMS mlz (%) = 427.3 (M+H)+.
Example 2: Receptor Expression. A. pCMV
Although a variety of expression vectors are available to those in the art, it is preferred that the vector utilized be pCMV. This vector was deposited with the American Type Culture Collection (ATCC) on October 13, 1998 (10801 University Blvd., Manassas, VA 20110-2209 USA) under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure. The DNA was tested by the ATCC and determined to be viable. The ATCC has assigned the following deposit number to pCMV: ATCC #203351.
B. Transfection Procedure
For the IP accumulation assay (Example 3), HEK293 cells were transfected while for the DOI binding assay (Example 3) COS7 cells were transfected. Several protocols well known
in the art can be used to transfect cells. The following protocol is representative of the transfection procedures used herein for COS7 or 293 cells.
On day one, COS-7 cells were plated onto 24 well plates, usually 1 x 105 cells/well or 2 x 105 cells/well, respectively. On day two, the cells were transfected by first mixing 0.25 μg cDNA in 50 μL serum-free DMEM/well and then 2 μL lipofectamine in 50 μL serum-free
DMEM/well. The solutions ("transfection media") were gently mixed and incubated for 15-30 min at room temperature. The cells were washed with 0.5 mL PBS and then 400 μL of serum free medium was mixed with the transfection media and added to the cells. The cells were then incubated for 3-4 hours at 37 °C/5% CO2. Then the transfection medium was removed and replaced with 1 mL/well of regular growth medium.
For 293 cells, on day one, 13 x 106293 cells per 150 mm plate were plated out. On day two, 2 mL of serum Optimeml (Invitrogen Corporation) was added per plate followed by addition of 60 μL of lipofectamine and 16 μg of cDNA. Note that lipofectamine must be added to the Optimeml and mixed well before addition of cDNA. While complexes between lipofectamine and the cDNA are forming, the medium was carefully aspirated and cells were gently rinsed with 5 mL of Optimeml medium followed by careful aspiration. Then 12 mL of Optimeml was added to each plate and 2 mL of transfection solution was added followed by a 5 h incubation at 37 0C in a 5% CO2 incubator. Plates were then carefully aspirated and 25 mL of Complete Media were added to each plate and cells were then incubated until used.
Example 3: Binding Assays.
Compounds of the invention were tested for their ability to bind to a 5-HT2A serotonin receptor clone membrane preparation using a radioligand binding assay. Briefly, COS cells were transiently transfected with a pCMV expression vector containing a human 5-HT2A receptor (for the sequence of the receptor see U.S. Patent No. 6,541 ,209, SEQ ID NO:24).
A. Preparation of Crude Membrane Preparations for Radioligand Binding Assays.
COS7 cells transfected with recombinant human 5-HT2A serotonin receptors were cultured for 48 h post transfection, collected, washed with ice-cold phosphate buffered saline, pH 7.4 (PBS) and then centrifuged at 48,000 g for 20 min at 4 0C. The cell pellet was then resuspended in wash buffer containing 20 mM HEPES, pH 7.4 and 0.1 mM EDTA, homogenized on ice using a Brinkman polytron and recentrifuged at 48,000 g for 20 min at 4 0C. The resultant pellet was then resuspended in 20 mM HEPES, pH 7.4, homogenized on ice and centrifuged (48,000 g for 20 min at 4 0C). Crude membrane pellets were stored at -80 0C until used for radioligand binding assays.
B. [125I]DOI Radioligand Binding Assay.
Radioligand binding assays for human 5-HT2A serotonin receptor were conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 10 μM DOI was used for all assays. For competitive binding studies, 0.5 nM [125I]DOI was used and compounds were assayed over a range of 0.01 nM to 10 μM. Assays were conducted in a total volume of ■ 200 μl in 96-well Perkin Elmer GF/C filter plates in assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 5 mM MgCl2 and 10 μM pargyline). Assay incubations were performed for 60 min at room temperature and were terminated by rapid filtration under reduced pressure of the reaction mixture over Whatman GF/C glass fiber filters presoaked in 0.5% PEI using a Brandell cell harvester. Filters were then washed several times with ice-cold wash buffer (50 mM Tris- HCl, pH 7.4). Plates were then dried at room temperature and counted in a Wallac MicroBeta scintillation counter. Certain compounds of the present invention and their corresponding activity values are shown in TABLE B.
TABLE B
Certain other compounds of the invention had activity values ranging from about 10 μM to about 1 nM in this assay.
Example 4: In vitro Human Platelet Aggregation Assays.
Compounds of the invention were tested for their ability to aggregate human platelets. Aggregation assays were performed using a Chrono-Log Optical aggregometer model 410.
Human blood (-100 mL) was collected from human donors into glass Vacutainers containing 3.8% sodium citrate (light blue tops) at room temperature. Platelet rich plasma (PRP) was isolated via centrifugation at 100 g for 15 min at room temperature. After removal of the aqueous PRP layer, the platelet poor plasma (PPP) was prepared via high speed centrifugation at 2400 g for 20 min. Platelets were counted and their concentration was set to 250,000 cells/μL by dilution with PPP. Aggregation assays were conducted according to the manufacturer's specifications. Briefly, a suspension of 450 μL PRP was stirred in a glass cuvette (1200 rpm) and, after baseline was established, 1 μM ADP followed by either saline or 1 μM 5-HT and compound of interest (at desired concentrations) were added and the aggregation response recorded. The concentration of ADP used causes approximately 10-20% of maximal aggregation. The 5-HT concentration corresponded to the concentration which produced maximal potentiation. Percent inhibition of aggregation was calculated from the maximum decrease in optical density of the controls and of the samples containing inhibitors. Only the
synergistic effect was assessed. Certain compounds of the invention had activity values ranging from about 80 μM to about 15 nM in this assay. Other compounds of the invention had activity values ranging from about 8 μM to about 50 nM in this assay.
Example 5: Inositol Phosphate (IP) Accumulation Assays.
A. 5-HT2A Receptor
Compounds of the invention can be tested for their ability to activate a 5-HT2A receptor clone using an IP accumulation assay. Briefly, HEK293 cells are transiently transfected with a pCMV expression vector containing a human 5-HT2A receptor (for the sequence of the receptor see U.S. Patent No. 6,541 ,209, SEQ TD NO:24). An IP accumulation assay can be performed as described in part C below.
B. Constitutively Active 5-HT2A Receptor
Compounds of the invention can be tested for their ability to inhibit a constitutively active 5-HT2A receptor clone using an IP accumulation assay. Briefly, 293 cells are transiently transfected with a pCMV expression vector containing a constitutively active human 5-HT2A receptor (for the sequence of the receptor see U.S. Patent No. 6,541,209, SEQ ID NO:30). The constitutively active human 5-HT2A receptor contains the human 5-HT2A receptor described in part A except that intracellular loop 3 (IC3) and the cytoplasmic tail are replaced by the corresponding human INI 5-HT2c cDNA. An EP accumulation assay can be performed as described in part C below.
C. IP Accumulation Assay Protocol
On the day after transfections, medium is removed and the cells are washed with 5 mL PBS followed by careful aspiration. Cells are then trypsinized with 2 mL of 0.05% trypsin for 20- 30 s followed by addition of 10 mL of warmed medium, gently triturated to dissociate cells and an additional 13 mL of warmed medium is gently added. Cells are then counted and 55,000 cells are added to 96-well sterile poly-D-lysine treated plates. Cells are allowed to attach over a six hour incubation at 37 0C in a 5% CO2 incubator. Medium is then carefully aspirated and 100 μL of warm inositol-free medium plus 0.5 μCi 3H-inositol is added to each well and the plates are incubated for 18-20 h at 37 0C in a 5% CO2 incubator. On the next day, the medium is carefully aspirated and then 0.1 mL of assay medium is added containing inositol -free/serum free medium, 10 μM pargyline, 10 mM lithium chloride and test compound at indicated concentrations. The plates are incubated for three hours at 37 0C and then the wells are carefully aspirated. Then 200 μL of ice-cold 0.1 M formic acid is added to each well. Plates are then frozen at -80 0C until further processing. Frozen plates are thawed over the course of one hour and the contents of the wells (approximately 220 μL) are placed over 400 μL of washed ion-exchange resin (AG 1-X8) contained in a Multi-Screen Filtration plate and incubated for 10 min followed by filtration under reduced pressure. The resin is
washed nine times with 200 μL of water and then tritiated inositol phosphates (IP, EP2 and DP3) are eluted into a collecting plate by the addition of 200 μL of 1 M ammonium formate followed by an additional 10 min incubation. The eluent is then transferred to 20 mL scintillation vials, 8 mL of SuperMix or Hi-Safe scintillation cocktail is added and the vials are counted for 0.5-1 5 min in a Wallac 1414 scintillation counter.
Example 6: Efficacy of Compounds of the Invention in the Attenuation of DOI-induced Hypolocomotion in Rats.
In this example, compounds of the invention were tested for inverse agonist activity by 10 determining whether these compounds could attenuate DOI-induced hypolocomotion in rats in a novel environment. DOI is a potent 5-HT2A/2c receptor agonist that crosses the blood-brain barrier. The standard protocol used is described briefly below. Animals:
Male Sprague-Dawley rats weighing between 200-350 g were used for all tests. Rats 15 were housed three to four per cage. Compounds:
(R)-DOI HCl (CnH16INO2-HCl) was obtained from Sigma- Aldrich and was dissolved in 0.9% saline. Compounds of the invention were synthesized at Arena Pharmaceuticals Inc., San Diego, CA and were dissolved in 100% PEG400. DOI was injected s.c. in a volume of 1 20 mL/kg, while compounds of the invention were administered p.o. in a volume of 1 mL/kg.
Procedure:
/
The "Motor Monitor" (Hamilton-Kinder, Poway, CA) was used for all activity measurement. This apparatus recorded rears using infrared photobeams.
Locomotor activity testing was conducted during the light cycle between 9:00 a.m. and 25 4:00 p.m. Animals were allowed 30 min acclimation to the testing room before testing began.
In determining the effects of compounds of the invention on DOI-induced hypoactivity, animals were first injected with vehicle or the compound of the invention (1-10 mg/kg) in their home cages. Twenty five minutes later, saline or DOI (1 mg/kg salt) was injected. Ten minutes after DOI administration, animals were placed into the activity apparatus and rearing activity 30 was measured for 10 min.
Statistics and Results:
Results (total rears over 10 min) were analyzed by t-test. P < 0.05 was considered significant. As shown in Figure 6, compound 18 attenuated DOI-induced hypolocomotion in rats. In addition, as shown in Figure 7, compound 19 also attenuated DOI-induced 35 hypolocomotion in rats.
Example 7: Serotonin 5-HT2A Receptor Occupancy Studies in Monkey.
In this example, the 5-HT2A receptor occupancy of a compound of the invention can be measured. The study can be carried out in rhesus monkeys using PET and 18F-altanserin.
Radioligand:
The PET radioligand used for the occupancy studies is 18F-altanserin. Radiosynthesis of 18F-altanserin is achieved in high specific activities and is suitable for radiolabeling 5-HT2A receptors in vivo (see Staley et al, Nucl. Med. Biol, 28:271-279 (2001) and references cited therein). Quality control issues (chemical and radiochemical purity, specific activity, stability, etc.) and appropriate binding of the radioligand are verified in rat brain slices prior to use in PET experiments. Drug Doses and Formulations:
Briefly, the radiopharmaceutical is dissolved in sterile 0.9% saline, pH approx 6-7. The compounds of the invention are dissolved in a mixture of 60% PEG 400 and 40% sterile saline on the same day of the PET experiment.
Serotonin 5-HT2A occupancy studies in humans have been reported for M100,907 (Grunder et al., Neuropsychopharmacology, 17:175-185 (1997) and Talvik-Lofti et al.,
Psychopharmacology, 148:400-403 (2000)). High occupancies of the 5 -HT2A receptors have been reported for various oral doses (doses studied ranged from 6 to 20 mg). For example, an occupancy of > 90% was reported for a dose of 20 mg (Talvik-Lofti et al., supra), which translates to approx. 0.28 mg/kg. It may therefore be anticipated that an i.v. dose of 0.1 to 0.2 mg/kg of M100,907 is likely to provide high receptor occupancy. A 0.5 mg/kg dose of a Compound of the invention can be used in these studies.
PET Experiments:
The monkey is anesthetized by using ketamine (10 mg/kg) and is maintained using 0.7 to 1.25% isoflurane. Typically, the monkey has two i.v. lines, one on each arm. One i.v. line is used to administer the radioligand, while the other line is used to draw blood samples for pharmacokinetic data of the radioligand as well as the unlabeled drugs. Generally, rapid blood samples are taken as the radioligand is administered which then taper out by the end of the scan. A volume of approximately 1 mL of blood is taken per time point, which is spun down and a portion of the plasma is counted for radioactivity in the blood. An initial control study is carried out in order to measure baseline receptor densities.
PET scans on the monkey are separated by at least two weeks. Unlabeled compound of the invention is administered intravenously, dissolved in 80% PEG 400:40% sterile saline.
PET Data Analysis:
PET data are analyzed by using cerebellum as the reference region and using the distribution volume region (DVR) method. This method has been applied for the analysis of 18F-altanserin PET data in non-human primate and human studies (Smith et al., Synapse, 30:380-392, (1998)).
Example 8: The Effect of Compounds of the Invention and Zolpidem on Delta Power in Rats.
In this example, the effect of compounds of the invention on sleep and wakefulness can be compared to the reference drug Zolpidem. Drugs are administered during the middle of the light period (inactivity period).
Briefly, compounds of the invention are tested for their effects on sleep parameters and are compared to Zolpidem (5.0 mg/kg, Sigma, St. Louis, MO) and vehicle control (80% Tween 80, Sigma, St. Louis, MO). A repeated measures design is employed in which each rat is to receive seven separate dosings via oral gavage. The first and seventh dosings are vehicle and the second through sixth are the test compounds and Zolpidem given in counter-balanced order. Since all dosings are administered while the rats are connected to the recording apparatus, 60% CO2/40% O2 gas is employed for light sedation during the oral gavage process. Rats are fully recovered within 60 seconds following the procedure. A minimum of three days elapses between dosings. In order to test the effect of the compounds on sleep consolidation, dosing occurs during the middle of the rats' normal inactive period (6 hours following lights on). Dosing typically occurs between 13:15 and 13:45 using a 24 hour notation. All dosing solutions are made fresh on the day of dosing. Following each dosing, animals are continuously recorded until lights out the following day (~30 hours). Animal Recording and Surgical Procedures:
Animals are housed in a temperature controlled recording room under a 12/12 light/dark cycle (lights on at 7:00 am) and have food and water available ad libitum. Room temperature (24 ± 2 0C), humidity (50 ± 20% relative humidity) and lighting conditions are monitored continuously via computer. Drugs are administered via oral gavage as described above, with a minimum of three days between dosings. Animals are inspected daily in accordance with NIH guidelines.
Eight male Wistar rats (300 ± 25 g; Charles River, Wilmington, MA) are prepared with chronic recording implants for continuous electroencephalograph (EEG) and electromyograph (EMG) recordings. Under isoflurane anesthesia (1-4%), the fur is shaved from the top of the skull and the skin is disinfected with Betadine and alcohol. A dorsal midline incision is made, the temporalis muscle retracted and the skull cauterized and thoroughly cleaned with a 2% hydrogen peroxide solution. Stainless steel screws (#000) are implanted into the skull and serve as epidural electrodes. EEG electrodes are positioned bilaterally at +2.0 mm AP from bregma and 2.0 mm ML and at -6.0 mm AP and 3.0 mm ML. Multi-stranded twisted stainless steel wire electrodes are sutured bilaterally in the neck muscles for recording of the EMG. EMG and EEG electrodes are soldered to a head plug connector that is affixed to the skull with dental acrylic. Incisions are closed with suture (silk 4-0) and antibiotics administered topically. Pain is relieved
by a long-lasting analgesic (buprenorphine) administered intramuscularly once post-operatively. Post-surgery, each animal is placed in a clean cage and observed until it is recovered. Animals are permitted a minimum of one week post-operative recovery before study.
For sleep recordings, animals are connected via a cable and a counter-balanced commutator to a Neurodata model 15 data collection system (Grass-Telefactor, West Warwick, RT). The animals are allowed an acclimation period of at least 48 hours before the start of the experiment and are connected to the recording apparatus continuously throughout the experimental period except to replace damaged cables. The amplified EEG and EMG signals are digitized and stored on a computer using SleepSign software (Kissei Comtec, Irvine CA). Data Analysis:
EEG and EMG data are scored visually in 10 second epochs for waking (W), REMS, NREMS. Scored data are analyzed and expressed as time spent in each state per half hour. Sleep bout length and number of bouts for each state are calculated in hourly bins. A "bout" consists of a minimum of two consecutive epochs of a given state. EEG delta power (0.5-3.5 Hz) within NREMS is also analyzed in hourly bins. The EEG spectra during NREMS are obtained offline with a fast Fourier transform algorithm on all epochs without artifact. The delta power is normalized to the average delta power in NREMS between 23:00 and 1 :00, a time when delta power is normally lowest.
Data are analyzed using repeated measures ANOVA. Light phase and dark phase data are analyzed separately. Both the treatment effect within each rat and the time by treatment effect within each rat is analyzed. Since two comparisons are made, a minimum value of P < 0.025 is required for post hoc analysis. When statistical significance is found from the ANOVAs, t-tests are performed comparing all compounds to vehicle and the test compounds to Zolpidem.
Those skilled in the art will recognize that various modifications, additions, substitutions and variations to the illustrative examples set forth herein can be made without departing from the spirit of the invention and are, therefore, considered within the scope of the invention. All documents referenced above, including, but not limited to, printed publications and provisional and regular patent applications, are incorporated herein by reference in their entirety.
Claims
1. A compound selected from compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates and hydrates thereof:
(Ia) wherein:
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of H, Ci-C6 acyl, C]-C6 acyloxy, Ci-C6 alkoxy, C]-C6 alkoxycarbonylamino, Ci-C6 alkyl, Ci-C6 alkylamino, C2-C8 dialkylamino, Ci-C6 alkylcarboxamide, Ci-C6 alkylsulfonamide, Ci-C6 alkylsulfinyl, Ci-C6 alkylsulfonyl, Ci-C6 alkylureyl, amino, aryl, aryl-Ci-C4-alkylenyl, carbo-C]-C6-alkoxy, carboxamide, carboxy, cyano, C3-C7 cycloalkyl, C2-C6 dialkylcarboxamide, Q-C6 haloalkoxy, Ci-C6 haloalkyl, Ci-C6 haloalkylsulfinyl, Ci-C6 haloalkylsulfonyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro and sulfonamide;
R6 and R7 are each independently selected from the group consisting of H, Q- C6 acyl, Ci-C3 alkyl, aryl, carboxamide, carboxy, C3-C7 cycloalkyl, Ci-C6 haloalkyl, heteroaryl and heterocyclyl;
R8 and R9 are each independently selected from the group consisting of H, Q- C6 acyl, Ci-C3 alkyl, aryl, carboxamide, Ci-C3 alkoxy, carboxy, cyano, C3-C7 cycloalkyl, Ci-C3 haloalkyl, halogen and hydroxyl; or R8 and R9 taken together form oxo; or
R8 and R9 together with the atom to which they are both bonded form a C3-C7 cycloalkyl ring; and R10, R1 ' , R12, R13 and R14 are each independently selected from the group consisting of H, Q-C6 acyl, Ci-C6 acyloxy, Q-C6 alkoxy, C]-C6 alkoxycarbonylamino, Q-C6 alkyl, Ci-C6 alkylamino, Q-C6 alkylcarboxamide, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonamide, Q-C6 alkylsulfonyl, Ci-C6 alkylureyl, amino, carbo-Q-C6 alkoxy, carboxamide, carboxy, cyano, C3-C6 cycloalkyl, C3-C7 cycloalkylcarbonyl, C2-C8 dialkylamino, C2-C6 dialkylcarboxamide, Ci-C6 haloalkoxy, Q-C6 haloalkyl, Ci-C6 haloalkylsulfinyl, Q-C6 haloalkylsulfonyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl, sulfonamide and sulfonic acid; wherein said phenyl group is optionally substituted with 1, 2 or 3 halogens.
2. The compound according to claim 1, wherein R1 and R2 are each independently selected from the group consisting of H, Ci-C6 acyloxy, C1-C6 alkoxy, CrC6 alkyl, C1-C6 alkylsulfonyl, aryl, aryl-C1-C4-alkylenyl, carbo-Ci-C6 alkoxy, carboxy, cyano, C3-C7 cycloalkyl, C1-C6 haloalkoxy, C1-C6 haloalkyl, halogen, heteroaryl, heterocyclyl and hydroxy 1.
3. The compound according to claim 1, wherein R1 and R2 are each independently selected from the group consisting of H, methyl, ?-butyl, phenyl, cyano, trifluoromethyl, chloro and bromo.
4. The compound according to claim 1, wherein R1 is H; and R2 is cyano, chloro or bromo.
5. The compound according to claim 1, wherein R1 and R2 are both H.
6. The compound according to any one of claims 1 to 5, wherein R3, R4 and R5 are each independently selected from the group consisting of H, methyl, methoxy and bromo.
7. The compound according to any one of claims 1 to 5, wherein R3, R4 and R5 are each H.
8. The compound according to any one of claims 1 to 8, wherein R6 and R7 are each independently selected from the group consisting of H and methyl.
9. The compound according to any one of claims 1 to 8, wherein R6 and R7 are both H.
10. The compound according to any one of claims 1 to 11, wherein:
R8 and R9 are each independently selected from the group consisting of H, C1- C3 alkyl, aryl, C1-C3 alkoxy, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen and hydroxyl; or
R8 and R9 taken together form oxo; or R8 and R9 together with the atom to which they are both bonded form a C3-C7 cycloalkyl ring.
11. The compound according to any one of claims 1 to 11 , wherein R8 and R9 are both H.
12. The compound according to any one of claims 1 to 11, wherein R8 and R9 together form oxo.
13. The compound according to any one of claims 1 to 12, wherein R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, Cj-C6 acyloxy, Q- C6 alkoxy, C1-C6 alkyl, Ci-C6 alkylamino, C2-C8 dialkylamino, Ci-C6 alkylcarboxamide, Ci-C6 alkylsulfonamide, C]-C6 alkylsulfonyl, amino, carboxamide, carboxy, cyano, C3- C6 cycloalkyl, C2-C6 dialkylcarboxamide, Ci-C6 haloalkoxy, Ci-C6 haloalkyl, halogen, heteroaryl, heterocyclyl, hydroxyl, nitro, phenyl, sulfonamide and sulfonic acid; wherein said phenyl group is optionally substituted with 1, 2 or 3 halogens.
14. The compound according to any one of claims 1 to 12, wherein R10, Ru, R12, R13 and R14 are each independently selected from the group consisting of H, methyl, methoxy, dimethylamino, -NHSO2CH3, methylsulfonyl, carboxamide, carboxy, cyano, cyclohexyl, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifluoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
15. The compound according to any one of claims 1 to 12, wherein: R10 and R12 are both F; and R11, R13 and R14 are each H.
16. The compound according to claim 1, selected from compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates or hydrates thereof:
(Ic) wherein:
R1 is selected from the group consisting of H, Ci-C6 alkyl, aryl and Ci-C6 haloalkyl;
R2 is selected from the group consisting of H, cyano and halogen; R8 and R9 are each independently selected from the group consisting of H and halogen; or
R8 and R9 together form oxo; and R12 and R14 are each independently selected from the group consisting of H and halogen.
17. The compound according to claim 1, selected from compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates or hydrates thereof:
(Ic) wherein:
R1 is selected from the group consisting of H, methyl, f-butyl, phenyl and trifluoromethyl;
R2 is selected from the group consisting of H, cyano, chloro and bromo; R8 and R9 are each independently selected from the group consisting of H and F; or R8 and R9 together form oxo; and
R12 and R14 are each independently selected from the group consisting of H, fluoro and chloro.
18. The compound according to claim 1, selected from compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates or hydrates thereof:
R6 and R7 are each independently selected from the group consisting of H and Ci-C3 alkyl;
R8 and R9 are each independently selected from the group consisting of H and halogen; or
R8 and R9 together form oxo; and
R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, Ci-C6 alkoxy, Ci-C6 alkyl, C2-C8 dialkylamino, Q-C6 alkylsulfonamide, C1-C6 alkylsulfonyl, carboxamide, carboxy, cyano, C3-C6 cycloalkyl, Ci-C6 haloalkoxy, Ci-C6 haloalkyl, heteroaryl, halogen, heterocyclyl, hydroxyl, nitro, phenyl and sulfonic acid.
19. The compound according to claim 1, selected from compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates or hydrates thereof:
(Ie) wherein:
R6 and R7 are both H; R8 and R9 are each independently selected from the group consisting of H and
F; or
R8 and R9 together form oxo; and
R10, R11, R12, R13 and R14 are each independently selected from the group consisting of H, methyl, methoxy, dimethylamino, -NHSO2CH3, methylsulfonyl, carboxamide, carboxy, cyano, cyclohexyl, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifluoromethyl, morpholin-4-yl, pyrrolidin-1-yl, thien-2-yl, hydroxyl, nitro, phenyl and sulfonic acid.
20. The compound according to claim 1 selected from the following compounds and pharmaceutically acceptable salts, solvates or hydrates thereof:
(3-bromoimidazo[l,2-α]pyridin-8-yl)(4-(2,4-difluorophenethyl)piperazin-l- yl)methanone;
8-(4-(2,4-difluorophenethyl)piperazine-l-carbonyl)imidazo[l,2-α]pyridine-3- carbonitrile; (4-(2 ,4-difluorophenethyl)piperazin- 1 -yl)(imidazo [ 1 ,2-α]pyridin-8 - yl)methanone; l-(4-fluorophenyl)-2-(4-(imidazo[l,2-α]pyridine-8-carbonyl)piperazin-l- yl)ethanone;
(4-(4-fluorophenethyl)piperazin-l-yl)(imidazo[l,2-α]pyridin-8-yl)methanone; (4-(4-fluorophenethyl)piperazin-l-yl)(2-(trifluoromethyl)imidazo[l,2-α]pyridin-
8-yl)methanone;
(2-ter/-butylimidazo[ 1 ,2-<z]pyridin-8-yl)(4-(4-fluorophenethyl)piperazin- 1 - yl)methanone;
(4-(4-fluorophenethyl)piperazin-l-yl)(2-methylimidazo[l,2-α]pyridin-8- yl)methanone;
(4-(4-fluorophenethyl)piperazin-l -yl)(2-phenylimidazo[ 1 ,2-α]pyridin-8- yl)methanone;
(4-(2-fluoro-2-(4-fluorophenyl)ethyl)piperazin-l-yl)(imidazo[l,2-α]pyridin-8- yl)methanone; (3-chloroimidazo[l,2-α]pyπdin-8-yl)(4-(2,4-difluorophenethyl)piperazm-l- yl)methanone; imidazo[l,2-α]pyndm-8-yl(4-(4-methoxyphenethyl)piperazm-l-yl)methanone;
(4-(3,4-dimethoxyphenethyl)piperazin-l-yl)(imidazo[l,2-α]pyπdin-8- yl)methanone;
(4-(3-fluorophenethyl)piperazin-l-yl)(imidazo[l,2-α]pyπdm-8-yl)methanone;
(4-(4-chlorophenethyl)piperazin-l -yl)(imidazo[ 1 ,2-α]pyπdin-8-yl)methanone;
(4-(3-chlorophenethyl)piperazin-l-yl)(imidazo[l,2-α]pyπdin-8-yl)methanone;
(4-(2-chlorophenethyl)piperazin-l-yl)(imidazo[l,2-α]pyπdm-8-yl)methanone; (4-(2-fluorophenethyl)piperazm-l -yl)(imidazo[ 1 ,2-α]pyπdin-8-yl)methanone;
(4-(2,4-dichlorophenethyl)piperazin-l-yl)(imidazo[l,2-α]pyπdm-8- yl)methanone; l-(2,4-difluorophenyl)-2-(4-(imidazo[l,2-α]pyridme-8-carbonyl)piperazin-l- yl)ethanone; 2-(4-(imidazo[ 1 ,2-a]pyπdme-8-carbonyl)piperazin-l -yl)- 1 -(4-(pyrrolidin- 1 - yl)phenyl)ethanone;
2-(4-(imidazo[ 1 ,2-a]pyπdme-8-carbonyl)piperazin- 1 -yl)- 1 -(4- (tπfluoromethoxy)phenyl)ethanone;
N-(2-hydroxy-5 -(2-(4-(1midazo[ 1 ,2-a]pyπdme-8-carbonyl)piperazm- 1 - yl)acetyl)phenyl)methanesulfonamide; l-(2-chloro-5-(tπfluoromethyl)phenyl)-2-(4-(imidazo[l,2-a]pyπdine-8- carbonyl)piperazm- 1 -yl)ethanone; l-(biphenyl-4-yl)-2-(4-(imidazo[l,2-a]pyπdine-8-carbonyl)piperazm-l- yl)ethanone; 2-(4-(imidazo[ 1 ,2-a]pyπdme-8-carbonyl)piperazm-l -yl)-l -(4-
(methylsulfonyl)phenyl)ethanone;
(4-(2,4-difluorophenethyl)piperazm-l-yl)(5,7-dimethylimidazo[l,2-a]pyndm-8- yl)methanone; l-(4-cyclohexylphenyl)-2-(4-(imidazo[l,2-a]pyridme-8-carbonyl)piperazm-l- yl)ethanone;
1 -(4-(difluoromethoxy)phenyl)-2-(4-(imidazo[ 1 ,2-a]pyπdine-8- carbonyl)piperazm- 1 -yl)ethanone;
2-(4-(imidazo[l,2-a]pyπdine-8-carbonyl)piperazin-l-yl)-l-phenylpropan-l-one;
1 -(4-chloro-2-fluoro-5-methylphenyl)-2-(4-(imidazo[ 1 ,2-a]pyπdme-8- carbonyl)piperazm- 1 -yl)ethanone; l-(5-chloro-2-methoxy-4-methylphenyl)-2-(4-(imidazo[l,2-a]pyπdine-8- carbonyl)pφerazin- 1 -yl)ethanone; l-(3,5-bis(trifluoromethyl)phenyl)-2-(4-(imidazo[l,2-a]pyridine-8- carbonyl)piperazin- 1 -yl)ethanone;
2-(4-(imidazo[ 1 ,2-a]pyridine-8-carbonyl)piperazin- 1 -yl)- 1 -(4- (trifluoromethyl)phenyl)ethanone; 2-(4-(imidazo[ 1 ,2-a]pyridine-8-carbonyl)piperazin- 1 -yl)- 1 -(4-(thiophen-2- yl)phenyl)ethanone;
(4-(2,4-difluorophenethyl)piperazin-l-yl)(7-methoxyimidazo[l,2-a]pyridin-8- yl)methanone;
2-hydroxy-5-(2-(4-(imidazo[l,2-a]pyridine-8-carbonyl)piperazin-l- yl)acetyl)benzamide;
2-(4-(imidazo[ 1 ,2-a]pyridine-8-carbonyl)piperazin- 1 -yl)- 1 -(2- (trifluoromethyl)phenyl)ethanone;
4-(2-(4-(imidazo[l,2-a]pyridine-8-carbonyl)piperazin-l-yl)acetyl)benzonitrile; l-(4-hydroxyphenyl)-2-(4-(imidazo[l,2-a]pyridine-8-carbonyl)piperazin-l- yl)ethanone; l-(4-(dimemylamino)phenyl)-2-(4-(imidazo[l,2-a]pyridine-8- carbonyl)piperazin- 1 -yl)ethanone; l-(5-chloro-2-methoxy-4-methyl-3-nitrophenyl)-2-(4-(imidazo[l,2-a]pyridine- 8-carbonyl)piperazin- 1 -yl)ethanone; 2-(4-(imidazo[l ,2-a]pyridine-8-carbonyl)piperazin-l -yl)-l -(4- moφholinophenyl)ethanone; and
(6-bromoimidazo[l,2-a]pyridin-8-yl)(4-(2,4-difluorophenethyl)piperazin-l- yl)methanone.
21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 and a pharmaceutically acceptable carrier.
22. A method for treating a 5-HT2A mediated disorder in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21.
23. The method according to claim 22, wherein said 5-HT2A mediated disorder is a sleep disorder.
24. The method according to claim 23, wherein said sleep disorder is a dyssomnia.
25. The method according to claim 23, wherein said sleep disorder is insomnia.
26. The method according to claim 23, wherein said sleep disorder is a parasomnia.
27. A method for increasing slow wave sleep in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21.
28. A method for improving sleep consolidation in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21.
29. A method for improving sleep maintenance in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21.
30. A method for treating a condition associated with platelet aggregation in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21.
31. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of a 5-HT2A mediated disorder.
32. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of a sleep disorder.
33. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of a dyssomnia.
34. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of insomnia.
35. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of a parasomnia.
36. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for increasing slow wave sleep.
37. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for improving sleep consolidation.
38. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for improving sleep maintenance.
39. Use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of a condition associated with platelet aggregation.
40. A compound according to any one of claims 1 to 20 for use in a method of treatment of the human or animal body by therapy.
41. A compound according to any one of claims 1 to 20 for use in a method for the treatment of a 5-HT2A mediated disorder.
42. A compound according to any one of claims 1 to 20 for use in a method for the treatment of a sleep disorder.
43. A compound according to any one of claims 1 to 20 for use in a method for the treatment of a dyssomnia.
44. A compound according to any one of claims 1 to 20 for use in a method for the treatment of insomnia.
45. A compound according to any one of claims 1 to 20 for use in a method for the treatment of a parasomnia.
46. A compound according to any one of claims 1 to 20 for use in a method for increasing slow wave sleep.
47. A compound according to any one of claims 1 to 20 for use in a method for improving sleep consolidation.
48. A compound according to any one of claims 1 to 20 for use in a method for improving sleep maintenance.
49. A compound according to any one of claims 1 to 20 for use in a method for the treatment of a condition associated with platelet aggregation.
50. A process for preparing a composition comprising admixing a compound according to any one of claims 1 to 20 and a pharmaceutically acceptable carrier.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES08795334T ES2421237T7 (en) | 2007-08-15 | 2008-08-14 | Imidazo [1,2-a] pyridine derivatives as modulators of the serotonergic 5ht2a receptor in the treatment of disorders related thereto |
US12/673,463 US9567327B2 (en) | 2007-08-15 | 2008-08-14 | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
JP2010521039A JP5393677B2 (en) | 2007-08-15 | 2008-08-14 | Imidazo [1,2-a] pyridine derivatives as modulators of 5-HT2A serotonin receptors for the treatment of disorders associated with 5-HT2A serotonin receptors |
EP08795334.5A EP2190844B3 (en) | 2007-08-15 | 2008-08-14 | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
US15/400,670 US10058549B2 (en) | 2007-08-15 | 2017-01-06 | Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US16/101,896 US20190142826A1 (en) | 2007-08-15 | 2018-08-13 | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
US17/015,358 US20210128552A1 (en) | 2007-08-15 | 2020-09-09 | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96484907P | 2007-08-15 | 2007-08-15 | |
US60/964,849 | 2007-08-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/673,463 A-371-Of-International US9567327B2 (en) | 2007-08-15 | 2008-08-14 | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US15/400,670 Continuation US10058549B2 (en) | 2007-08-15 | 2017-01-06 | Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009023253A2 true WO2009023253A2 (en) | 2009-02-19 |
WO2009023253A3 WO2009023253A3 (en) | 2009-04-09 |
Family
ID=39828967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/009740 WO2009023253A2 (en) | 2007-08-15 | 2008-08-14 | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
Country Status (5)
Country | Link |
---|---|
US (4) | US9567327B2 (en) |
EP (1) | EP2190844B3 (en) |
JP (1) | JP5393677B2 (en) |
ES (1) | ES2421237T7 (en) |
WO (1) | WO2009023253A2 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8148418B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8148417B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US20130123285A1 (en) * | 2010-05-14 | 2013-05-16 | University Of Rochester | Compositions and Methods for Targeting A3G:RNA Complexes |
US8716282B2 (en) | 2009-10-30 | 2014-05-06 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
US8785441B2 (en) | 2004-11-19 | 2014-07-22 | Arena Pharmaceuticals, Inc. | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8859543B2 (en) | 2010-03-09 | 2014-10-14 | Janssen Pharmaceutica Nv | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
US8871797B2 (en) | 2003-07-22 | 2014-10-28 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
CN104557922A (en) * | 2014-12-31 | 2015-04-29 | 定陶县友帮化工有限公司 | Synthetic method for 6-bromoimidazo[1,2-a]pyridine-8-carboxylic acid |
US9034911B2 (en) | 2008-10-28 | 2015-05-19 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
WO2015089218A1 (en) | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
US9199940B2 (en) | 2006-05-18 | 2015-12-01 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
US9434692B2 (en) | 2006-10-03 | 2016-09-06 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9550784B2 (en) | 2012-07-09 | 2017-01-24 | Beerse Pharmaceutica NV | Inhibitors of phosphodiesterase 10 enzyme |
US9556149B2 (en) | 2008-04-02 | 2017-01-31 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
KR20190088756A (en) * | 2018-01-19 | 2019-07-29 | 서울대학교산학협력단 | TSPO-binding ligand targeting the abnormal TSPO expression related diseases for PET radiotracer and fluorescence imaging as well as photodynamic therapy, and syntheses of them |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2968320B1 (en) | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR20230058736A (en) | 2013-12-03 | 2023-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | Novel methods |
JP2017509677A (en) | 2014-04-04 | 2017-04-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | Organic compounds |
EP3125893B1 (en) | 2014-04-04 | 2023-09-20 | Intra-Cellular Therapies, Inc. | Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors |
PT3407888T (en) | 2016-01-26 | 2021-03-19 | Intra Cellular Therapies Inc | Organic compounds |
IL297676B2 (en) | 2016-03-25 | 2023-12-01 | Intra Cellular Therapies Inc | A sustained-release or delayed-release pharmaceutical composition comprising a deuterated compound |
EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
IL304026A (en) | 2017-03-24 | 2023-08-01 | Intra Cellular Therapies Inc | Novel compositions and methods |
EP3684463A4 (en) | 2017-09-19 | 2021-06-23 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
BR112021003655A2 (en) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | new methods |
BR112021003838A2 (en) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | new methods |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021545A1 (en) * | 2003-09-03 | 2005-03-10 | Galapagos Nv | IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS |
WO2006086705A1 (en) * | 2005-02-10 | 2006-08-17 | Aventis Pharmaceuticals Inc. | Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists |
US20070043058A1 (en) * | 2005-08-17 | 2007-02-22 | Benny Bang-Andersen | Novel 2,3-dihydroindole compounds |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1643310A1 (en) | 1966-12-29 | 1971-06-03 | Dow Chemical Co | 4-alkyl-2,5-dimethoxy-alpha-methyl-phenaethylamine and its pharmacologically acceptable salts |
US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
DE2926517A1 (en) | 1979-06-30 | 1981-01-15 | Beiersdorf Ag | SUBSTITUTED 3-ARYL-PYRAZOLE AND 5-ARYL-ISOXAZOLE AND METHOD FOR THE PRODUCTION THEREOF |
DE2928485A1 (en) | 1979-07-14 | 1981-01-29 | Bayer Ag | USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
IL61721A (en) | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
US4555399A (en) | 1983-11-18 | 1985-11-26 | Key Pharmaceuticals, Inc. | Aspirin tablet |
US4985352A (en) | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
IT1227626B (en) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION |
EP0412798A3 (en) | 1989-08-08 | 1992-07-01 | Merck Sharp & Dohme Ltd. | Substituted pyridines, their preparation, formulations and use in dementia |
US5661024A (en) | 1989-10-31 | 1997-08-26 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonic (5-HT2) receptor and uses thereof |
US5077409A (en) | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
US5128351A (en) | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
JPH04334357A (en) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | Acyl derivative having enzyme-inhibiting action |
FR2682379B1 (en) | 1991-10-09 | 1994-02-11 | Rhone Poulenc Agrochimie | NEW FUNGICIDAL PHENYLPYRAZOLES. |
FR2690440B1 (en) | 1992-04-27 | 1995-05-19 | Rhone Poulenc Agrochimie | Arylpyrazoles fungicides. |
EP0714389B1 (en) | 1993-08-20 | 1998-06-17 | Smithkline Beecham Plc | Amide and urea derivatives as 5ht1d receptor antagonists |
FR2722369B1 (en) | 1994-07-13 | 1998-07-10 | Rhone Poulenc Agrochimie | FUNGICIDAL COMPOSITIONS BASED ON 3-PHENYL-PYRAZOLES FOR THE TREATMENT OF PLANT MULTIPLICATION MATERIALS, NEW 3-PHENYL-PYRAZOLES DERIVATIVES AND THEIR FUNGICIDAL APPLICATIONS |
KR970706242A (en) | 1994-10-04 | 1997-11-03 | 후지야마 아키라 | Urea derivatives and their use as ACAT-inhibitors (Urea derivatives and their use as ACAT-inhibitors) |
CA2135253A1 (en) | 1994-11-07 | 1996-05-08 | Michael Dennis | Compound screening based on a window of chemical-messenger-independent activity |
BR9607016A (en) | 1995-02-02 | 1997-10-28 | Smithkline Beecham Plc | Indole derivatives as a 5-ht receptor antagonist |
US6540981B2 (en) | 1997-12-04 | 2003-04-01 | Amersham Health As | Light imaging contrast agents |
EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | Il-8 receptor antagonists |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1996032931A2 (en) | 1995-04-20 | 1996-10-24 | Vectorpharma International S.P.A. | Composite with sodium starch glycolate as a support material and products thereof |
US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
WO1997003967A1 (en) | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
GB9607219D0 (en) | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
EP0906273B1 (en) | 1996-05-24 | 2002-10-16 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
AU2962297A (en) | 1996-05-24 | 1998-01-05 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
CZ425698A3 (en) | 1996-06-27 | 1999-06-16 | Smithkline Beecham Corporation | Il-8 receptor antagonist |
JP4863534B2 (en) | 1996-10-25 | 2012-01-25 | スパーナス ファーマシューティカルズ インコーポレイテッド | Soluble form osmotic dose delivery system |
JP2001508767A (en) | 1996-12-02 | 2001-07-03 | 藤沢薬品工業株式会社 | Indole-urea derivatives having 5-HT antagonism |
US6541209B1 (en) | 1997-04-14 | 2003-04-01 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6420541B1 (en) | 1998-04-14 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6297261B1 (en) | 1997-04-22 | 2001-10-02 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
US6696475B2 (en) | 1997-04-22 | 2004-02-24 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
US6028083A (en) | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
CA2294064A1 (en) | 1997-07-29 | 1999-02-11 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
KR20010023256A (en) | 1997-08-27 | 2001-03-26 | 헥살 아게 | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
DK1027328T3 (en) | 1997-10-31 | 2006-11-13 | Aventis Pharma Ltd | Substituted anilides |
JPH11183942A (en) | 1997-12-19 | 1999-07-09 | Nippon Mitsubishi Oil Corp | Electrochromic element |
EP1042305B1 (en) | 1997-12-22 | 2005-06-08 | Bayer Pharmaceuticals Corp. | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
EP1049664B1 (en) | 1997-12-22 | 2005-03-16 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
MXPA00010060A (en) | 1998-04-14 | 2004-04-23 | Arena Pharm Inc | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof. |
US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
NZ510098A (en) | 1998-10-22 | 2003-09-26 | Neurosearch As | Substituted phenyl derivatives, pharmaceuticals thereof and their use as blockers of the chloride channel |
US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
US6180138B1 (en) | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
WO2000057877A1 (en) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
US6469006B1 (en) | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
IT1312115B1 (en) | 1999-06-24 | 2002-04-04 | Nicox Sa | AMORPHOUS COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS |
DE19934433A1 (en) * | 1999-07-22 | 2001-01-25 | Merck Patent Gmbh | New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia |
EP1208097B1 (en) | 1999-07-28 | 2009-02-18 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl compounds |
US6541477B2 (en) | 1999-08-27 | 2003-04-01 | Scios, Inc. | Inhibitors of p38-a kinase |
WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
EP1108720A1 (en) | 1999-12-08 | 2001-06-20 | Basf Aktiengesellschaft | Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines |
EP1248770A1 (en) | 1999-12-16 | 2002-10-16 | Biostream Therapeutics | 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
WO2001046166A2 (en) | 1999-12-20 | 2001-06-28 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
AU2001241927A1 (en) | 2000-02-28 | 2001-09-12 | Scios Inc. | Inhibitors of p38-alpha kinase |
FR2810979B1 (en) | 2000-06-29 | 2002-08-23 | Adir | NOVEL DIPHENYLUREA DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
AU2002223492A1 (en) | 2000-11-14 | 2002-05-27 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
AR035521A1 (en) | 2000-12-22 | 2004-06-02 | Lundbeck & Co As H | DERIVATIVES OF 3-INDOLIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM |
US20020156068A1 (en) | 2001-03-22 | 2002-10-24 | Behan Dominic P. | Anti-psychosis combination |
ATE377413T1 (en) | 2001-06-29 | 2007-11-15 | Eurand Pharmaceuticals Ltd | METHOD FOR THE THERMODYNAMIC ACTIVATION OF WATER SOLUBLE DRUGS LOADED IN CROSS-LINKED POLYMERS |
JP4733877B2 (en) | 2001-08-15 | 2011-07-27 | 富士通セミコンダクター株式会社 | Semiconductor device |
GEP20074098B (en) | 2001-09-21 | 2007-05-10 | Bristol Myers Squibb Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
EP1509505A2 (en) | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO |
US6743864B2 (en) | 2002-03-12 | 2004-06-01 | Basell Poliolefine Italia S.P.A. | Polyolefin compositions having high tenacity |
AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
BR0314584A (en) * | 2002-09-20 | 2005-08-09 | Pfizer | Unsubstituted piperidinyl imidazopyridine compounds as modulators and 5-ht4 receptors |
AU2003275093A1 (en) | 2002-09-24 | 2004-04-19 | Arena Pharmaceuticals, Inc. | Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof |
WO2004045118A2 (en) | 2002-11-08 | 2004-05-27 | Interdigital Technology Corporation | Composite channel quality estimation techniques for wireless receivers |
WO2004046110A1 (en) | 2002-11-15 | 2004-06-03 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
AU2003297441A1 (en) | 2002-12-24 | 2004-07-22 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
WO2004085433A2 (en) | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
KR101157272B1 (en) | 2003-07-22 | 2012-06-15 | 아레나 파마슈티칼스, 인크. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5?ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto |
EP1695966A1 (en) | 2003-07-22 | 2006-08-30 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
AU2004266233A1 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
US7091236B1 (en) | 2003-08-20 | 2006-08-15 | Sciele Pharma, Inc. | Method for increasing the bioavailability of glycopyrrolate |
US20050054691A1 (en) | 2003-08-29 | 2005-03-10 | St. Jude Children's Research Hospital | Carboxylesterase inhibitors |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
CN1926114B (en) | 2004-03-23 | 2011-08-24 | 艾尼纳制药公司 | Processes for preparing substituted N-aryl-N'-[3-(1H-pyrazol-5-yl) phenyl] ureas and intermediates thereof |
WO2006004722A2 (en) | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
US20060172992A1 (en) | 2004-08-13 | 2006-08-03 | Eisai Co., Ltd. | Therapeutic agent for overactive bladder resulting from cerebral infarction |
US20080261952A1 (en) | 2004-08-16 | 2008-10-23 | Jason Bloxham | Aryl Urea Derivatives for Treating Obesity |
US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
EP2332527A3 (en) | 2004-10-20 | 2011-11-16 | Resverlogix Corp. | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases |
AU2005302669A1 (en) | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as CB1 antagonists |
US7563785B2 (en) | 2004-10-29 | 2009-07-21 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
WO2006050165A2 (en) | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
PE20061130A1 (en) | 2004-11-19 | 2007-01-05 | Arena Pharm Inc | 3-PHENYL-PIRAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR |
GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
AR051978A1 (en) | 2004-12-01 | 2007-02-21 | Divergence Inc | PESTICIDED COMPOSITIONS AND METHODS |
WO2006060762A2 (en) | 2004-12-03 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
DE102004061593A1 (en) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituted N-heterocyclic compounds and their therapeutic use |
EP1831172B1 (en) | 2004-12-28 | 2009-02-18 | Council of Scientific and Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
PL1858877T3 (en) | 2005-01-14 | 2014-08-29 | Gilead Connecticut Inc | 1,3 substituted diaryl ureas as modulators of kinase activity |
US20080200530A1 (en) | 2005-01-19 | 2008-08-21 | Unett David J | Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy |
AU2006206292B2 (en) | 2005-01-21 | 2009-09-03 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of zonisamide and methods for their manufacture |
AR052886A1 (en) | 2005-01-26 | 2007-04-11 | Arena Pharm Inc | PROCEDURES TO PREPARE PHENYLPIRAZOL REPLACED UREAS AND TO OBTAIN YOUR SYNTHESIS INTERMEDIARIES |
AU2006209397B2 (en) | 2005-01-27 | 2011-04-07 | Janssen Pharmaceutica N.V. | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5HT2 inhibitors in the treatment of CNS disorders |
WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
AU2006218403A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
GB0505437D0 (en) | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
GB0505725D0 (en) | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
PT1877390E (en) | 2005-04-26 | 2010-05-31 | Hypnion Inc | Benzisoxazole piperazine compounds and methods of use thereof |
EP1734039A1 (en) | 2005-06-13 | 2006-12-20 | Esbatech AG | Aryl urea compounds as BETA-secretase inhibitors |
AU2006261841B8 (en) | 2005-06-27 | 2012-12-06 | Exelixis Patent Company Llc | Pyrazole based LXR modulators |
US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
AU2006299656A1 (en) | 2005-09-29 | 2007-04-12 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions of a 5-HT2a serotonin receptor modulator useful for the treatment of disorders related thereto |
JP2009533442A (en) | 2006-04-10 | 2009-09-17 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 3-pyridinyl-pyrazole derivatives as modulators of 5-HT2A serotonin receptors useful for the treatment of 5-HT2A serotonin receptor related disorders |
GB0608655D0 (en) | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
EP2018371B1 (en) | 2006-05-18 | 2015-03-04 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
WO2007136680A2 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | 3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
MY154962A (en) | 2006-05-18 | 2015-08-28 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor |
WO2007136875A2 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
WO2008027483A1 (en) | 2006-08-31 | 2008-03-06 | Arena Pharmaceuticals, Inc. | Benzofuran derivatives as modulators of the 5-ht2a receptor |
TWI415845B (en) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
TW200823204A (en) | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
WO2008054748A2 (en) | 2006-10-31 | 2008-05-08 | Arena Pharmaceuticals, Inc. | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
US8097633B2 (en) | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
US8969402B2 (en) | 2006-11-15 | 2015-03-03 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
US9034890B2 (en) | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
CN101679297B (en) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | LXR and FXR modulators |
US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US20090082388A1 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals Inc. | Co-administration of pimavanserin with other agents |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
CN104784173B (en) | 2008-10-28 | 2019-07-26 | 艾尼纳制药公司 | For treating 5-HT2AThe 5-HT of 5-hydroxytryptamine receptor associated disorders2A5-hydroxytryptamine receptor regulating composition |
GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
AU2013274667B2 (en) | 2012-06-11 | 2018-03-08 | Psychogenics, Inc. | Treatment of motor and movement disorder side effects associated with Parkinson's disease treatments |
JOP20210047A1 (en) | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
WO2014085362A1 (en) | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
KR101472682B1 (en) | 2013-07-23 | 2014-12-15 | 고려대학교 산학협력단 | Methode for preparing metamaterial, metamaterial film prepared by the same and super-resolution imaging system using the the same |
-
2008
- 2008-08-14 US US12/673,463 patent/US9567327B2/en active Active
- 2008-08-14 JP JP2010521039A patent/JP5393677B2/en active Active
- 2008-08-14 WO PCT/US2008/009740 patent/WO2009023253A2/en active Application Filing
- 2008-08-14 EP EP08795334.5A patent/EP2190844B3/en active Active
- 2008-08-14 ES ES08795334T patent/ES2421237T7/en active Active
-
2017
- 2017-01-06 US US15/400,670 patent/US10058549B2/en active Active
-
2018
- 2018-08-13 US US16/101,896 patent/US20190142826A1/en not_active Abandoned
-
2020
- 2020-09-09 US US17/015,358 patent/US20210128552A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021545A1 (en) * | 2003-09-03 | 2005-03-10 | Galapagos Nv | IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS |
WO2006086705A1 (en) * | 2005-02-10 | 2006-08-17 | Aventis Pharmaceuticals Inc. | Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists |
US20070043058A1 (en) * | 2005-08-17 | 2007-02-22 | Benny Bang-Andersen | Novel 2,3-dihydroindole compounds |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871797B2 (en) | 2003-07-22 | 2014-10-28 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9273035B2 (en) | 2003-07-22 | 2016-03-01 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US10781180B2 (en) | 2004-11-19 | 2020-09-22 | Arena Pharmaceuticals, Inc. | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8785441B2 (en) | 2004-11-19 | 2014-07-22 | Arena Pharmaceuticals, Inc. | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9199940B2 (en) | 2006-05-18 | 2015-12-01 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
US8148418B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8148417B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8664258B2 (en) | 2006-05-18 | 2014-03-04 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9987252B2 (en) | 2006-05-18 | 2018-06-05 | Arena Pharmaceuticals, Inc. | Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
USRE45336E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8680119B2 (en) | 2006-05-18 | 2014-03-25 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9783502B2 (en) | 2006-05-18 | 2017-10-10 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
USRE45337E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10351531B2 (en) | 2006-10-03 | 2019-07-16 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9732039B2 (en) | 2006-10-03 | 2017-08-15 | Arena Pharmeceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9434692B2 (en) | 2006-10-03 | 2016-09-06 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10058549B2 (en) | 2007-08-15 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10787437B2 (en) | 2008-04-02 | 2020-09-29 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US9556149B2 (en) | 2008-04-02 | 2017-01-31 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10071075B2 (en) | 2008-10-28 | 2018-09-11 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US10117851B2 (en) | 2008-10-28 | 2018-11-06 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US10583122B2 (en) | 2008-10-28 | 2020-03-10 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US9353064B2 (en) | 2008-10-28 | 2016-05-31 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
US10543193B2 (en) | 2008-10-28 | 2020-01-28 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9801856B2 (en) | 2008-10-28 | 2017-10-31 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US9034911B2 (en) | 2008-10-28 | 2015-05-19 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US8716282B2 (en) | 2009-10-30 | 2014-05-06 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8859543B2 (en) | 2010-03-09 | 2014-10-14 | Janssen Pharmaceutica Nv | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
US20130123285A1 (en) * | 2010-05-14 | 2013-05-16 | University Of Rochester | Compositions and Methods for Targeting A3G:RNA Complexes |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
US9550784B2 (en) | 2012-07-09 | 2017-01-24 | Beerse Pharmaceutica NV | Inhibitors of phosphodiesterase 10 enzyme |
WO2015089218A1 (en) | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
CN104557922A (en) * | 2014-12-31 | 2015-04-29 | 定陶县友帮化工有限公司 | Synthetic method for 6-bromoimidazo[1,2-a]pyridine-8-carboxylic acid |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11304932B2 (en) | 2015-07-15 | 2022-04-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
KR102031652B1 (en) | 2018-01-19 | 2019-10-14 | 서울대학교산학협력단 | TSPO-binding ligand targeting the abnormal TSPO expression related diseases for PET radiotracer and fluorescence imaging as well as photodynamic therapy, and syntheses of them |
KR20190088756A (en) * | 2018-01-19 | 2019-07-29 | 서울대학교산학협력단 | TSPO-binding ligand targeting the abnormal TSPO expression related diseases for PET radiotracer and fluorescence imaging as well as photodynamic therapy, and syntheses of them |
Also Published As
Publication number | Publication date |
---|---|
EP2190844B1 (en) | 2013-04-10 |
EP2190844B3 (en) | 2013-07-17 |
ES2421237T3 (en) | 2013-08-29 |
US20170151236A1 (en) | 2017-06-01 |
ES2421237T7 (en) | 2013-09-30 |
JP2010536757A (en) | 2010-12-02 |
US9567327B2 (en) | 2017-02-14 |
WO2009023253A3 (en) | 2009-04-09 |
EP2190844A2 (en) | 2010-06-02 |
US20190142826A1 (en) | 2019-05-16 |
US20210128552A1 (en) | 2021-05-06 |
JP5393677B2 (en) | 2014-01-22 |
US10058549B2 (en) | 2018-08-28 |
US20110263592A1 (en) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210128552A1 (en) | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
US20210380537A1 (en) | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
AU2007254244B2 (en) | 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | |
US8785441B2 (en) | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | |
WO2008054748A2 (en) | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
WO2008027483A1 (en) | Benzofuran derivatives as modulators of the 5-ht2a receptor | |
WO2006060762A2 (en) | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
EP2004627A2 (en) | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08795334 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12673463 Country of ref document: US Ref document number: 2010521039 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008795334 Country of ref document: EP |